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ABSTRACT
In many clinical follow-up studies, patients are observed at irregular intervals for more than
one biomarker of disease severity. Although these biomarkers are often meant to measure the
same disease severity, they may differ due to the instruments or reagents used as well as the
scale of measurements. They could show different patterns for treatment because clinicians
prescribe medications based on the severity of disease. Moreover, if these markers are modeled
separately to determine the factors that are associated with disease progression over time
or to predict the event of interest given different treatments, they may yield misleading or
inefficient results. Joint modeling of correlated biomarkers alone or with time-to-event data
leads to efficient results, hence better clinical decisions.
In this study, we have first developed a joint model to analyze multivariate unbalanced
repeatedly measured outcomes of mixed types, in particular, continuous and ordinal outcomes.
Secondly, we have extended the first model to include time-to-event data. The postulated
models assumes that the outcomes are from distributions that are in the exponential family
and hence modeled as a multivariate generalized linear mixed effects model linked through
random effects. The Markov Chain Monte Carlo (MCMC) Bayesian approach is used to
approximate the posterior distribution and draw inference on the parameters. These joint
models provide a flexible framework to account for the hierarchical structure of the highly
unbalanced data as well as the association between the multiple mixed types of outcomes and
v
time-to-event. Moreover, the simulation studies show that estimates obtained from the joint
models are consistently less biased and more efficient than those obtained from the separate
models. We applied our models to diabetes data from an observational study.
Diabetes and its associated complications such as heart attack and stroke are of serious
public health concerns across the globe. Proper treatment can help control and prevent the
development of these complications and hence improve the quality of life of millions of people.
This work proposes to efficiently estimate the treatment effect by introducing state-of-the-art
statistical methods. This will help researchers identify effective treatments that can slow
down the disease progression.
Keywords: Diabetes; Generalized Linear Mixed Effects Models; Hierarchical Modeling; Joint
Modeling; Mixed Biomarkers; MCMC; Time-To-Event.
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1.0 INTRODUCTION
In the first part of this dissertation, we present a Bayesian hierarchical joint model of
repeatedly measured continuous and ordinal markers of diseases severity for highly unbalanced
data. The two outcomes are assumed to be from distributions that are in the exponential
family and hence modeled as a multivariate generalized linear mixed effects model linked
through correlated and/or shared random effects. The Markov Chain Monte Carlo (MCMC)
Bayesian approach is used to approximate the posterior distribution and draw inference on
the parameters. In the second part of this dissertation, we extend the joint model to include
time-to-event data. We employ same Bayesian methods for parameter estimation.
This dissertation is organized as follows. In Chapter 1, we give a background to our study
that includes both the clinical and statistical motivation. Chapter 2 shows the methods
for longitudinal data modeling and time-to-event or survival analysis in the univariate and
multivariate settings. We plan to write Chapter 3 and Chapter 4 of this dissertation as
independent papers, and because Chapter 4 builds on Chapter 3, there are likely to be some
repetitions in some sections.
1.1 BACKGROUND
In many clinical studies, more than one biomarker of disease severity is obtained and some
may be easier and cheaper to obtain than others. Although these biomarkers are often meant
to measure the same disease severity, they may differ due to the instruments/reagents used as
well as the scale of measurements. They could show different patterns for treatment because
clinicians prescribe medications based on the severity of disease. Moreover, if these markers
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are modeled separately to determine the factors that are associated with disease progression
over time or to predict the event of interest (i.e., time-to-remission) given different treatments,
they may yield different, misleading or inefficient results. Modeling these markers jointly
while accounting for their correlation is likely to provide more accurate and efficient results.
The motivation for our study is based on data collected retrospectively from medical
registries of diabetic patients in three Ugandan hospitals. These patients were recruited in
the diabetic clinics between January 1992 and December 2004. Diabetes is a progressive
illness occurs when the pancreas does not produce enough insulin or when the body does
not respond properly to varying levels of insulin. This results in increased concentrations of
glucose in the blood, which in turn damages many of the body’s systems, in particular the
blood vessels and nerves. Thus, the amount of glucose in the blood determines the state of
the disease at a point in time. In addition, the amount of glucose in the urine is used to detect
if the individual’s blood glucose level is above the renal threshold of 180 mg/dl. The amount
of glucose in the urine is interpreted using the + symbolic method or the actual amount in
the urine(mg/dl) depending on the manufacturer of the urine glucose reagent strips. That
is, Nil (no urine sugar), +(≈ 100 mg/dl), + + (≈ 250 mg/dl), + + +(≈ 500 mg/dl), and
+ + + + (≈ 1000 mg/dl), respectively. Thus, the two main biomarkers used to determine
the severity of the disease at any given time were blood glucose and urine glucose levels.
Of the two biomarkers, blood glucose which is measured by the fasting plasma glucose test
(FPG) or the oral glucose tolerance test (OGTT) is more accurate and hence recommended
by both the World Health Organization (WHO) and the American Diabetes Association
(ADA). The urine glucose tests to detect Glycosuria/Glucosuria (glucose in urine) are used
as an alternative to blood glucose tests especially in developing countries because they are
fast, do not require many reagents, easy to carry out and generally economical (Carter and
Lema, 2003)[10]. However, the urine glucose test for diabetes may be contaminated by drugs
and individual variations in the renal threshold for glucose. Thus, making a clinical decision
based on a urine test alone may be invalid or misleading.
According to the ADA, normal blood glucose level for diabetics is between 70 and 180 mg/dl.
Specifically, normal fasting blood glucose (before a meal) is between 70 and 130 mg/dl and
after a meal is less than 180 mg/dl. Blood glucose level below 70 mg/dl is referred to as
2
hypoglycemia and above 180 mg/dl is referred to as hyperglycemia. Thus, the clinical interest
is to detect that the blood glucose lies in the normal range of 70-180 mg/dl. Thus, a diabetic
person is said to be well if the blood glucose level is in the normal range. In addition,
having normal blood pressure can circumvent most of the common diabetes complications
that include diabetic retinopathy (which is damage to the back of the eye) and kidney
damage medically known as diabetic nephropathy. Studies have indicated that individuals
with adequately controlled blood pressure possess lower risk of mortality related to diabetes
complications such as heart attack and stroke. Moreover, body mass index (BMI) which is a
measure of body fat, is positively associated with Type 2 diabetes mellitus and hypertension
(high blood pressure). Thus, having normal blood pressure for diabetics is as important as
having good control of blood glucose levels and BMI.
During their hospital visits, the patients in the Ugandan study were periodically tested for
the amount of glucose in the blood or urine or both to determine the severity of the disease
so as to prescribe appropriate medication. Other measures that are associated with diabetes
like diastolic and systolic blood pressure, and body mass index (BMI) were also taken. The
data are highly unbalanced because this was an observational study where patients reported
for checkup at irregular intervals with the number of hospital visits varying from patient
to patient. Specifically, the number of hospital visits per patient varied from 2 to 78 with
a mean of 29 and standard deviation of 15. Out of 1010 patients, 301 were treated with
Sulphonyureas, 299 with Biguanides, 402 with Insulin, and 8 were on diet and exercise at
baseline. Clinically, blood glucose and urine glucose measure the same diabetes severity
although blood glucose is continuous and urine glucose is ordinal with five levels. In addition,
blood glucose, which is expensive to measure is associated with inexpensive biomarkers such
as blood pressure levels and body mass index. Joint modeling of the two markers (blood
glucose and urine glucose) simultaneously will produce efficient estimates because the two
markers are highly correlated. Moreover, a joint model that combines time to normalization
of blood glucose, blood pressure levels, and body mass index will lead to a more optimal way
of caring for diabetic patients. This will be beneficial to the patients, and to the health-care
personnel and institutions.
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Statistically, joint modeling allows for the assessment of the overall impact as well as the
separate and joint effects of a risk factor or treatment on all the outcomes while adjusting for
the correlation that exists between or among these outcomes. Joint modeling avoids multiple
testing by calculating an overall test of the effect of the predictor without having to resort
to ad hoc methods such as Bonferroni adjustment. Overall, joint modeling leads to more
efficient estimates than separate analyses.
The goal of this study is to propose a joint model that handles unbalanced repeatedly
measured outcomes of mixed types and time-to-event. Specifically, we propose to develop
two models:
Aim 1: Joint model for unbalanced repeatedly measured continuous and ordinal outcomes
that are measures of disease severity.
Aim 2: Joint model for repeatedly measured mixed outcomes and time-to-event data.
In the next chapter (Chapter 2), we give a critical review of the literature related to modeling of
longitudinal outcomes of mixed types and time-to-event, and briefly describe our contribution.
Chapters 3 and 4 shows the completed work on Aim 1 and Aim 2, respectively.
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2.0 METHODOLOGICAL REVIEW
Joint modeling of continuous and ordinal response variables are of primary interest in Part 1
(Chapter 3) of this study. The two outcome variables (e.g., urine glucose and blood glucose)
are measured repeatedly on each study participant at the same or varying time-points. The
important feature of our data is that it is highly unbalanced, and therefore, the methods that
handle these kinds of data are of paramount interest. Part 2 (Chapter 4) of this study extends
the joint model in Part 1 (Chapter 3) to include time-to-event. Thus, an understanding
of the treatment effects on both markers over time and time-to-event as well as modeling
the correlation between and/or among them are of interest. In this chapter, methods for
analyzing longitudinal continuous and discrete (binary, ordinal) outcomes, and time-to-event
(separately and jointly) are reviewed. These include marginal, generalized linear mixed effects,
survival, joint modeling of continuous and discrete (binary or ordinal) outcomes, and joint
modeling of longitudinal outcomes and time-to-event.
2.1 METHODS FOR LONGITUDINAL DATA MODELING
In longitudinal or repeated measured studies, the key issues are to capture the change in
a response over time as well as the within subject change or to account for the correlation
between the measurements. In addition, follow-up studies may have staggered entry, dropout,
intermittent missing data, and mistimed visits, which results in unbalanced datasets. Thus,
in longitudinal data analysis, appropriate or realistic methods that handle unbalanced
data should be employed to obtain reliable results. Modern linear mixed effects models
(Laird and Ware, 1982)[57] or generalized estimating equations (Zeger and Liang, 1986)[103]
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approaches accommodate these unbalanced data sets, subject to assumptions about the
missing data mechanism (Little and Rubin, 1987)[62]. Older standard methods for univariate
and multivariate analysis of repeated measures data are more restrictive in that they require
balanced datasets.
2.1.1 Notation
Let yij be the response variable and xij a vector of length p of explanatory variables observed at
the jth time-point, j = 1, . . . , ni on the i
th subject, i = 1, . . . , n. The set of repeated outcomes
for subject i are collected into an ni-vector and can be written as y
′
i = [yi1,yi2, . . . ,yini ]
′,
with mean E(yi) = µi. The set of explanatory variables or covariates are grouped into an
ni × p matrix xi = [x′i1,x′i2, . . . ,x′ini ]′.
2.1.2 Marginal models
Marginal or population averaged models are widely used in the biomedical sciences and are
very flexible in that they require no distributional assumption for the vector of responses,
only a model for the mean response. They are marginal in that the mean response depends
only on the covariates of interest and not on any random effects. The frequentist estimation
methods, Generalized Estimating equations (GEE) by Liang and Zeger (1986)[60] were
specifically developed for parameter estimation in these models. In case of independent
repeated measurements, the classical score equations for the estimation of β are given as :
Sk(β) =
k∑
i=1
dµi
dβk
ν−1i (yi − µi) = 0 k = 1, . . . , p, (2.1.21)
where β is a vector of unknown regression coefficients and νi is a diagonal matrix with
νij = V ar(yij) on the main diagonal. For longitudinal data, Liang and Zeger (1986)[60]
extended the score equations (2.1.21) to multivariate setting:
k∑
i=1
dµi
dβk
(A
1/2
i Ri(α)A
1/2
i /φ)(yi − µi) = 0, (2.1.22)
where Ri(α) is an ni × ni fully specified “working correlation” matrix which may depend
on a vector of unknown parameters α, which is assumed to be the same for all subjects,
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νi = (A
1/2
i Ri(α)A
1/2
i /φ) is the ”working covariance” matrix for yi , Ai is an ni × ni diagonal
matrix consisting of a function of the mean g(µij) along the main diagonal, and φ is a scale
parameter. The term ”working” is used to imply that the model assumes that the form of the
covariance may not be correctly specified (Zeger and Liang, 1986)[103]. The GEE estimator
of β is the solution to
k∑
i=1
dµi
dβk
(A
1/2
i Ri(αˆ)A
1/2
i /φˆ)(yi − µi) = 0, (2.1.23)
where αˆ and φˆ are consistent estimates of α and φ, respectively. The solution to Equation 2.1.41
is obtained via iteratively weighted least squares method (for more details see McCullagh
and Nelder, 1983[68]).
The strength of the GEE method is that it is robust to the choice of the “working
correlation” structure and only requires that the mean response be correctly specified. This
robustness property holds if data are complete or missing completely at random (MCAR)
(Rubin, 1976)[81]. A major limitation is that the GEE approach is not a likelihood-based
method and hence it is difficult to determine the goodness of fit, compare models, and to
draw statistical conclusions on the model parameters.
2.1.3 Generalized linear mixed effects model (GLMM)
In Section 2.1.2 we introduced marginal models where the GEE accounts for the within
individual correlation. Alternatively, random effects are incorporated into the mean model
to account for the association between repeated measurements within an individual. The
difference between random effects and marginal models is that the latter is population-specific
while random effects are subject-specific. Marginally, conditional on the random effects, the
repeated measurements within an individual are assumed to be independent observations
from a distribution belonging to the exponential family. This is known as the “conditional
independence assumption” (Laird and Ware, 1982)[57]. In general, the model with random
effects (i.e., Generalized linear mixed effects model) has three parts:
1. The conditional distribution of the jth response yij, given a vector of random effects bi
belongs to the exponential family, V ar(yij|bi) = V ar{E[yij|bi]}φ is a function of the
conditional mean, where φ is a scale parameter, and given bi the y
′
ijs are independent.
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2. The conditional mean depends on fixed covariates and random effects through the linear
predictor: ηij = x
′
ijβ + z
′
ijbi with g{E(yij|bi)} = ηij = x′ijβ + z′ijbi for a pre-specified
link function, g(.).
3. The random effects are assumed to have a multivariate distribution with mean vector 0
and q × q covariance matrix G and independent of the covariates.
2.1.4 Estimation in Generalized Linear Mixed Models
In contrast with marginal models the joint distribution of the vector of responses and the
vector of random effects is fully specified, hence inference and estimation are based on the
likelihood function. Based on the conditional independence assumption, the joint distribution
of the response yi and the random effects, bi can be written as
f(yi|bi) =
n∏
i=1
f(yi|bi)f(bi). (2.1.41)
The frequentist maximum likelihood estimates are then obtained by integrating out or
averaging over the unobserved random effects bi from (2.1.41) to obtain the marginal
likelihood which does not depend on bi (Equation 2.1.42):
L(β, φ,G) =
n∏
i=1
∫
f(yi|bi)f(bi)dbi, (2.1.42)
The maximum likelihood (ML) estimates are therefore the estimates of G, β and φ that
maximize Equation 2.1.42. In most cases, the likelihood in (2.1.42) can not be evaluated
analytically, therefore, numerical approximations are required. Numerical iterative methods
such as the Newton-Raphson (NR) method, the Fisher scoring method, and the EM and
modified EM algorithms are employed to obtain the ML estimates. The NR method is faster
but very sensitive to starting values hence unstable compared to EM algorithms. All in all,
these methods are analytically and computationally very intensive. In the next section, we
introduce the Bayesian Markov Chain Monte Carlo (MCMC) methods of estimation that are
computationally easier.
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2.1.5 Bayesian Methods
In the Bayesian approach, the unknown parameters are treated as random quantities, and
therefore assigned a prior probability distribution that describes the uncertainty about the
parameter values. Bayesian inferences are then based on the posterior distribution, the
conditional probability distribution of the parameters of interest θ, given the observed data
y. The posterior distribution is given by
pi(θ|y) = L(θ|y)pi(θ)∫∞
0
pi(θ)L(θ|y)dθ , (2.1.51)
where pi(θ) is the prior distribution of θ and L(θ|y) is the likelihood function. By ignoring
the normalizing constant (denominator) in 2.1.51, the posterior distribution is
pi(θ|y) ∝ L(θ|y)pi(θ),
which is a function of the likelihood and prior information/distribution. Originally, the EM
and modified algorithms were employed in Bayesian estimations but they can only estimate
the posterior mode and because Bayesian functions are more complex with inclusion of prior
distribution, these estimation methods made Bayesian methods very unattractive. However,
the introduction of MCMC methods has made Bayesian methods very appealing.
The MCMC methodology provides enormous scope for realistic statistical modeling of com-
plex models because they do not use direct integration methods such as Gaussian quadrature
and Laplace approximation (Tierney and Kadane,1986[91]; Shun and McCullagh,1995[84]),
which are computationally very intensive. The MCMC methods simulate direct draws from
some complex distribution of interest, where previous sample values are used to randomly
generate the next sample value, generating a Markov chain (as the transition probabilities
between samples values are only a function of the most recent sample value). From the
Markov chain theory, this chain in the long run converges to a stationary or equilibrium
distribution which is precisely the posterior distribution. There are many ways of constructing
these chains, but most of them, including the Gibbs sampler (Geman and Geman, 1984[29];
Gelfand and Smith,1990[23]), are special cases of the general framework of Metropolis et al.
(1953)[70] and Hastings (1970)[35]. Many MCMC algorithms are hybrids or generalizations
of the simplest methods: the Gibbs sampler and the Metropolis-Hasting algorithm.
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2.1.5.1 The Gibbs Sampler Many statistical applications of MCMC have used the
Gibbs sampler, which is easy to implement. Gelfand and Smith (1990)[23] gave an overview,
and suggested the approach for Bayesian computation. The Gibbs sampling algorithm is
described as follows: Let θ = (θ1, . . . , θq) be the parameters in the model of interest p(θ). Given
an arbitrary set of initial values θ0 =
(
θ01, . . . , θ
0
q
)
, we draw θ
(1)
1 from conditional distribution
P
(
θ1|θ(0)2 , . . . , θ(0)q
)
, then θ
(1)
2 from conditional distribution P
(
θ2|θ(1)1 , θ(0)3 , . . . , θ(0)q
)
and so
on up to θ
(1)
q from P
(
θq|θ(1)1 , . . . , θ(1)q−1
)
to complete one iteration of the scheme. This scheme
is a Markov chain, with equilibrium distribution p(θ) . After t such iterations, we would
arrive at the tth value θ(t) =
(
θ
(t)
1 , θ
(t)
2 , . . . , θ
(t)
q
)
. Thus, for t large enough, θ(t) can be viewed
as a simulated observation from p(θ). In essence, sampling long enough from this scheme will
result in sampling from the posterior distribution itself. So, after discarding an initial set of
samples (called burn-in) the remaining samples constitute the posterior sample from which
all inferences can be drawn.
2.1.5.2 The Metropolis-Hasting algorithm Although, the Gibbs sampler works well
for complex hierarchical models, it is limited to sampling from the full conditionals. When
the conditional distribution is not in closed form, a more general and powerful algorithm
is the Metropolis-Hastings (MH) algorithm formulated by Hastings (1970)[35], which is a
generalization of the method first proposed by Metropolis et al. (1953)[70]. This algorithm
also constructs a Markov Chain, but does not necessarily care about full conditionals. Let
p(θ) be the distribution of interest but suppose it is hard to sample from. Suppose at time
t, θt+1 is chosen by first sampling a candidate point v from a proposal distribution q(·|θt),
which is easy to sample from. The candidate v is accepted with probability
α(θ, v) = min
(
1,
p(v)q(θ|v)
p(θ)q(v|θ)
)
If the candidate point is accepted, the next state becomes θt+1 = v. If it is rejected, the
chain does not move. The proposal distribution can be any kind of continuous probability
density, however, empirical evidence suggests that the more it incorporates the structure
of the problem the faster is the convergence. Several possible proposals are discussed and
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compared by Tierney (1994)[90]. Again, for large enough t and sufficient burn-in period, the
stationary distribution of the chain will be p(θ).
2.1.5.3 Other sampling schemes In addition to these algorithms in pure form, a
number of hybrid schemes are available. For instance, one such scheme consists of combining
the Metropolis steps within the Gibbs sampler (Muller, 1991)[71] when the full conditionals
are formed but difficult to sample from. Here, a Metropolis step can be used to draw
samples from p(θ) by forming proposal densities q(θ|v) and acceptance probabilities α(θ, v)
based on the proposal and conditional posterior distributions of each parameter of interest.
In addition, several algorithms have been developed to improve the convergence of the
MCMC iterations. These include blocking of components (Liu et al.,1994; Cowles,1996;
Gamerman,1997)[63, 13, 20]. Gamerman [20], notes that for Gibbs sampler in pure forms
blocking correlated quantities generally speeds up convergence but the same is not necessarily
true for the Metropolis-Hastings algorithms. Accordingly, he developed an MCMC approach
that uses Metropolis-Hasting algorithm to sample from the posterior distributions of blocks
of correlated parameters (based on their conditional independence structure), which we adopt
in our study. This approach incorporates the structure of the model, that is, the form of
the likelihood and prior, leading to an algorithm requiring a single iterative procedure. In
addition, prior distributions for the regression coefficients and random effects distribution
are not restricted to normality with non-informative cases providing a link with frequentist
approaches. The resulting inference is based on samples from the posterior distribution of
all model parameters and standard assessments such as parameter significance and residual
analysis can be made without having to resort to asymptotic normality results.
2.2 METHODS FOR SURVIVAL ANALYSIS
In survival analysis, the exact survival times of the subjects are not known in most cases.
These are called censored observations or censored times which require special statistical
techniques to handle them. There are different forms of censoring but the most common form
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is right-censoring where an individual may withdraw from the study, be lost to follow-up, or
for economic or practical reasons it may require that the study ends before the outcome has
occurred. This is the censoring we are concerned about in this study.
2.2.1 Notation
Let Ti = min(T
∗
i , Ci) be the failure time and δi = I(T
∗
i ≤ Ci) an event indicator which
indicates whether the observed failure time is a true failure time, T ∗i , or a censoring time Ci
for the ith individual. In addition, let xi
′ = (xi1, xi2, · · · , xip) be a vector of baseline covariates
associated with the ith individual.
2.2.2 Likelihood for Right Censored Data
Given that xi
′ and the pairs of random variables (Ti, δi), i = 1, · · · , n, are independent, the
likelihood for (Ti, δi) conditional on xi
′ can be expressed as:
L(θ) ∝
n∏
i=1
f(ti, θ, xi)
δiS(ti, θ, xi)
1−δi , (2.2.21)
where θ are the parameters to be estimated, f(ti, θ, xi) is the probability density function for
a failure time, and S(ti, θ, xi) is the survival distribution for censored time. Because we can
write f(ti, θ, xi) = h(ti, θ, xi)S(ti, θ, xi) and S(ti, θ, xi) = exp{−H(ti, θ, xi)} the likelihood
(2.2.21) can written as
L(θ) ∝
n∏
i=1
h(ti, θ, xi)
δi exp{−H(ti, θ, xi)}, (2.2.22)
where h(ti, θ, xi) and H(ti, θ, xi) are the hazard and cumulative hazard functions for the i
th
individual, respectively. Simplifying (2.2.22) further gives the likelihood as
L(θ) ∝
n∏
i=1
h(ti, θ, xi)
δi exp
− ti∫
0
h(s, θ, xi)ds
 . (2.2.23)
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2.2.3 Cox proportional hazard model
The Cox proportional hazards model developed by Cox in 1972 is the most widely used
analytic tool for survival analysis [14]. This model has a strong assumption called the
“proportional hazard assumption” which is often violated. The class of accelerated failure
time models is an alternative when the proportionality assumption does not hold. Under the
proportional hazard assumption, the hazard function for the ith individual is
hi(t) = h0(t) exp (x
′
iβ) , (2.2.31)
where β is the vector of regression coefficients and h0(t) is the baseline hazard, which can be
fully parametric, or left unspecified. Maximum likelihood estimates of β in Equation 2.2.31
are obtained from the Cox’s partial likelihood function, L(β)(2.2.32), assuming independence
of failure times.
L(β) =
D∏
j=1
exp
(
x′jβ
)∑
l∈Rj
exp (x′lβ)
, (2.2.32)
where D is the number distinct event times, Rj is called the risk set (individuals who are at
risk at time j), and xj denotes the p× 1 vector of covariates for the individual who has the
event at time j. The estimator βˆ has been shown to be a consistent estimator for β and is
asymptotically normal as the marginal models are correctly specified (Lin, 1994 [61]). The
partial likelhood 2.2.32 can be extended to include time-dependent covariates and rewritten
as
L(β) =
D∏
j=1
exp
(
x′j (tj) β
)∑
l∈Rj
exp (x′l (tl) β)
, (2.2.33)
which can be maximized by iterative techniques, such as the Newton Raphson algorithm but
the Bayesian MCMC methods work best. However, this would imply complete knowledge
of the covariate at each unique event time, which is problematic when one would wish to
include a covariate measured longitudinally over time and examine its effect on an outcome.
The solution to this problem is one of our main goals for this study (see Chapter 4).
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2.2.4 Frailty Models
In the traditional survival analysis models, observations are assumed to be heterogeneous
and the population they come from is assumed to be homogeneous with respect to failure.
In a situation where this is questionable i.e., where some members are more failure-prone
(frail) than others due to unobserved heterogeneity, these models can lead to under- or
over-estimated standard errors of estimates.
Frailties are unobserved effects or unmeasurable genetic factors of an individual (individual-
specific or unshared) or shared by all members of the cluster or group (group-specific or
shared). Hougaard (1995)[47] pointed out that the impact of unmeasured covariates can
lead to transformation of the hazard function and the coefficients of the measured covariates.
There is also strong evidence that the hazard functions often converge in contradiction to the
proportional hazards assumption of the traditional Cox model. Thus, an introduction of a
frailty parameter in the traditional model to handle dependence between survival times is
much realistic (Keiding et al., 1997 [55] and Vaupel et al., 1979 [95]). The hazard for the jth
subject in ith cluster or subgroup, given the frailty wi = (wi1, · · · , wini)′, is defined as
hij(t) = h0(t) exp
(
σwi + x
′
ijβ
)
, i = 1, · · · , G, j = 1, · · · , ni, (2.2.41)
where h0(t) is an arbitrary baseline hazard rate, σ is a vector of parameters associated with
the frailties, xij is a vector of covariates, and β is the vector of coefficients. The frailties
are assumed to be from some distribution with mean zero and variance 1. The Gamma
distribution is the most common (where wij = 1, i.e., exp(σ) ∼ gamma(ζ, ζ) ) due to its
mathematical convenience but other distributions like Uniform, inverse Gaussian and Log-
normal can be considered. We note that when σ = 0 2.2.41 reduces to the proportional
hazards model 2.2.31.
Alternatively, 2.2.41 can be written as
hij(t) = h0(t)wi exp
(
x′ijβ
)
, i = 1, · · · , G, j = 1, · · · , ni. (2.2.42)
From 2.2.42, it is clearly seen that when wi > 1 individuals within a given group tend to
fail faster than those with wi < 1. Because the w
′
is are unobserved, estimation methods in
GLMM (Sections 2.1.4 and 2.1.5) are employed to estimate the parameters in frailty models.
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2.2.5 Common Parametric Survival Distributions
While in a Cox model (nonparametric), h0(t) is left unparameterized, in the parametric
approach a functional form for h0(t) is specified. The only requirement is that the survival
distribution be bounded between 0 (S(∞) = 0) and 1 (S(0) = 1). For instance, if
h0(t) = exp(α),
for some α then we have an exponential distribution. Here the baseline hazard is assumed
constant over time. If we assume
h0(t) = λt
λ exp(α),
then we have the Weibull model (see Klein and Moeschberger[56] for a more distributions).
Parameter estimation in parametric models is much easier than in semi-parametric ones. By
assigning prior distributions to parameters, the Bayesian methods in Section 2.1.5 are also
employed to estimate parameters by sampling from their respective full conditionals.
2.3 JOINT MODELING
In Sections 2.1 and 2.2, we introduced the general methods for modeling longitudinal and
survival data in a univariate setting, respectively. However, in biomedical studies where more
than one biomarker of the disease is measured over time on each individual as well as a set
of random times at which events of interest occur (time-to-event), joint modeling of either
longitudinal biomarkers together or longitudinal biomarker(s) with time-to-event has been
employed to improve the efficiency of the parameter estimates as they tend to account for
the variability that exists between or among the different processes.
2.3.1 Joint modeling of multiple longitudinal outcomes of mixed types
Joint modeling of longitudinal outcomes of mixed types has been shown to lead to efficient
estimates. For instance, Guerguieva and Sanacora (2006)[33] who studied joint models of
repeatedly observed continuous and ordinal measures of the same underlying disease severity
noted that when the trajectories over time may be related but measure distinct underlying
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trends, separate analyses may be more appropriate. However, accounting for the associations
between various outcomes through joint modeling leads to more efficient estimates compared
to separate analyses. Similar results were observed by McCulloch (2008)[69] who showed that
joint modeling leads to efficiency gain while separate analyses of mixed types longitudinal
outcomes can be inefficient. Also, when the data on one of the outcomes are more complete
than another then joint modeling can accommodate data that are missing at random instead
of the stronger assumption of missing completely at random (MCAR).
Several approaches have been proposed to jointly model multiple outcomes of mixed
types but there are two key approaches. The first approach uses the product of marginal
and conditional distributions. Letting y1 and y2 represent the continuous and discrete
outcome, respectively. Using the product of marginal and conditional distributions, the joint
distribution of y1 and y2 can be written as
f(y1,y2) = f(y1)f(y2|y1) = f(y2)f(y1|y2).
In this formulation, it is possible to have different results depending on whether the condi-
tioning variable is discrete or continuous. A major drawback of this method is that it is hard
to get easy expressions for the association between both continuous and discrete outcomes,
and it does not directly lead to marginal inference. In addition, in case of more than two
outcomes, there will be many more possible factorizations instead of only the two associated
with two outcomes. In this regard, the conditional model may not be the best choice in high
dimensional longitudinal data.
The second approach is that of random effects. In this method, different outcomes are
joined by imposing a common distribution for their random effects. These can be shared
(i.e., bi2 = γbi1) where bi2 is assumed proportional to bi1 with a restrictive correlation
structure between the two outcomes or correlated where bi1 and bi2 are assumed to follow a
multivariate distribution with a nonrestrictive covariance structure, which can be unstructured,
Toeplitz, exchangeable, etc. In general, the correlated random effects model allows for flexible
correlation structure but it has a disadvantage of high-dimensional vector of random effects
as the number of outcome variables gets large.
Catalano and Ryan (1992)[12] used the concept of a latent variable to derive the joint
distribution of a continuous and binary outcome for clustered data. The joint distribution
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was a product of a standard random effects model for the continuous variable and a correlated
Probit model for the discrete (binary) variable. Thus, they considered a linear regression
mode1 (2.3.11) on the latent variable yij:
yij = β0 + β1di + ij, ij ∼ N(0, σ2), (2.3.11)
where di is a vector of covariates for the i
th individual. The observed binary variable y∗ij and
the latent variable yij are such that:
y∗ij =
 1 if yij > 00 if yij ≤ 0, (2.3.12)
Then from the normal model (2.3.11), it follows that y∗ij follows a probit model
P (y∗ij = 1|di) = Φ
(
β0 + β1di
σ
)
(2.3.13)
They considered the bivariate model (2.3.14) for the observed continuous variable y1ij and
unobserved latent variable y2ij:
y1ij = α0 + α1di + 1ij
y2ij = β0 + β1di + 2ij
(2.3.14)
where,
ij =
 1ij
2ij
 ∼ N
 0
0
 ,
 σ21 τσ1σ2
τσ1σ2 σ
2
2
 .
And a probit model (2.3.15) for the unobserved latent variable y∗2
P (y∗2ij = 1|di) = Φ
(
β0 + β1di
σ
)
(2.3.15)
The joint distribution of the observed continuous y1ij and observed binary y
∗
2ij was formed as
a product of marginal and conditional distributions,
fy1ij ,y∗2ij(y1, y
∗
2) = fy1ij(y1)fy∗2ij(y
∗
2|y1),
The two processes were linked through the residual errors. Parameter estimation was done
in two steps using Generalized Estimating equations (Liang and Zeger, 1986; and Zeger
and Liang, 1986)[60, 103]. In the first step they estimated the parameters of the marginal
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distribution and in the second step they estimated the parameters of the correlated probit
model. Catalano (1997)[11] extended this approach to jointly model continuous and ordinal
outcomes, where the ordinal response was modeled using a correlated Probit model.
Fitzmaurice and Laird (1995)[19] also used the same product method to jointly model
binary and continuous outcomes with clustering but conditioned on the discrete outcome.
They assumed a Bernoulli distribution for the binary response Yi and a Gaussian distribution
for the continuous response Xi. The joint model was a product of marginal distribution of
binary and conditional distribution of the continuous response, i.e.,
fXi,Yi(xi,yi) = fYi(yi)fXi|Yi(xi|yi).
The marginal distribution of the binary response was related to covariates using a logit
link function, whereas the conditional distribution of the continuous response was related
to covariates using a linear link function with a conditional mean that depends on the
binary response. Thus, this dependence induced association or correlation between the two
responses. The parameters were estimated using GEE (Liang and Zeger, 1986)[60]. Here,
the regression parameters have a marginal interpretation because the models do not include
random (subject–specific) effects.
Furthermore, Gueorguieva and Agresti (2001)[32] proposed a correlated probit model for
joint modeling of clustered binary and continuous responses by employing a linear mixed
effects model for the continuous observed and unobserved latent variable as suggested by
Catalano and Ryan [12] but instead modeled the two outcomes through shared random effects.
In addition, they used Monte Carlo Expectation-Conditional maximization (ECM) algorithm
which is a modification of EM algorithm for parameter estimation. While Gueorguieva and
Sanocora (2006)[33] extended the method of Gueorguieva and Agresti to model the ordinal
and continuous responses. These models were rewritten so as to be fit using maximum
likelihood with standard software using procedures like NLMIXED in SAS or GLLAMM in
STATA.
In summary, other than Fitzmaurice and Laird who modeled the binary outcome as a
Bernoulli linked to its covariates by a logit link and the continuous outcome as a Gaussian
with a linear link function, the other authors employed the latent variable approach where the
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binary/ordinal observed response is modeled with a Probit/correlated Probit model and its
underlying latent continuous variable and the observed continuous response with linear mixed
effects model. This enabled the two responses to be modeled jointly as a bivariate normal,
linked through either correlated residual errors or shared random effects. However, much as
the Probit and Logistic models are both used in modeling binary or ordinal data and both
have symmetric S-shape cumulative distributions, the logistic places more probability in the
tails than does the Probit and hence more stable when dealing with outlying data. In addition,
the logistic link function is more popular in the biomedical field and the interpretation is
easier than the probit link function.
2.3.2 Joint modeling of longitudinal outcomes and time-to-event
In Section 2.3.1, we gave a review of literature in relation to joint modeling of longitudinal
outcomes of mixed types, however, the concept of joint modeling has been widely used in
simultaneous modeling of longitudinal outcomes and time-to-event data. The goal of joint
modeling in this context include (1) Modeling the distribution of the time to a terminal
event conditional on a longitudinal measurement sequence. This kind of modeling was first
used in AIDS research, where CD4 cell count or estimated viral load was used to predict
the time to onset of clinical AIDs (e.g. Tsiatis, DeGruttola, and Wulfsohn, 1995)[94]. The
primary interest here was in survival time but the longitudinal measurements were used as
time-varying covariate. (2) Adjusting inference about a longitudinal measurement sequence
to allow for informative dropout. That is, the absence of longitudinal observations beyond
the event time is a form of non-ignorable missingness, so that a joint distribution is specified
for the longitudinal and missingness (survival) processes (e.g. Hu and Sale, 2003)[48]. (3)
Modeling the joint evaluation of a measurement and an event-time process. For instance, in
the Diabetes study, our interest is to model jointly the time to when blood glucose reaches
normal range and the longitudinal evolution of cheaply measured markers that are associated
with diabetes progression such as systolic and diastolic blood pressure and body mass index
(BMI).
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Joint models that combine the longitudinal and time-to-event processes have been widely
studied by different authors. Hogan and Laird (1997a)[44], Tsiatis and Davidian (2004)[93],
and Ibrahim, Chen, and Sinha (2001, Chapter 7)[51] give a detailed discussion of joint
modeling. Pawitan and Self (1993)[73], DeGruttola and Tu (1994)[16], Tsiatis, DeGruttola,
and Wulfsohn (1995)[94], Faucett and Thomas (1996)[18], Lavalley and De Gruttola (1996)[58],
Wulfsohn and Tsiatis (1997)[100], Henderson, Diggle, and Dobson (2000)[42], Xu and Zeger
(2001a)[101], Tsiatis and Davidian (2001)[92], Wang and Taylor (2001)[97], Guo and Carlin
(2004)[34], Brown and Ibrahim (2003) [6, 7], Ibrahim, Chu, and Chen(2010)[52], Wang, Shen,
and Boye (2012)[96], Huang, Hu, and Dagne (2014)[49] all have worked on one longitudinal
outcome and time-to-event processes. Rizopoulos and Ghosh (2010)[79] and Hatfield, Boye,
and Carlin (2011)[36] extended the longitudinal outcome to the multivariate case.
In most of the literature cited above, the joint modeling of the survival and longitudinal
components is usually done by assuming that the longitudinal model follows a linear mixed
effects model and that the survival model depends on the random effects from this process.
Inference is then based on the integrated conditional joint likelihood where the random
effects usually follow a multivariate normal distribution. Initially the two processes are
assumed to be conditionally independent given the data and parameters of interest and
only correlated through the induced random effects or the underlying latent process. For
instance, Henderson, Diggle, and Dobson (2000)[42] linked the longitudinal and survival
model with two correlated latent Gaussian processes allowing the trend to vary with time.
They assumed that longitudinal and survival data are conditionally independent given
the linking latent process and covariates. Given there are n subjects with longitudinal
measurements {yij : j = 1, · · · , ni} at times {tij : j = 1, · · · , ni}. When the interval of
follow-up is [0, τ), let {Ni(s) : 0 ≤ s ≤ τ} denote a counting process for the events and
{Hi(s) : 0 ≤ s ≤ τ} denote an indicator for whether the subject is at risk of an event at
time s. Let Wi(t) = {W1i(t),W2i(t)} denote a latent zero-mean bivariate Gaussian process,
which is realized independently in different subjects. They considered the following model for
longitudinal data:
yij = µi(tij) +W1i(tij) + ij,
where ij is a measurement error term assumed to be mean-zero normally distributed with
20
var(ij) = σ
2
 and µi(tij) is the mean response assumed by a linear model
µi(tij) = x1i(t)
Tβ1
in which the vectors x1i(t) and β1 represent possibly time-varying covariates and their
corresponding regression coefficients, respectively. For the survival model, they considered a
semi-parametric multiplicative model:
λi(t) = Hi(t)α0(t) exp{x2i(t)Tβ2 +W2i(t)},
with the form of α0(t) left unspecified. In contrast with Tsiatis, DeGruttola, and Wulfson
(1995)[94], Faucett and Thomas (1996)[18], and Wulfsohn and Tsiatis (1997)[100] worked
with similar models but assumed W1i(t) = U1i + U2it and W2i(t) proportional to W1i(t),
Henderson et al.[42] defined W1i(t) and W2i(t) respectively as
W1i(t) = Z1i(t)
TU1i + V1i(t) and W2i(t) = γ1U1i + γ2U2it+ γ3(U1i + U2it) + U3i,
where Z1i(t) is a vector of covariates, U1i is a corresponding vector of random effects that
follow a multivariate normal distribution with mean zero and variance-covariance matrix Σ1,
V1i(t) is a stationary Gaussian process with mean zero, variance σ
2
v1 and correlation function
r1(s) = cov{V1i(t), V1i(t− s)}/σ2v1, and the frailty term U3i ∼ N(0, σ23) is independent of the
(U1i, U2i). The parameters γ1, γ2, and γ3 measure the association between the longitudinal
and survival models induced through the random intercepts, slopes, and the current value of
W1i at time t. They estimated the parameters using EM algorithm proposed by Wulfsohn
and Tsiatis [100] in 1997 and noted the identifiability problems which can arise when W2i(t) is
allowed to be time-varying in conjunction with a non-parametric specification of the baseline
intensity λ0(t).
Other authors have used similar general methods but with different distributions for
the survival and/or longitudinal process or estimation procedures. For instance, Faucett
and Thomas (1996)[18] used a linear mixed model and Bayesian methods for the parameter
estimation. Xu and Zeger (2001a)[101] used a latent variable approach and implemented a
Markov Chain Monte Carlo Algorithm for the estimation, and De Gruttola and Tu (1994)[16]
implemented a fully parametric joint model by assuming that the survival and longitudinal
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processes follow a multivariate normal distribution by transformation of the survival times to
follow a normal distribution and estimation was via the EM algorithm. Tsiatis et al.(1995)[94]
used a two stage approach (Partial likelihood approach), where the true value of the covariate
at the event time was estimated by a linear mixed effects model in the first stage and then
substituted into the hazards model in the second stage. Guo and Carlin (2004)[34] used the
flexible joint model proposed by Henderson et al. (2000)[42] but used Bayesian approach
via MCMC for parameter estimation. While Rizopoulos and Ghosh (2010)[79] proposed a
Bayesian semiparameteric multivariate joint model that relates multiple longitudinal outcomes
(Continuous and binary) and time-to-event. They used a spline-based approach to model the
subject specific longitudinal evolutions and the baseline risk function in the Cox model for
time-to-event outcome was assumed piece-wise constant.
Most of the joint models in the literature above (Section 2.3.2) are for one continuous
longitudinal outcome and time-to-event. To the best of our knowledge, no one has worked on
joint modeling of continuous, ordinal, and time-to-event outcomes.
2.4 OUR CONTRIBUTION
In Section 2.3.1, we noted that all of the previously proposed joint models for continuous and
ordinal outcomes employed the Probit link function to model the ordinal outcome because of
its flexibility (underlying normal framework) to reduce the computational burden. However,
there are several disadvantages of using a Probit link as compared to Logit link functions. In
addition, EM or modified EM algorithms were employed for parameter estimation which are
computationally very intensive. Furthermore, no work has been done on joint modeling of
continuous, ordinal, and time-to-event outcomes (Section 2.3.2). Thus, we propose a joint
model for unbalanced repeatedly measured continuous and ordinal outcomes and time-to-event
data. In the first part we develop a model for continuous and ordinal outcomes (Aim 1).
Here, we employ a Cumulative Logit link function for the ordinal outcome and identity link
function for the continuous outcome and model the two outcomes jointly as a multivariate
generalized linear mixed effects model linked through correlated and/or shared random effects.
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Secondly, we extend the model in Aim 1 to include time-to-event (Aim 2). Time-to-event is
modeled parametrically using a Weibull distribution with an unshared frailty model. The
Bayesian approach (i.e. MCMC) is employed for parameter estimation in both parts because
it has the capacity to handle complex models with ease. The Aim 1 of this work is described
in Chapter 3, while Aim 2 work, is discussed in Chapter 4.
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3.0 BAYESIAN HIERARCHICAL JOINT MODELING OF REPEATEDLY
MEASURED CONTINUOUS AND ORDINAL MARKERS OF DISEASE
SEVERITY
3.1 INTRODUCTION
In many clinical studies, more than one biomarker of disease severity is obtained and some
may be easier and cheaper to obtain than others. Although these biomarkers are often meant
to measure the same disease severity, they may differ due to the instruments/reagents used
as well as the scale of measurements. They could show different patterns for treatment
because clinicians prescribe medications based on the severity of disease. Moreover, if these
markers are modeled separately to determine the factors that are associated with disease
progression over time or to predict the event of interest (i.e. time to remission) given different
treatments, they may yield different or misleading results. Modeling these markers jointly
while accounting for correlation between the two markers is likely to provide more valid
results.
The motivation for our study is based on data collected retrospectively from medical
registries of diabetic patients in three Ugandan hospitals. These patients were recruited in the
diabetic clinics between January 1992 and December 2004. Diabetes which is a progressive
illness occurs when the pancreas does not produce enough insulin or when the body does
not respond properly to varying levels of insulin. This results in increased concentrations of
glucose in the blood, which in turn damages many of the body’s systems, in particular the
blood vessels and nerves. Thus, the amount of glucose in the blood determines the state of
the disease at a point in time. In addition, the amount of glucose in the urine is used to detect
if the individual’s blood glucose level is above the renal threshold of 180 mg/dl. The amount
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of glucose in the urine is interpreted using the + symbolic method or the actual amount in
the urine(mg/dl) depending on the manufacturer of the urine glucose reagent strips. That
is, Nil (no urine sugar),+(≈ 100 mg/dl), + + (≈ 250 mg/dl), + + +(≈ 500 mg/dl), and
++++(≈ 1000 mg/dl), respectively. Of the two biomarkers, blood glucose which is measured
by fasting plasma glucose test (FPG) or oral glucose tolerance test (OGTT) is more accurate
and hence recommended by both the World Health Organization (WHO) and the American
Diabetes Association (ADA). The urine glucose tests to detect Glycosuria/Glucosuria (glucose
in urine) are used as an alternative to blood glucose tests especially in developing countries
because they are fast, do not require many reagents, easy to carry out and generally economical
(Carter and Lema, 2003)[10]. However, it is important to note that the urine glucose test
for diabetes may be contaminated by drugs and individual variations in renal threshold for
glucose. Thus, making a clinical decision based on a urine test alone may be invalid or
misleading.
During the hospital visits (follow-up period), the patients in the Ugandan study were
periodically tested for the amount of glucose in the blood or urine or both to determine
the severity of the disease so as to prescribe appropriate medication. The data are highly
unbalanced because this was an observational study where patients reported for checkup
at irregular intervals with the number of hospital visits varying from patient to patient.
Clinically, the two markers measure the same diabetes severity although blood glucose is
continuous and urine glucose is ordinal with five levels. Thus, for analysis purposes, joint
modeling of the two markers simultaneously will produce optimal results because the two
markers are highly correlated. In addition, an appropriate way of handling the unbalanced
data will result in efficient estimates.
Joint modeling of longitudinal outcomes with mixed types have been studied by many
authors. Catalano and Ryan (1992)[12], Guergieva and Agresti (2001)[32], Fitzmaurice
and Laird (1995)[19] have worked on the combination of binary and continuous responses.
Guerguieva and Sanacora (2006)[33], and Catalano (1997)[11] have dealt with a combination
of ordinal and continuous responses. In modeling the relationship between the two processes,
they used random effects (Guerguieva and Sanacora, 2006)[33] or the product of marginal
distribution and conditional distributions where the association is induced through the mean
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responses (Fitzmaurice and Laird, 1995) or correlated residual errors (Catalano and Ryan,
1992[12]; Guergieva and Agresti, 2001[32]; Catalano, 1997[11]). Although, the random effects
approach has the disadvantage of handling high-dimensional vectors of random effects, the
product distribution approach can lead to very different results depending on whether the
conditioning variable is discrete or continuous. It can also be difficult to obtain easy expressions
for the association between both continuous and discrete outcomes and it does not directly lead
to marginal inference. Fitzmaurice and Laird[19], Catalano and Ryan[12], and Catalano[11]
used the generalized estimating equations (GEE) approach of Liang and Zeger (1986)[60]
for parameter estimation whereas Guerguieva and Sanacora[33] parameterized their models
to be fit using NLMIXED procedure in SAS (Wolfinger, 1999)[99] which employs Gaussian
quadrature methods to obtain the maximum likelihood (ML) estimates. Gueorguieva and
Agresti[32] employed a modified EM algorithm or Monte Carlo ECM algorithm for parameter
estimation. Compared with ML approaches, the GEE method is computationally easy to
implement and leads to consistent parameter estimates even when the working correlation
structure is misspecified under mild regulatory conditions. However, GEE is not a likelihood-
based method and hence it is difficult to determine the goodness of fit of a model, to compare
models, and to draw statistical conclusions on the model parameters. In addition, it will only
produce consistent estimates for unbalanced data or missing data when the data are missing
completely at random (Little and Rubin, 1987)[62]. On the other hand, both the Gaussian
quadrature and the Monte Carlo ECM algorithm methods are computationally very intensive.
This computational burden grows exponentially with the number of random effects in the
model. In this paper, we propose a hierarchical joint model to handle unbalanced repeatedly
measured continuous and ordinal markers of disease severity. We employ the Markov Chain
Monte Carlo (MCMC) method for parameter estimation because it has the capacity to handle
high-dimensional data with ease.
The remainder of this chapter is organized as follows: Section 3.2 presents the formulation
of the multivariate generalized linear mixed effects model, the associated joint likelihood, and
the prior and posterior distributions. Sections 3.3 and 3.4 show the estimation procedures
of the parameters from their full conditionals and the convergence diagnostics and model
assessment tools, respectively. Section 3.5 shows the simulation study and Section 3.6
indicates the application of the proposed joint model to diabetes data.
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3.2 MODEL SPECIFICATIONS
3.2.1 Model formulation
Let yi = (y
′
i1,y
′
i2, . . . ,y
′
iL)
′, denote the L-variate response vector for ith subject (i = 1, . . . , n),
where yil, l = 1, . . . , L, is an nil × 1 vector of longitudinal biomarker for a certain disease
severity taken at time points, j = 1, . . . , nil. For instance, yi1 and yi2 can be a vector of blood
glucose and urine glucose levels for the ith patient, respectively. Because these responses
are assumed to have different scales of measurements (i.e., continuous, ordinal), for each
response, we adopt a generalized linear mixed effects model (GLMM) which is an extension of
generalized linear model (GLM) (Nelder and Wedderburn, 1972[72]; McCullagh and Nelder,
1989[68]). In particular, marginally, the conditional distribution of yil given a vector of
random effects bil is assumed to be a member of exponential family, with linear predictor
given by
gl(µij,l) = gl(E[yij,l|bil]) = ηij,l, (3.2.11)
where gl(·) denotes a known one-to-one monotonic link function, and yij,l denotes the value
of the lth longitudinal outcome for the ith subject at jth time point. The unknown function
ηij(·) is assumed to describe the true, presumably nonlinear, longitudinal profile for the lth
outcome (Rizopoulos and Ghosh, 2011)[79].
In general, the distribution of the jth component of the lth vector yil is given by
fl(yij,l|bil) = exp
[
yij,lθij,l − b(θij,l)
φl
+ c(yij,l, φl)
]
, (3.2.12)
where θij,l is the canonical parameter, φl is the scale parameter for the l
th outcome. The
conditional mean µij,l = E(yij,l|bil) is related to the canonical parameter θij,l via µij,l = b′(θij,l)
and to the regression coefficients via the link relation gl(µij,l) = ηij,l = x
′
ij,lβl + z
′
ij,lbil,
where xij,l is an p × 1 covariate vector and zij,l is an r × 1 design vector for random
effects. The conditional variance vij,l = Var(yij,l|bil) is a function of the mean, that is,
vij,l = b
′′(θij,l)φl = vl(µij,l)φl. The link and variance functions gl and vl, respectively, and
the scale parameter φl are assumed to be known. Because we have repeatedly measured
outcomes where observations are correlated, the linear predictor includes the fixed effects
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and random effects and hence is modeled as a multivariate GLMM. Conditional on these
random effects, the outcomes are assumed to be independent and the repeated measurements
within an individual are assumed to be independent observations from a distribution fl(·).
This is referred to as the “conditional independence assumption” (Laird and Ware, 1982)[57].
Thus, the shared latent terms or the random effects bil account for all dependencies among
the observed data (Diggle et al., 2002, pp.129)[17]. The random effects bil are mutually
independent with a common underlying multivariate distribution gl(bil; Γl).
Let θ denote a vector of parameters, which is a conglomerate of outcome-specific parame-
ters θ1, θ2, . . . , θL, i.e., θ = (θ1, θ2, . . . , θL). Then we model the joint distribution of yi based
on full conditional independence assumption as
f(yi|bi, θ) =
L∏
l=1
fl(yil|bil, θl). (3.2.13)
To estimate the parameters of interest using Bayesian methods, we specify the priors for the
parameters and then the posterior inference is obtained by using the likelihood to convert
prior uncertainty into posterior probability statements. The joint posterior of the parameters
based on the observed data y and random effects bi is
pi(θ|y,bi) ∝
n∏
i=1
L∏
l=1
fl(yil|bil, θl)× pi(θ1, θ2, . . . , θL), (3.2.14)
where pi(θ1, θ2, . . . , θL) denotes the prior distribution of θ. Because random effects are
unknown, they need to be included in the posterior distribution and then integrated over
to obtain the marginal posterior distributions of the parameters of interest. Thus, the joint
posterior distribution for bi and other parameters of interest is given by the hierarchical
model
pi(θ,bi|y) ∝
n∏
i=1
L∏
l=1
fl(yil|bil, θl)g(bi|Γ)× pi(θ1, θ2, . . . , θL)pi(Γ). (3.2.15)
Motivated by our data set, we consider two response variables, continuous and ordinal and
hence, yi = (yi1,yi2) with identity and logit links, respectively. Specifically, for the continuous
outcome, we have
yij,1 = x
′
ij,1β1 + z
′
ij,1bi1 + ij,1, (3.2.16)
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where i1 ∼ N(0, σ2e1) is the measurement or intra-subject error and the linear predictor or
mean is given as
µij,1 = E [yij,1|bi1] = ηij,1 = x′ij,1β1 + z′ij,1bi1.
For the ordinal response variable yi2 with K ordered categories coded as k = 1, 2, · · · , K, we
define the conditional cumulative probabilities for the K categories as
pijk,2 = Pr(yij,2 ≤ k) =
k∑
m=1
pijm,2, (3.2.17)
where pijk,2 represents the conditional probability of response being in category k, k =
1, . . . , K, of the ith subject at the jth time point. Then the logistic GLMM for the conditional
cumulative probabilities is given in terms of the cumulative logit as
log
[
pijk,2
1− pijk,2
]
= ηijk,2 = αk −
[
x′ij,2β2 + z
′
ij,2bi2
]
, (3.2.18)
with K − 1 strictly increasing model thresholds αk (i.e., α1 < α2 · · · < αK−1). The thresholds
allow the cumulative response probabilities to be different. For identifiability, either the first
threshold α1 or the model intercept β20 ∈ β2 is usually set to zero. In this formulation, we
are assuming the proportional odds assumption (McCullagh, 1980 [67]) where the covariates
do not vary across categories. The conditional probability of a response in category k is
obtained as the difference of two conditional cumulative probabilities:
piijk = Pr(yij,2 = k|bi2, xi2, zi2) = Ψ(ηijk,2)−Ψ(ηijk−1,2), (3.2.19)
where Ψ(ηijk,2) is the logistic cumulative distribution function (cdf) given as
Ψ(ηijk,2) =
exp(ηijk,2)
1 + exp(ηijk,2)
=
1
1 + exp(−ηijk,2) .
Here, α0 = −∞ and αK =∞ , and so Ψ(ηij0,2) = 0 and Ψ(ηijK,2) = 1. Thus, the proposed
multivariate generalized linear mixed effects model assumes
yij,1|bi1 ∼ N
(
x′ij,1β1 + z
′
ij,1bi1, σ
2
e1
Ini
)
,
(yij1,2, . . . , yijK−1,2)|bi2 ∼ multinomial(piij1, . . . , piijK−1).
(3.2.110)
The random effects bi1 and bi2 are assumed to follow a Gaussian distribution with mean
vectors of zeros and precision matrices Γ1
−1 and Γ2−1, respectively. In this paper, we
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investigate both the shared and correlated random effects. In the shared random effect
model, bi2 is assumed proportional to bi1 (e.g. bi2 = γbi1) with a restrictive correlation
structure between the two outcomes while in the correlated random effects model, bi1 and bi2
are assumed to follow a multivariate distribution with a nonrestrictive covariance structure,
which can be unstructured, Toeplitz, exchangeable, etc. In this particular case, with just two
processes we considered the simple correlation structure.
3.2.2 Likelihood, Prior, and Posterior distribution for the proposed model
Let θ1 =
{
β1, σ
2
e1
}
, θ2 = {β2, α} where α = (α1, . . . , αK−1) are the ordered threshold parame-
ters for ordinal process, θ = (θ1, θ2), and Γ = (Γ1,Γ2) denote the parameters associated with
the continuous, ordinal, combined processes, and random effects, respectively. In addition, let
y1 and y2 be the observed continuous and ordinal data, and b the combined random effects.
Under the correlated normal random effect model, the joint likelihood of the two processes is
then given as
L(θ,Γ|b,y) = L1(θ1|b,y1)L2(θ2|b,y2)g(b1,b2|Γ)
=
n∏
i=1
[
ni1∏
j=1
1
(2piσ2e1)
1/2
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}]
×[
ni2∏
j=1
K∏
k=1
{Ψ(ηijk,2)−Ψ(ηijk−1,2)}yijk,2
] [ |Γ|−1/2
2pi
exp
{
−bi
′Γ−1bi
2
}]
,
(3.2.21)
where
µij,1 = x
′
ij,1β1 + z
′
ij,1bi1, Ψ(ηijk,2) =
exp(αk−µij,2)
1+exp(αk−µij,2) , Ψ(ηijk−1,2) =
exp(αk−1−µij,2)
1+exp(αk−1−µij,2) , and
µij,2 = x
′
ij,2β2 + z
′
ij,2bi2.
Furthermore, let β˚1 and β˚2 , Σ˚1 and Σ˚2 denote the mean vectors and variance-covariance
matrices for β1 and β2, respectively. We assume non-informative multivariate normal priors
for the β′s, β1 ∼ MVN
(
β˚1, Σ˚1
)
, β2 ∼ MVN
(
β˚2, Σ˚2
)
and truncated normal prior for
the thresholds α, αk ∼ N (µαk , σ2α) I(αk−1, αk+1) k = 1, . . . , K − 1, where I(·, ·) denotes
truncation to specified interval, by having large variances or small precision. Alternatively,
a uniform prior could be used for the thresholds. Furthermore, an Inverse Wishart prior is
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assumed for the variance-covariance matrix of the random effects (Γ ∼ IW (ν,Λ)) and an
Inverse Gamma for the error variance σ2e1 , that is, σ
2
e1
∼ IG(ζ, ω), which are both conjugate
priors for the variance-covariance matrix in the multivariate and univariate normal likelihoods,
respectively (Carlin and Louis, 2009)[9]. We choose non-informative priors so that the priors
will have little impact relative to the data on the inferences made. Then given the prior
distributions of all unknowns, and the observed data, the full conditional assumption presented
in Section 3.2 implies that the joint posterior distribution can be expressed as
pi (θ,Γ,b|y) ∝ L(θ,Γ|b,y)pi (θ) pi (Γ)
∝ L(θ,Γ|b,y)× (σ2e1)−(ζ+1) exp{− ωσ2e1
}
× exp
{
−1
2
(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)}
×
K−1∏
k=1
exp
{
−(αk − µα)
2
2σ2α
}
I[.,.] (αk)
× exp
{
−1
2
(
β2 − β˚2
)′
Σ˚−12
(
β2 − β˚2
)}
× |Γ|−ν/2 exp
{
−1
2
tr
(
Γ−1Λ
)}
,
(3.2.22)
where L(θ,Γ|b,y) is given by Equation (3.2.21). For ease of sampling, the parameters are
divided into blocks of correlated parameters based on their conditional independence. The
full conditional posterior distributions for the blocks β1, σ
2
e1
, (α, β2), b, and Γ are then
determined by averaging the joint posterior distribution (3.2.22) over or integrating out the
remaining parameters. Let pi(θ|.) represent the full conditional distribution of parameter θ
given other parameters in the model. The full conditionals for the blocks β1 and (α, β2) are
given as:
pi
(
β1|σ2e1 ,bi1
)
∝ exp
{
−1
2
(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)}
× exp
{
− 1
2σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
}
∝ N (β1∗,Σ1∗) ,
(3.2.23)
where β∗1 = Σ1
∗ ×
[
Σ˚−11 β˚1 +X
′
1σ
−2
e1

]
,Σ1
∗ =
[
Σ˚−11 +X
′
1X1σ
−2
e1
]−1
,
 =
n∑
i=1
ni1∑
j=1
(yij,1 − zij,1bi1).
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pi (α, β2|bi2) = pi (α|bi2) pi (β2|α,bi2)
∝
K−1∏
k=1
exp
{
−(αk − µα)
2
2σ2α
}
I[αk−1,αk+1] (αk)×
n∏
i=1
ni2∏
j=1
K∏
k=1
{
exp(αk − µij,2)
1 + exp(αk − µij,2) −
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2)
}yijk,2
× exp
{
−1
2
(
β2 − β˚2
)′
Σ˚−12
(
β2 − β˚2
)}
(3.2.24)
The full conditional posterior distributions for blocks σ2e1 , b, and Γ are derived in the similar
manner as:
pi
(
σ2e1|β1,bi1
)
∝
(
σ2e1
)−n(ζ+1)
exp
{
− ω
σ2e1
}
×
n∏
i=1
ni1∏
j=1
1
(σ2e1)
1/2
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}
∝
(
σ2e1
)−n(ζ+1)
exp
{
− ω
σ2e1
}
× (σ2e1)−n/2 exp
{
− 1
2σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
}
∝
(
σ2e1
)−( 2ζ+n2 +1) exp{− 1
σ2e1
[
ω +
1
2
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
]}
∝ IG
(
ζ +
n
2
, ω +
1
2
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
)
(3.2.25)
pi (b|.) ∝ |Γ|−n/2 exp
{
−1
2
n∑
i=1
b′iΓ
−1bi
}
× |Γ|−ν/2 exp
(
−1
2
tr
(
Γ−1Λ
))
× exp
{
− 1
2σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
}
×
n∏
i=1
ni2∏
j=1
K∏
k=1
{
exp(αk − µij,2)
1 + exp(αk − µij,2) −
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2)
}yijk,2
(3.2.26)
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pi (Γ|b) ∝ |Γ|−n/2 exp
{
−1
2
n∑
i=1
b′iΓ
−1bi
}
× |Γ|−ν/2 exp
(
−1
2
tr
(
Γ−1Λ
))
∝ |Γ|−(n+ν)/2 exp
(
−1
2
tr
[
Γ−1
(
Λ +
n∑
i=1
bib
′
i
)])
∝ IW
(
ν + n,Λ +
n∑
i=1
bib
′
i
)
.
(3.2.27)
3.3 ESTIMATION
The parameters of interest are estimated by drawing random variates from their full condi-
tional posterior distributions. To estimate, the variance-covariance parameters σ2e1 ,Γ, Gibbs
sampling is employed, while for the fixed and random effects parameters, (β1, α, β2) and
bi, Gamerman’s one step Metropolis-Hasting (M-H) method is employed to sample from
their respective conditional posterior distributions (Gamerman, 1997)[20]. In this one step
M-H method, the full conditionals of the parameters of interest are approximated by a
Gaussian distribution, which is obtained by accomplishing one Fisher scoring step in every
iteration of the sampler. In essence, to estimate parameter ϕ using a single iterative method
of Gamerman[20], the following steps are taken.
Step 1: Start with ϕ = ϕ(0) and set t = 1;
Step 2a: Sample ϕ∗ from N(m(t), c(t)) proposal density and
Step 2b: Accept it with probability λ(ϕ(t−1), ϕ∗) and set ϕ(1) = ϕ∗; Otherwise, stay at
ϕ(t) = ϕ(t−1);
Step 3: Increase t by 1 and return to Step 2.
The moments of the proposal density are given by
m(t) = (Σ−1ϕ +X
′W (ϕ(t−1))X)−1 × {Σ−1ϕ µϕ +X ′W (ϕ(t−1))[y˜(ϕ(t−1))− η˜]}
c(t) = (Σ−1ϕ +X
′W (ϕ(t−1))X)−1 (3.3.01)
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where µϕ and Σϕ are respectively, the mean and variance-covariance matrix of the prior
distribution for ϕ, W (ϕ(t−1)) = diag(W11, · · · ,Wnni) is the usual weight matrix for iterative
weighted least squares (IWLS) algorithm. The vector η˜ known as the offset in GLM is the
part of the predictor associated with all the remaining effects in the model. The components
of the weight matrix Wij and the transformed observations y˜ij are defined as
y˜ij(ϕ) = ηij + (yij − µij)g′(µij) and
W−1ij (ϕ) = Vij {g′(µij)}2 , i = 1, . . . , n; j = 1, . . . , ni, (3.3.02)
where Vij is the conditional variance function of the outcome variable, and g
′(µij) is the
derivative of the link function with respect to the the mean value function. The acceptance
probability is defined as
λ(ϕ(t−1), ϕ∗) = min
(
1,
pi(ϕ∗)q(ϕ(t−1), ϕ∗)
pi(ϕ(t−1))q(ϕ∗, ϕ(t−1))
)
, (3.3.03)
where pi(ϕ∗) and pi(ϕ(t−1)) is the posterior density of ϕ evaluated at ϕ∗ and ϕ(t−1), respectively;
q(ϕ(t−1), ϕ∗) is the density specified in Step 2a evaluated at ϕ∗ and q(ϕ∗, ϕ(t−1)) is a N(m∗, c∗)
density evaluated at ϕ(t−1). Thus, to draw samples from the full conditionals pi(β1|.), pi(α, β2|.),
and pi(bi|.) = pi (bi1, bi2|.), the steps above are followed.
For the β1 block, the transformed observations are y˜ij,1(β1) = x
′
ij,1β1+(yij,1−x′ij,1β1)g′(x′ij,1β1)
which gives the original observations, yij,1; the offset is the random effect part, z
′
ij,1bi1,
and the weights are Wij,1(β1) = σ
2
e1
Ini1 , i = 1, . . . , n; j = 1, . . . , ni1. The proposal density
N(m1
(t), c1
(t)) has moments
m1
(t) = (Σ˚−11 +X
′
1W1(β
(t−1)
1 )X1)
−1 ×
{
Σ˚−11 β˚1 +X
′
1W1(β
(t−1)
1 )
[
y˜1(β
(t−1)
1 )− z′1b1
]}
c1
(t) = (Σ˚−11 +X
′
1W1(β
(t−1)
1 )X1)
−1 (3.3.04)
where W1 = diag(W11,1, . . . ,Wnni1,1);X1 is the design matrix of fixed effects for outcome y1.
For the θ2 = {α, β2} block associated with the ordinal outcome y2 with response vector
for the ith subject defined as yi2 = (yi1,2, · · · , yij,2, · · · , yini2,2)′, we define y∗ij,2 = 1 if yij,2 = k, 0
otherwise, with its expectation piij,2 = E(y
∗
ij,2) defined as in Equation (3.2.19). Thus, the
ni2 × 1 dimensional ordinal response vector yi2 is transformed into a ni2(K − 1) dimensional
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binary vector y∗i2 = (yi11, · · · , yi1K−1, yi21, · · · , yini2K−1)′ with expectation pii2 = E(y∗i2). The
variance-convariance matrix Vi2 of the dichotomized binary response vector y
∗
i2 has typical
elements
cov(yijk, yij′k′) =

piijk(1− piijk) if j = j′, k = k′,
−piijkpiijk′ if j = j′, k 6= k′,
corr(yijk,yij′k′ )
[piijk(1−piijk)piij′k′ (1−piij′k′ )]
−1/2 if j 6= j′, any k, k′
(3.3.05)
Let µθ2 = (µα, β˚2) and Σθ2 =
 σ2αIK−1 0
0 Σ˚2
 be the mean vector and variance-
covariance matrix of θ2, respectively. Thus, the transformed observations used in estimating
θ2, are y˜ij,2(θ2) = ηij,2(θ2) + (y
∗
ij,2 − piij,2(θ2))g′(piij,2(θ2)), where ηij,2(θ2) = αk − x′ij,2β2. The
offset and weights are z′ij,2bi2 and Wij,2(θ2) = [ni2Vij,2 {g′(piij,2(θ2))}2]−1, respectively, where
[g′(piij,2(θ2))]−1 is the derivative of the mean function with respect to the linear predictor
whose elements are given as follows:
[g′(piij,2(θ2))]−1 =

exp(αk−x′ij,2β2)
(1+exp(αk−x′ij,2β2))2 k = 1,[
exp(αk−x′ij,2β2)
(1+exp(αk−x′ij,2β2))2 −
exp(αk−1−x′ij,2β2)
(1+exp(αk−1−x′ij,2β2))2
]
k ≥ 2.
(3.3.06)
The proposal density N(m2
(t), c2
(t)) has moments
m2
(t) = (Σ−1θ2 +X
′
2W2(θ
(t−1)
2 )X2)
−1 ×
{
Σ−1θ2 µθ2 +X
′
2W2(θ
(t−1)
2 )[y˜2(θ
(t−1)
2 )− z′2b2]
}
c2
(t) = (Σ−1θ2 +X
′
2W2(θ
(t−1)
2 )X2)
−1 (3.3.07)
where W2 = diag(W11,2, . . . ,Wnni2,2) and X2 is the design matrix of fixed effects for the binary
outcome associated with y2.
Following the same steps, for the bi = (bi1, bi2) block, when estimated separately, then for the
bi1 block, we draw samples from the full conditional pi(bi1|.). The transformed observations
and weights are y˜ij,1(bi1) = z
′
ij,1bi1 + (yij,1 − z′ij,1bi1)g′(z′ij,1bi1) = yij,1 and Wij,1(bi1) = σ2 Ini1 ,
respectively. The proposal density is N(m
(t)
i1 , c
(t)
i1 ) with moments
m
(t)
i1 = (Γ
−1
1 + Z
′
i1Wi1(b
(t−1)
i1 )Zi1)
−1Zi1Wi1(b
(t−1)
i1 )×
{
y˜i1(b
(t−1)
i1 )−X ′i1β1
}
c
(t)
i1 = (Γ
−1
1 + Z
′
i1Wi1(b
(t−1)
i1 )Zi1)
−1 (3.3.08)
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where Wi1 = diag(Wi1,1, . . . ,Wini1,1) and Zi1 = (zi1,1, . . . , zini1,1)
′.
And for the bi2 block, we draw samples from the full conditional pi(bi2|.). The transformed
observations and weights for bi2 are y˜
∗
ij,2(bi2) = ηij,2(bi2) + (y
∗
ij,2 − piij,2(bi2))g′(piij,2(bi2)) and
Wij,2(bi2) = [ni2Vij,2{g′(piij,2(bi2))}2]−1, respectively. The proposal density is N(m(t)i2 , c(t)i2 )
with moments
m
(t)
i2 = (Γ
−1
2 + Z
′
i2Wi2(b
(t−1)
i2 )Zi2)
−1Zi2Wi2(b
(t−1)
i2 )×
{
y˜∗i2(b
(t−1)
i2 )− (αk −X ′i2β2)
}
c
(t)
i2 = (Γ
−1
2 + Z
′
i2Wi2(b
(t−1)
i2 )Zi2)
−1 (3.3.09)
where Wi2 = diag(Wi1,2, . . . ,Wini2,2) and Zi2 = (zi1,2, . . . , zini2,2)
′.
Our goal is to estimate the random effects from a multivariate distribution. Thus, following
the same steps above, we draw samples from the full conditional pi(bi|.). The proposal density
is
qbi ∼MVN
 m(t)i1
m
(t)
i2
 ,
 c(t)i1 ρ
√
c
(t)
i1
√
c
(t)
i2
ρ
√
c
(t)
i1
√
c
(t)
i2 c
(t)
i2
 , (3.3.010)
where ρ is the correlation between the continuous and ordinal processes, which is estimated
from the data.
3.4 CONVERGENCE DIAGNOSTICS AND MODEL ASSESSMENT
3.4.1 Convergence Diagnostics
From the theory of Markov chains governing the MCMC methods of estimation, the chains
are expected to converge to the stationary distribution, which is also the target distribution,
in the long run. In addition, as noted earlier, the first samples are discarded as burn-in, and
inferences are made from the remaining samples. Thus, determining how much burn-in is
optimal and whether the chains are mixing well or converged to the distribution of interest are
of paramount interest in Bayesian analysis. Several methods that include visual inspection
and statistical tests have been developed to diagnose convergence. These methods are full
implemented in CODA (Convergence Diagnosis and Output Analysis) package (Best et al.,
1996; Plummer et al., 2006)[3, 74] available in R software[75].
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3.4.1.1 Visual Inspection One way to see if the chain has converged is to see how well
that chain is mixing, or moving around the parameter space. If the chain is taking a long
time to move around the parameter space, then it will take longer to converge. In this study,
we employed trace and density plots, and autocorrelations to visually examine the mixing of
the chains for each of the parameters, and to determine the optimal burn-in (Gilks et al.,
1996)[31].
Trace and Density plots
A trace plot is a plot of the iteration number against the value of the draw of the parameter
at each iteration. Proper mixing of the chains, hence convergence is exhibited if the chains
remain stable for a longer period of time. A density plot on the other hand shows a smoothed
probability density curve of the draws or the distribution of the parameters. A multimodal
density may indicate non-convergence of the chain.
Autocorrelation
Another way to assess convergence is to assess the autocorrelations between the draws of the
Markov chain. The lag k autocorrelation ρk is the correlation between every draw and its k
th
lag:
ρk =
n−k∑
i=1
(xi − x¯)(xi+k − x¯)
n∑
i=1
(xi − x¯)2
The kth lag autocorrelation is expected to be smaller as k increases (e.g., the 2nd and 50th
draws should be less correlated than the 2nd and 4th draws). If autocorrelation is still relatively
high for higher values of k, it is an indication of high degree of correlation between the draws
and slow mixing.
3.4.1.2 Statistical Diagnostic Tests To substantiate the visual inspection results, we 
carried out statistical diagnostic tests that included Gelman and Rubin Multiple Sequence 
(Gelman and Rubin, 1992)[26], Geweke (Geweke, 1992)[30], and Heidelberg and Welch 
(Heidelberger and Welch, 1983) [41] diagnostic tests.
Gelman and Rubin Multiple Sequence Diagnostic
The Gelman and Rubin Multiple Sequence Diagnostic is based on comparing two or more 
parrallel chains drawn from different starting points and checking to see if they are not different
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Comparison of the within and between chain variances for each parameter is carried out, 
where convergence is assumed to be reached when the within variance is equal or not less 
than the between chain variance. To implement Gelman and Rubin test, the following steps are 
carried out for each parameter:
1. Run m ≥ 2 chains of length 2n from overdispersed starting values.
2. Discard the first n draws in each chain.
3. Calculate the within-chain and between-chain variance.
4. Calculate the estimated variance of the parameter as a weighted sum of the within-chain
and between-chain variance.
5. Calculate the potential scale reduction factor.
The within-chain variance is defined as
W =
1
m
m∑
j=1
S2j
where
S2j =
1
n− 1
n∑
i=1
(θij − θ¯j)2,
is the variance of the jth chain. Thus, W is the mean of the variance of each chain. To
some extent, the within-chain variance underestimates the true variance of the stationary
distribution because the chains may have not reached all the points of the stationary
distribution.
The between-chain variance B is
B =
n
m− 1
m∑
j=1
(θ¯j − θ¯)2
where
θ¯ =
1
m
m∑
j=1
θ¯j.
Thus, B is the variance of the chain means multiplied by n because each chain is based on n
draws.
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The estimated variance of the stationary distribution is by
ˆV ar(θ) =
(
1− 1
n
)
W +
1
n
B
Because of overdispersion of the starting values, the estimated variance overestimates the
true variance, but is unbiased if the starting distribution equals the stationary distribution
(if starting values were not overdispersed).
The potential scale reduction factor is
Rˆ =
√
ˆV ar(θ)
W
When Rˆ is high (i.e., greater than 1.1 or 1.2), the chains should be run longer to improve
convergence to the stationary distribution. The potential reduction factor is calculated for
each parameter of interest. Brooks and Gelman (1997) proposed a multivariate potential
scale reduction factor which is computed for all parameters [5].
Geweke Diagnostic
The Geweke diagnostic takes two nonoverlapping parts (usually the first 10% and last 50%)
of the Markov chain and compares the means of both parts, using equality of the means
test. If the samples are drawn from the stationary distribution of the chain, the two means
are equal and Geweke’s statistic has an asymptotically standard normal distribution. The
test statistic is a standard Z-score: the difference between the two sample means divided
by its estimated standard error. The standard error is estimated from the spectral density
at zero and so takes into account any autocorrelation. The Z-score is calculated under the
assumption that the two parts of the chain are asymptotically independent, which requires
that the sum of first proportion and last proportion be strictly less than 1.
Heidelberg and Welch Diagnostic
The Heidelberg and Welch diagnostic calculates a test statistic (based on the Cramer-von
Mises test statistic) to accept or reject the null hypothesis that the Markov chain is from a
stationary distribution. The diagnostic consists of two parts.
• First Part:
1. Generate a chain of N iterations and define an α level.
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2. Calculate the test statistic on the whole chain. Accept or reject null hypothesis that
the chain is from a stationary distribution.
3. If null hypothesis is rejected, discard the first 10% of the chain. Calculate the test
statistic and accept or reject null.
4. If null hypothesis is rejected, discard the next 10% and calculate the test statistic.
5. Repeat until null hypothesis is accepted or 50% of the chain is discarded. If test still
rejects null hypothesis, then the chain fails the test and needs to be run longer.
• Second Part:
– If the chain passes the first part of the diagnostic, then it takes the part of the chain
not discarded from the first part to test the second part.
– The halfwidth test calculates half the width of the (1− α)% credible interval around
the mean.
– If the ratio of the halfwidth and the mean is lower than some , then the chain passes
the test. Otherwise, the chain must be run out longer.
3.4.2 Model Assessment
To asses the model fit and compare different models, we employed the Deviance Information
Criterion (DIC) (Spiegelhalter et al., 2002)[87]. This model assessment tool was chosen
because it is readily available in BUGS software and can be used with informative priors,
noninformative priors, or improper priors. Let θ denote the vector of the model parameters
and y denote the observed data, then the deviance D(θ) is defined as
D(θ) = −2 log f(y|θ) + log h(y),
where f(y|θ) is the likelihood function and h(y) is a standardizing function of the data alone
(Carlin and Louis, 2009)[9]. The DIC is then computed with the formula:
DIC = θ + 2PD,
where PD = D(θ)−D(θ) is the effective number of parameters that measure model complexity.
Smaller values of DIC are better as with other known model selection tools like Akaike
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Information Criterion (AIC) and the Bayesian Information Criterion (BIC), and a difference
of 10 is said to be meaningful. DIC is a generalization of AIC and BIC is more suitable for
assessing goodness of fit for hierarchical models[9].
Other appropriate model assessment tools partly explored in this study include the
Conditional Predictive Ordinate (CPO) statistic and the logarithm of the Pseudomarginal
likelihood (LPML) statistic or its average value (ALPML). For the ith observation, the CPO
statistic is defined as
CPOi = f(yi|D(−i)) =
∫
f(yi|θ,xi)pi(θ|D(−i))dθ,
where yi denotes the response variable and xi is the vector of covariates for case i, D
(−i)
denotes the data with the ith case deleted, and pi(θ|D(−i)) is the posterior density of θ based
on the data D(−i) (see Ibrahim et al.(2001), Chapter 6.3 for more details)[51]. The LPML
statistic (Geisser and Eddy, 1979)[21] is derived from the CPO as
LPML =
n∑
i=1
log(CPOi).
To compare LPML’s from two different studies for a given model, the average LPML, given
by
ALPML =
LPML
n
,
where n is the sample size is preferred. In contrast with DIC, larger values of CPO or LPML
or ALPML imply a better fitting model.
3.5 SIMULATION STUDY
To examine the performance of the regression estimators from the proposed joint model and
to compare them to the estimators from the separate regression models, we performed a series
of simulation studies. The data were simulated from the proposed joint model of continuous
and ordinal outcomes correlated through correlated and/or shared random effects. From
each of the joint models, we simulated 500 data sets of sample sizes n = 100 and n = 50.
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In all simulations, number of repeated measures per subject ranged randomly from 1 to
10. For each subject, time t between successive visits were generated uniformly between 0.5
and 2.0 to mimic the motivating dataset. In addition, we generated one baseline covariate
(treatment variable indicator) x from a Bernoulli (0.5) distribution. Motivated by the dataset,
the models included only random intercepts. For the correlated random effects models, the
random effects were generated from a multivariate normal distribution with mean vector zero
and variance-covariance matrix Γ =
 σ2b1 = 5.87 ρσb1σb2
ρσb1σb2 σ
2
b2
= 4.89
. We considered different
correlation values, ρ = (0.9, 0.6, 0.0) which formed Part I of our simulations. For the shared
random effects models (bi2 = γbi1), we considered γ = (0.9, 0.6) in Part II of our simulations.
The models for constructing the continuous and ordinal outcomes are as in Equation (3.2.110).
The error ij,1 for the continuous outcome was simulated from N
(
0, σ21 = 7.4
)
. For the
ordinal outcome, we considered three categories; the first threshold value was set to zero
to guard against identifiability issues. Let the β′s, (β10, β11, β12, β13) and (β20, β21, β22, β23)
denote the regression coefficients for the fixed effects (intercept, time, treatment, and time
by treatment interaction) for the continuous and ordinal outcomes, respectively, and α2
the threshold parameter for the ordinal outcome. The true values for all the variance and
regression parameters were chosen based on the results of a joint correlated random effects
model fit to the motivating dataset, namely, β10 = 15.34, β11 = −0.56, β12 = −0.50, β13 = 0.3,
and α2 = 1.25, β20 = 1.8, β21 = −0.35, β22 = −0.50, β23 = 0.1. Once the latent parameters
(bi1,bi2) were generated from their respective distributions, we generated yij,1|bi1 from a
normal distribution with mean µij,1 = β10 + β11 × tij + β12 × xi + β13 × tij × xi + bi1 and
standard deviation σ1 . For the ordinal outcome, we simulated data from a multinomial
distribution. The multinomial probabilities were the marginal probabilities constructed
from the cumulative logit model as specified in Equation (3.2.19), where ηijk,2 = αk −
[β20 + β21 × tij + β22 × xi + β23 × tij × xi + bi2].
After generating the data, we fitted the joint (correlated through correlated and shared
random effects) and separate models to each data set. For the MCMC sampling we ran two
chains of 10,000 iterations with 2,000 iterations of each chain used as burn-in period. The initial
values for MCMC sampling were taken from a linear mixed model fit to the continuous data and
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a generalized linear mixed model fit to the ordinal data. The following priors were considered
for the different parameters: β1 ∼ N4 (0, 100I4), β2 ∼ N4 (0, 100I4), α2 ∼ N (0, 106) I(0, ),
σ2e1 ∼ IG (0.001, 0.001), σ2b1 ∼ IG (0.001, 0.001), σ2b2 ∼ IG (0.001, 0.001), γ ∼ N (0, 100), and
Γ ∼ IW (3, 1I2), where Iq indicates an q×q identity matrix, and N, IG, and IW , respectively
stand for Normal, Inverse Gamma, and Inverse Wishart. The MCMC sampling was done
using OpenBUGS (version 3.2.2) software and its R interface BRugs Version 0.4-1.
The simulation results for Part I are shown in Tables 1-3. In each of the tables, the
estimated Bias, Posterior Standard Deviation (SD), Coverage Probabilities (CP) of the 95%
highest posterior density (HPD) intervals, and the Relative Efficiency (RE) are shown. RE is
calculated as the ratio of the mean squared error (MSE) of estimates from the fitted models
to the mean squared error (MSE) of estimates for the same parameters from the true model.
All estimates were calculated based on 500 replicates.
The results in Table 1 (ρ = 0.9), indicate that when the true processes were correlated
through correlated random effects both joint model and separate model fits provided unbiased
estimates but the estimated posterior means were more biased for separate models with larger
SD. These biases were larger for the ordinal outcome which may be due to the less informative
nature of ordinal data as compared to continuous data. The gain in efficiency using joint
model relative to the separate model was as high as 15% and was more pronounced in the
ordinal outcome. However, when a shared random effects model was fitted to this correlated
random effects data, the estimates from the shared random effects were smaller with similar
SD with virtually no gain in efficiency when compared to estimates from correlated random
effects model. In addition, the results in Table 1 indicate that nominal coverage of 95% HPD
intervals was maintained for all the fitted models. The coverage probabilities were robust to
the sample size as seen from the bottom panel of Table 1.
The results for moderate correlation of ρ = 0.6 are shown in Table 2. The results showed
a similar trend as in Table 1. Specifically, when we fitted the correct model (JC) the biases
were smaller than those when fitted the JS model. The standard errors (SD) were smaller
for the JC (true) model compared to the JS model. In most cases there were considerable
gain in efficiency as high as 2.35 for the threshold parameter α2 with sample size n = 100
and extremely high for the variance parameters (highlighted in red). Coverage of 95% HPD
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intervals were adequate except some subject–specific covariates for the ordinal outcome
modeled through shared random effects.
Table 3 also indicates that when the true processes were uncorrelated (ρ = 0) the estimates
from the separate and joint correlated random effects models were quite similar, though there
was still some gain in efficiency for ordinal outcome estimates. Meanwhile, if a shared random
effects model was fitted to this uncorrelated data, most of estimates were more biased and
the trend of results was similar to those when ρ = 0.6.
Similar results were seen when separate models were fitted to data that were correlated
through shared random effects (see Appendix A: Tables 19 & 20). Although fitting joint
correlated random effects model to the shared random effects data resulted in more biased
estimates, less efficient estimates, and slightly larger standard errors (SD) for some of the
parameters for the ordinal outcome, the coverage of 95% HPD intervals were quite similar in
all scenarios. In general, a joint correlated random effects model did not perform as poorly
as a shared random effects model did in Part I simulations.
In essence, the estimates from fitting true models became less biased with smaller standard
errors as the sample size increased in all scenarios. The coverage probabilities were quite
robust to the sample size. The gain in efficiency, which was more pronounced in the ordinal
outcome, reduced with the increase in sample size keeping the correlation constant, and
decreased with the decrease in correlation between the two outcomes.
44
Table 1: Results when data were correlated under a correlated random effects model with strong correlation (ρ = 0.9): SD and
CP, stand for posterior standard deviation and coverage probabilities of the 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias SD CP Bias SD CP RE1 =
MSEJS
MSEJC
Bias SD CP RE2 =
MSESP
MSEJC
Correlated
Continuous Process
(n=50)
β10: intercept 15.34 -0.032 0.581 0.94 -0.096 0.595 0.94 1.02 -0.051 0.601 0.94 0.98
β11: time -0.56 0.001 0.070 0.94 0.001 0.070 0.94 1.02 0.001 0.072 0.94 1.07
β12: treatment -0.50 0.017 0.841 0.95 0.132 0.851 0.94 1.00 0.060 0.850 0.94 1.00
β13: time×treatment 0.30 -0.003 0.099 0.95 -0.003 0.100 0.95 1.01 -0.002 0.102 0.95 1.10
Ordinal Process
α2: threshold 1.25 0.038 0.164 0.94 0.007 0.164 0.95 0.93 0.045 0.165 0.94 1.05
β20: intercept 1.80 0.069 0.561 0.95 -0.062 0.559 0.95 0.98 0.096 0.614 0.95 1.15
β21: time -0.35 -0.013 0.073 0.95 -0.003 0.069 0.96 0.99 -0.012 0.076 0.94 1.13
β22: treatment -0.50 -0.076 0.788 0.95 0.079 0.789 0.95 0.99 -0.102 0.841 0.94 1.13
β23: time×treatment 0.10 0.003 0.099 0.95 -0.003 0.092 0.95 1.01 0.001 0.103 0.95 1.11
Association Parameters & Variances
ρ 0.90 0.012 0.050 0.97 - - - - - - - -
γ 0.91 - - - 0.064 0.148 0.93 - - - - -
σ2b1 : bi1 5.87 -0.136 1.464 0.95 -0.202 1.520 0.95 1.20 0.202 1.586 0.95 1.20
σ2b2 : bi2 4.89 0.379 1.730 0.94 - - - - 0.984 2.081 0.89 1.94
σ2e1 : error 7.40 0.121 0.651 0.95 0.414 0.680 0.91 1.45 0.079 0.649 0.95 0.98
Correlated
Continuous Process
(n=100)
β10: intercept 15.34 -0.009 0.417 0.95 -0.003 0.410 0.95 0.98 -0.036 0.425 0.94 1.01
β11: time -0.56 0.000 0.048 0.96 0.001 0.048 0.96 1.01 -0.001 0.050 0.96 1.06
β12: treatment -0.50 0.024 0.598 0.94 0.039 0.583 0.95 1.00 0.047 0.605 0.94 1.01
β13: time×treatment 0.30 -0.001 0.069 0.94 -0.001 0.069 0.94 1.02 -0.001 0.071 0.94 1.04
Ordinal Process
α2: threshold 1.25 0.016 0.115 0.94 -0.015 0.114 0.96 0.99 0.028 0.119 0.94 1.06
β20: intercept 1.80 0.030 0.400 0.95 -0.023 0.376 0.95 0.96 0.011 0.404 0.96 1.07
β21: time -0.35 -0.004 0.050 0.95 0.005 0.049 0.96 1.00 -0.004 0.053 0.95 1.10
β22: treatment -0.50 -0.013 0.556 0.95 0.031 0.517 0.95 0.97 0.042 0.553 0.94 1.05
β23: time×treatment 0.10 0.003 0.066 0.96 -0.001 0.065 0.96 1.01 -0.002 0.071 0.94 1.14
Association Parameters & Variances
ρ 0.90 0.010 0.038 0.96 - - - - - - - -
γ 0.91 - - - 0.017 0.096 0.95 - - - - -
σ2b1 : bi1 5.87 -0.084 1.026 0.95 -0.291 1.012 0.93 1.29 0.103 1.076 0.95 1.12
σ2b2 : bi2 4.89 0.142 1.139 0.95 - - - - 0.443 1.283 0.93 1.56
σ2e1 : error 7.40 0.057 0.449 0.95 0.369 0.476 0.88 1.81 0.020 0.446 0.95 0.98
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Table 2: Results when data were correlated under a correlated random effects model with moderate correlation (ρ = 0.6): SD
and CP, stand for posterior standard deviation and coverage probabilities of the 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias SD CP Bias SD CP RE1 =
MSEJS
MSEJC
Bias SD CP RE2 =
MSESP
MSEJC
Correlated
Continuous Process
(n=50)
β10: intercept 15.34 -0.066 0.589 0.94 -0.107 0.568 0.93 1.03 -0.075 0.603 0.94 0.98
β11: time -0.56 -0.004 0.072 0.95 -0.001 0.075 0.95 1.23 -0.004 0.072 0.95 1.01
β12: treatment -0.50 0.048 0.838 0.94 0.138 0.809 0.95 1.02 0.082 0.850 0.95 0.99
β13: time×treatment 0.30 0.005 0.101 0.95 0.002 0.106 0.96 1.21 0.005 0.102 0.95 1.01
Ordinal Process
α2: threshold 1.25 0.029 0.165 0.94 -0.079 0.159 0.93 1.29 0.048 0.166 0.94 1.09
β20: intercept 1.80 0.031 0.575 0.95 -0.193 0.524 0.93 1.02 0.085 0.624 0.95 1.05
β21: time -0.35 -0.006 0.075 0.94 0.024 0.068 0.94 1.07 -0.011 0.076 0.94 1.11
β22: treatment -0.50 -0.051 0.790 0.95 0.104 0.733 0.95 0.87 -0.091 0.852 0.96 1.06
β23: time×treatment 0.10 0.000 0.101 0.94 -0.008 0.090 0.95 0.97 0.002 0.103 0.96 1.12
Association Parameters & Variances
ρ 0.60 0.033 0.122 0.93 - - - - - - - -
γ 0.91 - - - 0.133 0.232 0.93 - - - - -
σ2b1 : bi1 5.87 -0.229 1.466 0.94 -1.511 1.334 0.73 4.39 0.189 1.579 0.94 1.05
σ2b2 : bi2 4.89 0.292 1.782 0.94 - - - - 1.092 2.119 0.90 1.88
σ2e1 : error 7.40 0.153 0.661 0.95 1.585 0.858 0.68 7.55 0.093 0.649 0.96 0.94
Correlated
Continuous Process
(n=100)
β10: intercept 15.34 -0.029 0.420 0.95 -0.013 0.394 0.95 1.01 -0.046 0.426 0.95 1.01
β11: time -0.56 0.001 0.050 0.95 0.001 0.052 0.96 1.12 0.001 0.050 0.94 1.02
β12: treatment -0.50 0.037 0.597 0.95 0.037 0.558 0.95 1.02 0.047 0.605 0.95 1.01
β13: time×treatment 0.30 -0.002 0.070 0.95 -0.001 0.073 0.94 1.16 -0.003 0.071 0.96 1.01
Ordinal Process
α2: threshold 1.25 0.004 0.115 0.94 -0.124 0.110 0.81 2.35 0.019 0.119 0.94 1.06
β20: intercept 1.80 0.023 0.407 0.94 -0.163 0.349 0.91 1.12 0.017 0.405 0.95 1.05
β21: time -0.35 -0.001 0.052 0.95 0.036 0.048 0.91 1.45 -0.004 0.053 0.94 1.06
β22: treatment -0.50 -0.035 0.567 0.95 0.045 0.472 0.95 0.84 0.021 0.553 0.95 1.04
β23: time×treatment 0.10 -0.003 0.069 0.94 -0.016 0.063 0.94 1.02 -0.006 0.071 0.95 1.06
Association Parameters & Variances
ρ 0.60 0.008 0.088 0.94 - - - - - - - -
γ 0.91 - - - 0.033 0.142 0.95 - - - - -
σ2b1 : bi1 5.87 -0.085 1.032 0.96 -1.513 0.906 0.57 8.11 0.133 1.081 0.95 1.08
σ2b2 : bi2 4.89 0.162 1.192 0.95 - - - - 0.510 1.296 0.92 1.42
σ2e1 : error 7.40 0.049 0.451 0.96 1.536 0.612 0.45 13.94 0.020 0.446 0.96 0.98
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Table 3: Results when data were uncorrelated (ρ = 0.0): SD and CP, stand for posterior standard deviation and coverage
probabilities of the 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias SD CP Bias SD CP RE1 =
MSEJS
MSEJC
Bias SD CP RE2 =
MSESP
MSEJC
Uncorrelated
Continuous Process
(n=50)
β10: intercept 15.34 -0.041 0.586 0.94 -0.032 0.530 0.96 1.04 -0.049 0.599 0.94 0.99
β11: time -0.56 0.001 0.071 0.96 0.004 0.079 0.95 1.51 0.002 0.071 0.96 1.00
β12: treatment -0.50 0.006 0.831 0.94 0.013 0.749 0.95 1.04 0.037 0.847 0.94 0.99
β13: time×treatment 0.30 0.002 0.101 0.95 0.001 0.111 0.95 1.51 0.001 0.101 0.95 1.00
Ordinal Process
α2: threshold 1.25 0.021 0.164 0.96 -0.183 0.164 0.92 3.62 0.038 0.165 0.95 1.06
β20: intercept 1.80 0.079 0.579 0.95 -0.248 0.487 0.94 1.24 0.115 0.628 0.95 1.13
β21: time -0.35 -0.019 0.077 0.94 0.038 0.071 0.95 1.67 -0.023 0.077 0.93 1.07
β22: treatment -0.50 -0.066 0.786 0.95 0.063 0.654 0.95 0.72 -0.113 0.858 0.95 1.11
β23: time×treatment 0.10 0.013 0.102 0.95 0.000 0.088 0.93 0.88 0.015 0.103 0.95 1.06
Association Parameters & Variances
ρ 0.00 -0.002 0.175 0.95 - - - - - - - -
γ 0.91 - - - -0.668 3.144 0.96 - - - - -
σ2b1 : bi1 5.87 -0.225 1.468 0.93 -2.941 1.278 0.64 19.04 0.176 1.575 0.94 1.04
σ2b2 : bi2 4.89 0.388 1.827 0.93 - - - - 1.199 2.162 0.90 1.91
σ2e1 : error 7.40 0.096 0.650 0.95 2.858 1.204 0.73 32.26 0.061 0.643 0.96 0.97
Uncorrelated
Continuous Process
(n=100)
β10: intercept 15.34 -0.010 0.419 0.95 0.007 0.398 0.96 1.01 -0.018 0.426 0.95 1.00
β11: time -0.56 -0.001 0.050 0.96 -0.002 0.053 0.95 1.24 -0.001 0.050 0.96 1.00
β12: treatment -0.50 -0.004 0.595 0.96 -0.018 0.568 0.96 1.00 -0.005 0.606 0.95 0.99
β13: time×treatment 0.30 0.003 0.071 0.95 0.004 0.075 0.94 1.17 0.002 0.072 0.94 1.00
Ordinal Process
α2: threshold 1.25 0.005 0.116 0.94 -0.377 0.096 0.44 15.17 0.018 0.119 0.95 1.04
β20: intercept 1.80 0.039 0.416 0.94 -0.520 0.262 0.77 3.57 0.022 0.406 0.95 1.00
β21: time -0.35 -0.007 0.053 0.95 0.101 0.045 0.76 5.77 -0.009 0.053 0.96 1.03
β22: treatment -0.50 -0.049 0.568 0.94 0.121 0.335 0.93 0.60 0.021 0.555 0.94 1.01
β23: time×treatment 0.10 0.006 0.071 0.94 -0.025 0.056 0.93 1.03 0.002 0.071 0.94 1.01
Association Parameters & Variances
ρ 0.00 -0.001 0.124 0.95 - - - - - - - -
γ 0.91 - - - -1.130 0.980 0.89 - - - - -
σ2b1 : bi1 5.87 -0.097 1.036 0.95 -1.258 1.072 0.80 16.68 0.121 1.080 0.94 1.05
σ2b2 : bi2 4.89 0.200 1.214 0.94 - - - - 0.548 1.304 0.91 1.41
σ2e1 : error 7.40 0.073 0.452 0.95 1.322 0.717 0.81 28.80 0.053 0.449 0.95 0.98
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The results in Tables 1-3 further indicated very high efficiency gain in variances, which
could have been due to the choice of prior distributions assigned to them. To determine
their (i.e. the prior distribution for variance parameters) effect on the the main effects
regression parameters, we performed a sensitivity analysis. The priors considered were
Gamma(.001,.001), Gamma(0.5,0.5), Gamma(1,1), Pareto(0.5,.0001), and Pareto(0.5,0.01)
for the precision, and half-Cauchy(s=25) and half-Cauchy(s=20) for the standard deviations.
We simulated 200 data sets of size n = 50 from a joint model correlated through correlated
random effects but with ρ = 0.0 and then fitted a joint and separate models to the data
generated. We chose ρ = 0.0 for better comparison of the performance of the priors through
relative efficiency. Evidence of no gain in efficiency of the estimates from the joint and
separate models would imply a more appropriate prior distribution. We employed the models
used in the main simulation study to simulate the data. In fitting the models, we also
maintained same prior distributions for the regression parameters β. For the joint models,
Inverse Wishart prior was employed for the variance-covariance matrix Γ of the random
effects while we varied the priors for the error variance. For the separate models, we varied
the priors for the error variance and random effects variances.
The results are summarized in Figures 1, 2, and 3. The variance estimates differed when
we varied the hyper-parameters for Gamma and half-Cauchy but not Pareto (Figure 1).
The effect was more pronounced in the estimates of random effects variances and when we
varied hyper-parameters of Gamma prior (right panel of Figure 1). However, the regression
coefficient estimates remained similar under all the above prior distributions (Figures 2 & 3).
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The priors 1A, 1B, 1C, 2A, 2B, 3A, 3B, stand for Gamma(.001,.001), Gamma(0.5,0.5), Gamma(1,1),
Pareto(0.5,.0001), Pareto(0.5,0.01), half-Cauchy(s=25), half-Cauchy(s=20), respectively. In the joint model
(left panel) where we varied the prior for the error variance keeping the prior for the precision matrix of
random effects as Wishart(3, 1I2), the estimates are quite similar to each other. Meanwhile, in the separate
models (right panel) where we varied the priors for the error and random effects variances, the variance
estimates for random effects varied when we varied the hyper-parameters for Gamma prior (1A, 1B, 1C).
Figure 1: Box plots of estimates for the error variance, σ2e1 , and random effects variances, σ
2
b1
and σ2b2 , under different priors.
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The effect of error variance prior on the regression parameter estimates. The horizontal dotted,
solid, and dashed lines represent the true values for Beta11/Beta21, Beta12/Beta22, and Beta13/Beta23,
respectively. The priors 1A, 1B, 1C, 2A, 2B, 3A, 3B, stand for Gamma(.001,.001), Gamma(0.5,0.5),
Gamma(1,1), Pareto(0.5,.0001), Pareto(0.5,0.01), half-Cauchy(s=25), half-Cauchy(s=20), respectively.
The regression parameter estimates are similar across different priors.
Figure 2: Mean estimates and 95% credible intervals for the Joint Model.
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The effect of error and random effects variance priors on the regression parameter estimates.
The horizontal dotted, solid, and dashed lines represent the true values for Beta11/Beta21, Beta12/Beta22,
and Beta13/Beta23, respectively. The priors 1A, 1B, 1C, 2A, 2B, 3A, 3B, stand for Gamma(.001,.001),
Gamma(0.5,0.5), Gamma(1,1), Pareto(0.5,.0001), Pareto(0.5,0.01), half-Cauchy(s=25), half-Cauchy(s=20),
respectively. The regression parameter estimates are similar across different priors.
Figure 3: Mean estimates and 95% credible intervals for the Separate Models.
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3.6 ANALYSIS OF UGANDAN DIABETES DATA
In this section, we present the analysis of the diabetes data introduced in Section 3.1. Our
interest is to jointly model the continuous and ordinal measures of disease severity. We
considered diabetes data that were collected retrospectively from three hospitals (Mulago,
Nsambya, and Rubaga all in Kampala, Uganda). The data were monthly records of 321
diabetic patients from the medical registries in the three hospitals (for details see Buhule
et al., 2007 [8]) who had at least two measurements of both blood and urine glucose and
taken on the same occasions. The covariates of interest included treatment (Biguanides,
Sulphonyureas, and Insulin (baseline)), baseline age in years, gender (male=1, female=0),
time of hospital visits in months, and time and treatment interaction. The profile plots of
the 321 individuals grouped by treatment are shown in Figure 4. We observed that both
blood glucose and urine glucose levels tended to increase over time for individuals who were
treated with Biguanides at baseline. For those on Insulin, blood glucose levels were fairly
constant over time while the urine glucose showed slight decline. Lastly for individuals on
Sulphonyureas, blood glucose seemed to remain constant but urine glucose showed a U-shape
trend based on the smooth lowess plot. The U-shape trend might be due to outliers or
sparsity of data at large time values. The summary statistics for baseline characteristics of
the 321 patients are also indicated in Table 4. Most of the patients were Type 2 diabetics
because it is the main form of diabetes. They were all adults although Type 1 diabetics were
younger on average. Their BMI levels were about 29 on average indicating majority of these
patients were overweight at baseline. The majority of the patients were female, and were
mostly treated with Insulin at baseline; however, considering type of diabetes, Sulphonyureas
treatment was only given to Type 2 diabetics.
The two biomakers (blood glucose and urine glucose) were modeled jointly through
correlated random effects and shared random effects and then compared to separate models.
To improve normality, we used square root transformation of blood glucose levels which were
linked to the linear predictor (covariates) with an identity link. That is,
yij,1 = β10 + β11 × timeij + β12 ×Biguanidesij + β13 × Sulphonyureasij + β14 × agei + β15
× genderi + β16 ×Biguanidesij × timeij + β17 × Sulphonyureasij × timeij + bi1 + ij,1,
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The distribution of blood glucose (upper panel) and urine glucose (lower panel) by
treatment. The thick lines represent the lowess smooth curves.
Figure 4: Distribution of Blood/Urine glucose by treatment over time.
where, yij,1 is the square root of blood glucose (mg/dl) for the i
th subject measured at the jth
occasion/hospital visit, bi1 is the random intercept and ij,1 ∼ N(0, σ2e1) is the measurement
error independent of bi1.
The marginal probabilities of urine glucose levels were linked to the covariates through a
cumulative logit link as follows:
log
(
Pr(yij,2 ≤ k)
1− Pr(yij,2 ≤ k)
)
= αk − [β21 × timeij + β22 ×Biguanidesij + β23 × Sulphonyureasij
+ β24 × agei + β25 × genderi + β26 ×Biguanidesij × timeij
+ β27 × Sulphonyureasij × timeij + bi2] ,
where k = 1, . . . , 5 and bi2 is the random intercept. In this cumulative logistic model, a
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Table 4: Descriptive statistics for baseline characteristics
All Type 1 Type 2
Variable n = 321 n = 69 n = 252
Age (years), x¯ (s) 49.7 (13.1) 37.4 (12.6) 53.1 (11.1)
BMI (kg/m2), x¯ (s) 28.6 (5.9) 28.9 (5.2) 28.5 (6.1)
Gender
Male, n (%) 70 (21.8) 16 (23.2) 54 (21.4)
Female, n (%) 251 (78.2) 53 (76.8) 198 (78.6)
Treatment
Biguanides, n (%) 116 (36.1) 20 (29.0) 96 (38.1)
Sulphonyureas, n (%) 85 (26.5) 0 (0.0) 85 (33.7)
Insulin, n (%) 120 (37.4) 49 (71.0) 71 (28.2)
positive regression coefficient indicates a higher probability of being in higher category of
urine glucose level.
For all parameters, we assumed similar priors as those used in the simulation study.
Time was standardized while age was centered to improve estimation. The MCMC was run
for 30, 000 iterations with the first 5, 000 discarded as burn-in. The models were fitted in
OpenBUGS (version 3.2.2) and its R interface BRugs Version 0.8.3. The standard MCMC
diagnostic tests (Table 5) indicated that all parameters estimated converged according to
the Gelman and Rubin diagnostics test [26] and its multivariate test proposed by Brook and
Gelman[5]. The few parameters that marginally failed the Geweke[30] and the Heidelberg and
Welch[41] diagnostic tests could be improved by running longer chains. The diagnostic plots
further indicated proper mixing of the chains and convergence to the stationary distributions
(see Appendix D Figures 5-7).
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Table 5: Convergence Diagnostic tests results for analysis of Diabetes data
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
Gelman Geweke Heidelberg Gelman Geweke Heidelberg Gelman Geweke Heidelberg
Parameter Estimate Z-score Stationarity Halfwidth Estimate Z-score Stationarity Halfwidth Estimate Z-score Stationarity Halfwidth
Continuous Process: blood glucose levels
Intercept 1.00 1.137 passed passed 1.00 2.286 passed passed 1.00 -1.440 passed passed
Time 1.00 1.348 passed passed 1.00 -1.333 passed passed 1.00 -0.315 passed passed
Treatment
Biguanides 1.00 -1.925 passed passed 1.00 -1.265 passed passed 1.00 -0.416 passed passed
Sulphonyureas 1.00 -1.211 passed passed 1.00 -1.697 passed passed 1.00 0.668 passed passed
Age 1.00 1.247 passed failed 1.00 -0.144 passed failed 1.00 -1.778 passed failed
Male 1.00 -1.188 passed passed 1.00 -1.386 passed passed 1.00 0.699 passed passed
Treatment×Time
Biguanides×Time 1.00 0.186 passed failed 1.00 1.960 passed failed 1.00 -0.924 passed passed
Sulphonyureas×Time 1.00 -0.294 passed passed 1.00 -0.031 passed passed 1.00 0.247 passed passed
Ordinal Process: urine glucose categories
Threshold-1 1.01 -0.971 passed passed 1.00 -1.799 passed passed 1.00 -0.494 passed passed
Threshold-2 1.01 -1.016 passed passed 1.00 -1.702 passed passed 1.00 -0.531 passed passed
Threshold-3 1.01 -1.088 passed passed 1.00 -1.606 passed passed 1.00 -0.565 passed passed
Threshold-4 1.00 -1.319 passed passed 1.00 -1.396 passed passed 1.00 -0.673 passed passed
Time 1.00 -0.465 passed passed 1.00 -0.622 passed passed 1.00 1.774 passed passed
Treatment
Biguanides 1.00 -1.814 passed passed 1.00 -0.712 passed passed 1.00 -1.798 passed passed
Sulphonyureas 1.00 -0.977 passed passed 1.00 -1.282 passed failed 1.00 -0.932 passed passed
Age 1.00 1.677 passed passed 1.00 0.134 passed passed 1.00 0.976 passed passed
Male 1.00 -2.381 passed passed 1.00 -1.471 passed passed 1.01 0.958 passed passed
Treatment×Time
Biguanides×Time 1.00 1.787 passed passed 1.00 -0.042 passed passed 1.00 -1.174 passed passed
Sulphonyureas×Time 1.00 0.575 passed passed 1.01 0.315 passed passed 1.00 -2.740 passed passed
Association Parameters & Variances
ρ 1.00 1.124 passed passed - - - - - - - -
γ - - - - 1.00 1.016 passed passed - - - -
σ2b1 1.00 -1.264 passed passed 1.00 -1.287 passed passed 1.00 0.290 passed passed
σ2b2 1.00 -0.297 passed passed - - - - 1.00 -0.973 passed passed
σ2e1 1.00 1.472 passed passed 1.00 1.063 passed passed 1.00 -1.138 passed passed
Multivariate Test 1.01 - - - 1.01 - - - 1.01 - - -
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The posterior estimates of the regression coefficients and their 95% credible intervals (CI)
for the joint (correlated random effects or shared random effects) versus separate analyses
are summarized in Table 6. The point estimates from the separate and joint analyses were
quite similar but the CIs somewhat differed. Time and gender were found to be significantly
associated with urine glucose levels in all the three models, such that the urine glucose levels
declined over time, and the males tended to have higher urine glucose levels compared to
females. In addition, gender was significantly associated with blood glucose levels in the
shared random effects model, implying, male patients had lower blood glucose levels as
compared to female patients. Although Biguanides treatment was found to be significantly
associated with urine glucose levels in the joint correlated model and separate models, the
interaction between Biguanides and time was not statistically significant in these two models.
However, there was a statistically significant interaction effect between Biguanides and time
in the shared random effects model; indicating patients who were treated with Biguanides
at baseline had higher urine glucose levels over time as compared to those treated with
Insulin, which is also evident in the profile plot (Figure 4). Moreover, the posterior estimates
of the association parameters ρ and γ in the joint analyses were positive and significantly
different from zero, providing strong evidence of association between the blood glucose and
urine glucose sub-models and indicating that the initial level of blood glucose was positively
associated with the urine glucose levels. The credible intervals shrunk in the joint models
with the shared random effects model having more shrinkage. All the measures of fit , that
is, DIC, LPML, and ALPML showed that the joint correlated random effects model fitted
the data better than the shared random effects model. Although DIC indicated that the
joint correlated random effects model fitted the data better than the separate models, the
LPML and ALPML measures showed no significant difference between the joint correlated
and separate models.
We also analyzed only type 2 diabetics data and the results (see Appendix A: Table 22)
were not very different those from the combined (type 1 and type 2 diabetics) data in Table 6.
Moreover, the convergence diagnostic results (see Appendix A: Table 21 and Appendix D:
Figures 8-10) indicated proper mixing of the chains and/or convergence of parameters to
their target distributions. Because age was not significantly associated with any of the two
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Table 6: Analysis of Diabetes Data
Joint-Correlated Random Effects Joint-Shared Random Effects Separate
Parameter Mean 95% CI Mean 95% CI Mean 95% CI
Continuous Process: blood glucose levels
Intercept 15.68 (15.20, 16.17) 15.86 (15.43, 16.28) 15.66 (15.15, 16.16)
Time -0.10 (-0.42, 0.22) 0.18 (-0.12, 0.48) -0.20 (-0.53, 0.12)
Treatment
Biguanides -0.15 (-0.71, 0.41) -0.35 (-0.86, 0.16) -0.15 (-0.74, 0.43)
Sulphonyureas -0.33 (-0.96, 0.29) -0.48 (-1.05, 0.09) -0.23 (-0.88, 0.42)
Age in years 0.00 (-0.02, 0.02) 0.00 (-0.02, 0.02) 0.00 (-0.03, 0.02)
Male -0.75 (-1.53, 0.03) -1.11 (-1.76, -0.45) -0.64 (-1.43, 0.15)
Treatment×Time
Biguanides×Time -0.01 (-0.44, 0.44) -0.02 (-0.46, 0.41) 0.07 (-0.39, 0.52)
Sulphonyureas×Time 0.22 (-0.35, 0.79) 0.19 (-0.35, 0.73) 0.23 (-0.36, 0.81)
Ordinal Process: urine glucose categories
Threshold-1 -0.90 (-1.28, -0.54) -0.81 (-1.16, -0.46) -1.02 (-1.41, -0.66)
Threshold-2 -0.42 (-0.79, -0.07) -0.35 (-0.69, -0.00) -0.54 (-0.93, -0.18)
Threshold-3 0.46 (0.09, 0.82) 0.49 (0.15, 0.84) 0.34 (-0.05, 0.70)
Threshold-4 2.64 (2.24, 3.04) 2.57 (2.20, 2.95) 2.53 (2.13, 2.93)
Time -0.36 (-0.59, -0.14) -0.40 (-0.62, -0.19) -0.25 (-0.49, -0.01)
Treatment
Biguanides -0.43 (-0.83, -0.04) -0.37 (-0.74, 0.01) -0.59 (-0.98, -0.19)
Sulphonyureas -0.20 (-0.65, 0.23) -0.18 (-0.58, 0.26) -0.26 (-0.73, 0.19)
Age in years -0.01 (-0.03, 0.01) -0.01 (-0.03, 0.01) -0.01 (-0.03,0.01)
Male 0.90 (0.33, 1.48) 1.00 (0.45, 1.56) 0.78 (0.18, 1.36)
Treatment×Time
Biguanides×Time 0.16 (-0.16, 0.48) 0.16 (0.14, 0.46) 0.15 (-0.18, 0.49)
Sulphonyureas×Time 0.30 (-0.10, 0.68) 0.28 (-0.10, 0.65) 0.29 (-0.13, 0.71)
Association Parameters & Variances
ρ 0.61 (0.49, 0.72) - - - -
γ - - 0.98 (0.75, 1.23) - -
σ2b1 5.86 (4.60, 7.34) 3.05 (2.05, 4.25) 5.99 (4.68, 7.52)
σ2b2 3.17 (2.35, 4.17) - - 3.11 (2.30, 4.09)
σ2e1 8.02 (7.34, 8.74) 10.15 (9.23, 11.13) 7.98 (7.30, 8.70)
Goodness of Fit
Outcome DIC LPML (ALPML) DIC LPML (ALPML) DIC LPML (ALPML)
Continuous 6913 -2098 (-1.539) 7109 -2259 (-1.657) 6930 -2096 (-1.538)
Ordinal 3432 -1604 (-1.177) 3482 -1649 (-1.210) 3455 -1605 (-1.178)
Total 10350 -3702 (-2.716) 10590 -3908 (-2.867) - -
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outcomes in Table 6 results, we excluded it from this second analysis but instead included
BMI. Sulphonyureas treatment and gender were significantly associated with blood glucose
levels in the shared random effects model. Patients who were treated with Sulphonyureas at
baseline had their blood glucose levels decrease as compared to those treated with Insulin.
Male patients had lower blood glucose levels compared to their female counterparts. On
the other hand, Biguanides treatment was found to be significantly associated with urine
glucose levels in all the three models, and gender and time were significant in the joint models
(correlated and shared). The patients who were treated with Biguanides had lower urine
glucose levels compared to those treated with Insulin, and males tended to have higher urine
glucose levels compared to females. Overall, these patients had lower urine glucose levels
over time. Again,the posterior estimates of the association parameters ρ and γ in the joint
analyses were positive and significantly different from zero, providing strong evidence of
association between the blood glucose and urine glucose sub-models and indicating that the
initial level of blood glucose was positively associated with the urine glucose levels. The DIC
also indicated that the joint correlated random effects model fitted the data better than the
shared random effects model and the separate models.
3.7 DISCUSSION
In this dissertation we have proposed a full Bayesian hierarchical multivariate generalized
linear mixed effects model for multiple repeatedly measured mixed outcomes (continuous
and ordinal) that are measures of disease severity. The key features of our model are the
Bayesian hierarchical formulation for modeling the subject-specific random effects when data
are highly unbalanced. We employed the nested indexing approach of handling unbalanced
data (Lunn, Thomas, and Spiegelhalter, 2000) [65] in formulating the proposed model.
Furthermore, the use of Bayesian approach that is fully implemented in freely available
software like WinBUGS (Lunn et al., 2000) [65] and OpenBUGS (Lunn et al., 2009)[64]
avoids the difficulties of routinely implementing maximum likelihood-based methods to these
complex and useful models. Currently, probit models are very widely used in complex
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applications involving categorical ordinal data due to ease of modeling and computation using
the underlying normal framework. Our approach uses the cumulative logit model which is
more stable especially in handling outlying data and easier to interpret than the probit models,
particularly for biomedical researchers who routinely use logistic regression in analyses of
binary outcomes. We have considered the cumulative logit model (proportional odds model)
but this proportional odds assumption can be relaxed by fitting a non-proportional or partial
proportional cumulative logit model as proposed by Hedeker and Mermelstein (1998)[40].
This extension allows the covariates to vary across the cumulative logits or cut points. As it
is straight forward to generalize our approach to essentially any data structure, the proposed
methodology would be a useful toolkit in the statistician’s toolbox.
The simulation study results demonstrated that joint modeling leads to efficient estimates
and adequate 95% coverage probabilities for the population parameters. The efficiency gain
was larger for the ordinal outcome estimates compared to that for the continuous outcome.
Overall, ordinal outcome regression coefficient estimates gained more efficiency when the the
joint model was correlated through correlated random effects than through shared random
effects. The efficiency gain was justified as modeling of mixed outcome types using shared
random effects is disadvantages to outcomes having non-normal distributions especially those
that have a natural tie between the mean and variance (McCulloch, 2008)[69]. In general,
our results agreed with those of Guerguieva and Sanacora (2006)[33] who found more efficient
gain in the ordinal outcome than the continuous outcome when they jointly modeled balanced
longitudinal data. Moreover, our real data example indicated improved efficiency when
blood glucose and urine glucose were modeled jointly. Finally, varying priors for variance
parameters was found to have no effect on the parameters of interest, although differences
in the estimates of the variance parameters were observed especially when we varied the
hyper-parameters for Gamma priors as indicated by Gelman (2006) [25].
In the next chapter (Chapter 4) we extend the proposed joint model to include time-to-
event data.
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4.0 BAYESIAN HIERARCHICAL JOINT MODELING OF REPEATEDLY
MEASURED MIXED BIOMARKERS OF DISEASE SEVERITY AND
TIME-TO-EVENT
4.1 INTRODUCTION
Joint modeling has been widely used in simultaneous modeling of longitudinal outcomes and
time-to-event data. When repeatedly measured markers over time are used as time-dependent
covariates in survival analysis, they are likely to lead to biased estimates. Bias occurs because
these markers are prone to measurement errors and have increased within patient variability
due to biological fluctuations. Modeling these markers and time-to-event data jointly leads
to unbiased and more efficient estimates. The goal of joint modeling in this context may
include: modeling the distribution of the time to a terminal event conditional on longitudinal
measurement sequence, adjusting inference about a longitudinal measurement sequence to
allow for informative dropout or joint evaluation of a measurement and an event-time process.
Most of the work in this field has focused on joint modeling of a single longitudinal outcome
and time-to-event data. However, in clinical studies where associations between the event
process and more than one biomarker are of interest, joint modeling of all the markers and
the event process is likely to increase the efficiency of the estimates.
This study is motivated by data for diabetic patients that were collected retrospectively
from three Ugandan hospitals. These patients attended the diabetic clinics between January
1992 and December 2004 during which several clinical measurements were taken. Blood
glucose in mg/dl was taken as the main biomaker reflecting disease severity. In addition,
urine glucose levels were taken as a compliment or substitute to blood glucose because the
urine glucose test is cheaper and faster. Other variables that are known to be associated with
60
Type 2 diabetes like body mass index (BMI) and blood pressure in mm Hg (both systolic
and diastolic) were also collected often during hospital visits. These patients were mostly
treated with Sulphonyureas or Biguanides or Insulin at baseline (the first time they visited the
diabetes clinic). Because diabetes is a chronic illness with no known cure, these treatments
are only used to control and prevent the development of diabetes complications. Thus, they
slow down diabetes progression by reducing the rate of further injury to the biological system
without necessarily improving the current level of functioning.
The normal range for blood glucose is between 70 to 130 mg/dl or 70 to 180 mg/dl
depending on whether someone is fasting or not at the time of testing. The clinical interest
is to ensure the blood glucose is in the normal range. In addition, maintaining normal
blood pressure and BMI for diabetics is known to reduce the risk of mortality from diabetes
compilations such as heart attack and stroke. Of the three biomarkers (i.e., blood glucose,
blood pressure, and BMI), blood glucose is expensive to measure and yet it is the main
biomarker of disease severity for diabetes. Normalization of the blood glucose levels is one
important objective for all diabetic patients. However, since blood glucose levels are more
expensive to measure it may be reasonable to establish the association between normalization
of it and other biomarkers such as blood pressure levels and BMI.
Joint models that combine the longitudinal and time-to-event processes have been widely
studied by many authors. Hogan and Laird (1997a)[44], Tsiatis and Davidian (2004)[93],
and Ibrahim, Chen, and Sinha (2001, Chapter 7)[51] give a detailed discussion of joint
modeling. Pawitan and Self (1993)[73], DeGruttola and Tu (1994)[16], Tsiatis, DeGruttola,
and Wulfsohn (1995)[94], Faucett and Thomas (1996)[18], Lavalley and De Gruttola (1996)[58],
Wulfsohn and Tsiatis (1997)[100], Henderson, Diggle, and Dobson (2000)[42], Xu and Zeger
(2001a)[101], Tsiatis and Davidian (2001)[92], Wang and Taylor (2001)[97], Guo and Carlin
(2004)[34], Brown and Ibrahim (2003) [6, 7], Ibrahim, Chu, and Chen(2010)[52], Wang, Shen,
and Boye (2012)[96], Huang, Hu, and Dagne (2014)[49] all have worked on one longitudinal
outcome and time-to-event. While Rizopoulos and Ghosh (2010)[79] and Hatfield, Boye, and
Carlin (2011)[36] extended the longitudinal outcome to multivariate case.
In this literature, the models employed for each outcome included mainly a proportional
hazards model (semi-parametric or parametric) for the survival times and a linear mixed
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effects model for the longitudinal measurements. The two outcomes were jointly modeled
through partial likelihood models or joint likelihood models. In the partial likelihood models,
the longitudinal measurements are taken to be time-dependent covariates in the hazard
function of survival times. This method also known as two-stage approach was used by
Tsiatis, DeGruttola, and Wulfsohn (1995) [94], who first estimated the true longitudinal
measurements at each event time by method of moments and then plugged the fitted
values into the Cox’s partial likelihood before maximizing it to obtain the estimates of
the regression parameters. This method does not make use of all the information and is
known to lead to biased estimates because covariate values are often measured with error
(Prentice, 1982)[76]. In the joint likelihood models approach, on the other hand, the model
for survival is conditioned on the observed longitudinal covariate or the other way around,
depending on whether the interest is in the survival or longitudinal outcome, respectively.
The random effects model (Laird and Ware, 1982 [57]) is often used to model the longitudinal
outcome and the individual random effects are included in the survival model. This leads to
more efficient estimates than the two-stage approach because it uses the full likelihood in
estimation and hence makes more use of the data. Parameter estimation is carried out using
maximum likelihood (ML) methods like EM algorithms or Bayesian Markov Chain Monte
Carlo (MCMC) methods; however, ML methods are computationally very intensive.
Faucett and Thomas (1996) [18], Xu and Zeger (2001a) [101], DeGruttola and Tu (1994) [16],
Henderson, Diggle, and Dobson (2000) [42], Wang and Taylor (2001)[97], Guo and Carlin
(2004) used the likelihood approach to jointly model the longitudinal marker and time-to-
event; however, Faucett and Thomas (1996) [18], Xu and Zeger (2001a) [101], Wang and
Taylor (2001)[97], Guo and Carlin (2004) [34] employed the Bayesian MCMC methods for
parameter estimation while others implemented EM algorithms. Henderson, Diggle, and
Dobson (2000) [42] and Xu and Zeger (2001a) [101] introduced a stationary Gaussian process
(as part of random effects) to allow the longitudinal trajectory to vary with time, while Wang
and Taylor (2001)[97] incorporated an integrated Ornstein–Uhlenbeck (IOU) process to moni-
tor the biological fluctuations in the longitudinal process about a smooth trend. Furthermore,
Rizopoulos and Ghosh (2010) [79] proposed a Bayesian semiparameteric multivariate joint
model that relates multiple longitudinal outcomes (continuous and binary) and time-to-event.
62
They used a spline-based approach to model the subject-specific longitudinal evolution, and
the baseline risk function in the Cox model for time-to-event outcome was assumed piece-wise
constant.
Although these joint models are very complex and computationally intensive, ignoring the
association between processes leads to inefficient if not biased estimation of the parameters
involved. Irrespective of the methods employed, joint modeling in most cases results in
efficient and unbiased parameter estimates when compared to separate modeling. As noted
earlier, most of the joint models have focused on one longitudinal outcome and time-to-event,
and to the best of our knowledge, no one has worked on joint modeling of mixed longitudinal
outcomes (e.g. continuous, ordinal) and time-to-event. Therefore, we propose a hierarchical
joint model to handle unbalanced repeatedly measured continuous and ordinal markers of
disease severity, and time-to-event. We use Bayesian methods to construct the posterior
distribution of the parameters of interest. Markov Chain Monte Carlo (MCMC) methods
are employed for parameter estimation because they avoid the difficulties of dealing with
high-dimensional integrals by sampling from the posterior distribution.
The remainder of this chapter is organized as follows: Section 4.2 presents the formulation
of the multivariate generalized linear mixed effects model, the associated joint likelihood, and
the prior and posterior distributions. Section 4.3 shows the derivation of the full conditionals
and estimation procedures of the parameters from these full conditionals, Section 4.4 shows
the simulation study, and Section 4.5 indicates the application of the proposed joint model to
diabetes data.
4.2 MODEL SPECIFICATIONS
4.2.1 Model formulation
Let yi = (y
′
i1,y
′
i2, . . . ,y
′
iL)
′, denote the L-variate response vector for ith subject (i = 1, . . . , n),
where yil, l = 1, . . . , L, is an ni × 1 vector of longitudinal biomarker for a certain disease
severity taken at time points, j = 1, . . . , ni. In addition, let Ti = min(T
∗
i , Ci) be the failure
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time and δi = I(T
∗
i ≤ Ci) an event indicator which indicates whether the observed failure
time is a true failure time, T ∗i , or a censoring time Ci for the i
th subject. For example,
in the Ugandan Diabetes data set, yi1 is a vector of systolic blood pressure levels, yi2 is
a vector of BMI levels, and Ti is time to normalization of blood glucose levels, for the i
th
patient. Because these responses are assumed to be of mixed types, we employ generalized
linear mixed effects models (GLMM) to unify them. Under this framework (GLMM), the
conditional distribution of each response is assumed to be a member of exponential family. In
particular, the conditional mean µ is linked to the linear predictor η (including fixed effects
and random effects) through a known one-to-one monotonic link function g(·).
Motivated by our data set, we consider two repeatedly measured response variables (con-
tinuous and ordinal) and one time-to-event outcome. Thus, yi = (yi1,yi2) for the continuous
and ordinal outcomes, respectively. For the continuous outcome, the jth component is linked
to the linear predictor through an identity link as in 4.2.11
yij,1 = x
′
ij,1β1 + z
′
ij,1bi1 + ij,1, (4.2.11)
where i1 ∼ N(0, σ2e1) is the measurement error, xij,1 and zij,1 are vectors of fixed covariates
and random effects, respectively, β1 are the regression parameters for the fixed part and bi1
is random effect of the ith subject. The linear predictor or mean is given as
µij,1 = E [yij,1|bi1] = ηij,1 = x′ij,1β1 + z′ij,1bi1.
For the ordinal response variable yi2 withK ordered categories k = 1, 2, · · · , K, the conditional
cumulative probabilities pijk,2 for the K categories defined as
pijk,2 = Pr(yij,2 ≤ k) =
k∑
m=1
pijm,2, (4.2.12)
are linked to the linear predictor ηijk,2 through a cumulative logit 4.2.13
log
[
pijk,2
1− pijk,2
]
= ηijk,2 = αk −
[
x′ij,2β2 + z
′
ij,2bi2
]
, (4.2.13)
with K − 1 strictly increasing model thresholds αk (i.e., α1 < α2 · · · < αK−1). In this
cumulative logit, we are assuming the proportional odds assumption (McCullagh, 1980) [67],
and a positive regression coefficient implies a higher probability of being in higher category.
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The first threshold α1 or the model intercept β20 is set to zero to guard against identifiability
problems. The conditional marginal probability piijk for category k is given by a difference
between two conditional cumulative probabilities as
piijk = Pr(yij,2 = k|bi2, xi2, zi2) = Ψ(ηijk,2)−Ψ(ηijk−1,2), (4.2.14)
where Ψ(ηijk,2) is the logistic cumulative distribution function (cdf) given as
Ψ(ηijk,2) =
exp(ηijk,2)
1 + exp(ηijk,2)
=
1
1 + exp(−ηijk,2) .
The thresholds α0 and αK are respectively set to −∞ and ∞, such that Ψ(ηij0,2) = 0 and
Ψ(ηijK,2) = 1.
For the time-to-event Ti, we define the hazard for the i
th individual by the proportional
hazards model
hi(t) = h0(t)wi exp (x
′
i3β3) , (4.2.15)
where xi3 is a vector of baseline covariates, β3 is a vector of regression coefficients of covariates,
and h0(t) is baseline hazard function, which can be assumed to be of parametric form or left
unspecified. The latent parameter wi is the unshared (individual-specific) frailty accounting
for unobservable heterogeneity and is assumed to have a log-normal distribution. By letting
bi3 = exp(wi), Equation 4.2.15 is rewritten as
hi(t) = h0(t) exp (x
′
i3β3 + bi3) , (4.2.16)
where bi3 is now assumed to be normally distributed. We assume a parametric Weibull
distribution describes the errors in a proportional hazards model (4.2.16), such that the hazard
for the ith individual at time t, hi(t), is a product of baseline hazard function h0(t) = λt
λ−1
and µi3(t) = exp (x
′
i3β3 + bi3). Thus, every individual has a survival time that is Weibull
with a fixed shape parameter (λ) and a scale parameter (µi3), which depends on the covariates.
A Weibull distribution is chosen because of its flexibility. It allows a monotonous increasing
and decreasing hazard rate and by setting λ = 1 we have an Exponential distribution, which
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assumes a constant hazard rate. Putting together, our proposed multivariate generalized
linear mixed model for the three processes is expressed as
yij,1|bi1 ∼ N
(
x′ij,1β1 + z
′
ij,1bi1, σ
2
e1
Ini
)
,
(yij1,2, . . . , yijK−1,2)|bi2 ∼ multinomial(piij1, . . . , piijK−1),
Ti|bi3 ∼ Weibull(λ, µi3),
log(µi3) = xi3
′β3 + bi3.
(4.2.17)
The random effects bi1, bi2, and bi3 are assumed to follow a Gaussian distribution with
mean vectors of zeros and variance-covariance matrices Γ1, Γ2, and Γ3, respectively. Given
these random effects, the three processes are assumed to be independent of each other and
the repeated measures within an individual are assumed to be independent observations
from a distribution fl(·). Thus, by having the latent parameters bi1, bi2, and bi3 correlated
induces the association among the three processes. In this dissertation, both the shared and
correlated random effects are explored. In the shared random effects model, the random
effects bi2 and bi3 are assumed proportional to bi1, that is, bi2 = γ1bi1 and bi3 = γ2bi1. This
formulation assumes a restrictive correlation structure among the outcomes. Meanwhile, in
the correlated random effects model, the random effects bi1, bi2, and bi3 are assumed to
follow a multivariate normal distribution with a nonrestrictive covariance structure, which
could be exchangeable or any other correlation structure.
4.2.2 Likelihood for the proposed model
Let θ1 =
{
β1, σ
2
e1
}
, θ2 = {β2, α} where α = (α1, . . . , αK−1) are the ordered threshold param-
eters for ordinal process, denote the parameters associated with the continuous and ordinal
processes, respectively. In addition, let θ3 = {β3, λ}, Θ = (θ1, θ2, θ3), and Γ = (Γ1,Γ2,Γ3)
denote parameters associated with survival process, combined three processes, and random
effects, respectively. Furthermore, let y1, y2, and y3 be the observed continuous, ordinal,
and survival data, respectively, and b be the combined random effects. The survival data are
right censored and we assume censoring is noninformative. The full conditional independence
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assumption (Laird and Ware, 1982)[57] is also assumed such that, under the correlated normal
random effects model, the joint likelihood of the three processes is given as
L(Θ,Γ|b,y, t) = L1(θ1|b,y1)L2(θ2|b,y2)L3(θ3|b,y3)g(b1,b2,b3|Γ),
where
L1(θ1|b,y1) =
n∏
i=1
f1(yi1|bi1; θ1) =
n∏
i=1
ni1∏
j=1
1
(2piσ2e1)
1/2
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}
,
µij,1 = x
′
ij,1β1 + z
′
ij,1bi1.
L2(θ2|b,y2) =
n∏
i=1
f2(yi2|bi2; θ2) =
n∏
i=1
ni2∏
j=1
K∏
k=1
{Ψ(ηijk,2)−Ψ(ηijk−1,2)}yijk,2
Ψ(ηijk,2) =
exp(αk − µij,2)
1 + exp(αk − µij,2) , Ψ(ηijk−1,2) =
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2) ,
µij,2 = x
′
ij,2β2 + z
′
ij,2bi2.
L3(θ3|b,y3) =
n∏
i=1
f3(ti, δi|bi3, θ3)δiS3(ti, δi|bi3, θ3)1−δi
=
n∏
i=1
[h0(ti) exp(x
′
i3β3 + bi3)]
δi × exp{−
ti∫
0
h0(s) exp(x
′
i3β3 + bi3)ds}
(4.2.21)
Likelihood (4.2.21) can be written as
L3(θ3|b,y3) =
n∏
i=1
[
µδii exp(−µi)
] [ h0(ti)
H0(ti)
]δi
,
where
µi = H0(ti)µi3, µi3 = exp(x
′
i3β3 + bi3), and H0(ti) =
ti∫
0
h0(s)ds.
By assuming Weibull distribution, h0(ti) = λt
(λ−1)
i , H0(ti) = t
λ
i ,
h0(ti)
H0(ti)
=
λ
ti
.
Therefore,
L3(θ3|b, t) =
n∏
i=1
[
µδii exp(−µi)
]︸ ︷︷ ︸
A
[
λ
ti
]δi
︸ ︷︷ ︸
B
, µi = t
λ
i exp(x
′
i3β3 + bi3).
(4.2.22)
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Part A in Equation (4.2.22) was first shown by Aitkin and Clayton (1980) [1] to be the kernel
of the likelihood function for n independent “Poisson variates” δi with mean µi . Thus, the
log-linear model for the hazard function implies a log-linear model for the Poisson mean:
log µi = log(t
λ
i ) + x
′
i3β3 + bi3, where log(t
λ
i ) is the offset. This formulation allows us to model
the three processes as multivariate GLMM. The joint distribution of b = (bi1,bi2,bi3) is
assumed to be a multivariate normal with mean vector of zero and variance-covariance matrix
Γ. That is, 
bi1
bi2
bi3
 ∼ N3


0
0
0
 ,Γ =

Γ1 Γ12 Γ13
Γ21 Γ2 Γ23
Γ31 Γ32 Γ3

 .
Combining the above, the joint likelihood for the three processes is given as
L(Θ,Γ|b,y) =
n∏
i=1
[
ni1∏
j=1
1
(2piσ2e1)
1/2
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}]
×
[
ni2∏
j=1
K∏
k=1
{Ψ(ηijk,2)−Ψ(ηijk−1,2)}yijk,2
]
×
[[
µδii exp(−µi)
] [λ
ti
]δi]
×
[ |Γ|−1/2
2pi
exp
{
−bi
′Γ−1bi
2
}]
,
where,
bi = (bi1,bi2,bi3), µij,1 = x
′
ij,1β1 + z
′
ij,1bi1, µij,2 = x
′
ij,2β2 + z
′
ij,2bi2,
Ψ(ηijk,2) =
exp(αk − µij,2)
1 + exp(αk − µij,2) , Ψ(ηijk−1,2) =
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2) , and
µi = t
λ
i exp(x
′
i3β3 + bi3).
(4.2.23)
4.2.3 Prior Specifications and Posterior distribution
Bayesian inferences are based on the posterior distribution, which is a function of the likelihood
and prior distribution. Prior distributions are chosen to have less influence on the inferences
made and conjugate (i.e., prior whose kernel has same form as that of the likelihood) where pos-
sible. Let β˚1 β˚2, and β˚3 denote the mean vectors, and Σ˚1, Σ˚2, and Σ˚3 the variance-covariance
matrices for β1, β2, and β3, respectively. Non-informative multivariate normal priors were
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assumed for the β′s, β1 ∼MVN
(
β˚1, Σ˚1
)
, β2 ∼MVN
(
β˚2, Σ˚2
)
, β3 ∼MVN
(
β˚3, Σ˚3
)
and
truncated normal prior for the thresholds α, αk ∼ N (µαk , σ2α) I(αk−1, αk+1) k = 1, . . . , K−1,
where I(·, ·) denotes truncation to specified interval. For the variance parameters, an In-
verse Wishart prior was assumed for the variance-covariance matrix of the random effects
(Γ ∼ IW (ν,Λ)) and an Inverse Gamma prior for the error variance (σ2e1 ∼ IG(ζ, ω)), which
are both conjugate priors in the multivariate and univariate normal likelihoods, respectively
(Carlin and Louis, 2009)[9]. In separate models, we assumed Inverse Gamma for the variance
of each random effects. Alternatively, a half-Cauchy prior is assumed for the standard
deviation of random effects (Gelman, 2006)[27]. Lastly, for the shape parameter λ if 6= 1 a
Gamma prior was assumed (i.e., λ ∼ G(%, ξ)) which is also a conjugate prior. By using vague
or non-informative priors we allow the likelihood or the data to dominate the inferences made.
Because random effects are unknown they are included as parameters in the posterior distri-
bution and hence estimated together with other parameters. Given the prior distributions of
all the unknowns and the observed data, the joint posterior distribution can be expressed as
pi (Θ,Γ,b|y) ∝ L(Θ,Γ|b,y)pi (Θ)pi (Γ)
∝
n∏
i=1
[
ni1∏
j=1
1
(2piσ2e1)
1/2
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}
× ω
ζ
Γ(ζ)
(
σ2e1
)−(ζ+1)
exp
{
− ω
σ2e1
}
× |Σ˚1|
−1/2
exp
{
−1
2
(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)}
×
ni2∏
j=1
K∏
k=1
{
exp(αk − µij,2)
1 + exp(αk − µij,2) −
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2)
}yijk,2
×
K−1∏
k=1
(
2piσ2α
)−1/2
exp
{
−(αk − µα)
2
2σ2α
}
I[αk−1,αk+1] (αk)
× |Σ˚2|
−1/2
exp
{
−1
2
(
β2 − β˚2
)′
Σ˚−12
(
β2 − β˚2
)}
× [µδii exp(−µi)] [λti
]δi
× ξ
%
Γ(%)
λ(%−1) exp {−ξλ}
× |Σ˚3|
−1/2
exp
{
−1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
×|Γ|−1/2 exp
{
−b
′
iΓ
−1bi
2
}
× |Γ|−ν/2 exp
(
−1
2
tr
(
Γ−1Λ
))]
.
(4.2.31)
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Ignoring constants in Equation 4.2.31 gives the joint posterior as
pi (Θ,Γ,b|y) ∝ L(Θ,Γ|b,y)pi (Θ)pi (Γ)
∝ L(Θ,Γ|b,y)× (σ2e1)−(ζ+1) exp{− ωσ2e1
}
× exp
{
−1
2
(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)}
×
K−1∏
k=1
exp
{
−(αk − µα)
2
2σ2α
}
I[.,.] (αk)
× exp
{
−1
2
(
β2 − β˚2
)′
Σ˚−12
(
β2 − β˚2
)}
× exp
{
−1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
× (λ)(%−1) exp {−ξλ}
× |Γ|−ν/2 exp
{
−1
2
tr
(
Γ−1Λ
)}
,
(4.2.32)
where, L(Θ,Γ|b,y) is given by Equation (4.2.23). From the joint posterior distribution
in Equation (4.2.32), we can draw inferences about the parameters of interest; however,
to determine the appropriate MCMC sampling method or specifically to implement Gibbs
sampling, the full conditionals or conditional marginal distributions for each parameter need
to be constructed. In the next section (Section 4.3), we show the derivation of the full
conditionals and estimation procedures for these parameters.
4.3 FULL CONDITIONAL DISTRIBUTIONS AND ESTIMATION
The conditional marginal posterior distributions or full conditionals are determined by
averaging the joint posterior distribution (4.2.32) over or integrating out the remaining
parameters. If a parameter distribution is proportional to some known, standard distribution,
then sampling can be done using standard Gibbs sampling method. However, if a distribution
is not standard and also to improve the convergence, we use the one iteration Metropolis-
Hasting algorithm (Gamerman, 1997) [20]. This method uses Metropolis-Hasting algorithm
with weighted least squares (WLS) proposal to draw samples from full conditional distributions.
Because some of these parameters are correlated, which can lead to slow convergence, the
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full conditional distributions are formed as blocks of correlated parameters according to their
conditional independence [57][20]. Thus, in our case we have blocks β1, σ
2
e1
, (α, β2), λ, β3, b,
and Γ and their full conditional distributions are derived below.
Let pi(θ|.) represent the full conditional distribution of parameter θ given as parameters,
then:
pi
(
β1|σ2e1 ,bi1
)
∝ exp
{
−1
2
(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)}
×
n∏
i=1
ni1∏
j=1
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}
∝ exp
{
−1
2
(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)}
× exp
{
− 1
2σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
}
∝ exp
{
−1
2
[(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)
+
1
σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
]}
∝ exp
{
−1
2
[(
β1 − β˚1
)′
Σ˚−11
(
β1 − β˚1
)
+
1
σ2e1
(y1 −X1β1 − Z1b1)′ (y1 −X1β1 − Z1b1)
]}
∝ exp
{
−1
2
[
β′1Σ˚
−1
1 β1 − 2β′1Σ˚−11 β˚1 + β˚1
′
Σ˚−11 β˚1 + σ
−2
e1
(y′1y1 − 2y′1X1β1 − y′1Z1b1
+β′1X
′
1X1β1 + 2β
′
1X
′
1Z1b1 − b′1Z ′1y1 + b′1Z ′1Z1b1)]}
Ignoring the terms that do not involve β1 in the exponent above leads to
∝ exp
{
−1
2
[
β′1Σ˚
−1
1 β1 − 2β′1Σ˚−11 β˚1 + σ−2e1 (−2y′1X1β1 + β′1X ′1X1β1 + 2β′1X ′1Z1b1)
]}
(4.3.01)
Simplifying 4.3.01 further gives
pi
(
β1|σ2e1 ,bi1
)
∝ exp
{
−1
2
[
β′1Σ˚
−1
1 β1 + β
′
1X
′
1X1σ
−2
e1
β1 − 2β′1
(
Σ˚−11 β˚1 +X
′
1σ
−2
e1
(y1 − Z1b1)
)]}
∝ exp
{
−1
2
[
β′1[Σ˚
−1
1 +X
′
1X1σ
−2
e1
]β1 − 2β′1
(
Σ˚−11 β˚1 +X
′
1σ
−2
e1
(y1 − Z1b1)
)]}
∝ exp
{
−1
2
[
β′1[Σ˚
−1
1 +X
′
1X1σ
−2
e1
]β1 − 2β′1
(
[Σ˚−11 +X
′
1X1σ
−2
e1
]−1 × [Σ˚−11 +X ′1X1σ−2e1 ]
×
[
Σ˚−11 β˚1 +X
′
1σ
−2
e1

])]}
∝ N (β1∗,Σ1∗) ,
where,
β∗1 = Σ1
∗ ×
[
Σ˚−11 β˚1 +X
′
1σ
−2
e1

]
, Σ1
∗ =
[
Σ˚−11 +X
′
1X1σ
−2
e1
]−1
,
 =
n∑
i=1
ni1∑
j=1
(
yij,1 − z′ij,1bi1
)
.
(4.3.02)
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pi
(
σ2e1|β1,bi1
)
∝
(
σ2e1
)−n(ζ+1)
exp
{
− ω
σ2e1
}
×
n∏
i=1
ni1∏
j=1
1
(σ2e1)
1/2
exp
{
−(yij,1 − µij,1)
2
2σ2e1
}
∝
(
σ2e1
)−n(ζ+1)
exp
{
− ω
σ2e1
}
× (σ2e1)−n/2 exp
{
− 1
2σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
}
∝
(
σ2e1
)−( 2ζ+n2 +1) exp{− 1
σ2e1
[
ω +
1
2
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
]}
∝ IG
(
ζ +
n
2
, ω +
1
2
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
)
(4.3.03)
pi (α, β2|bi2) = pi (α|bi2) pi (β2|α,bi2)
∝
K−1∏
k=1
exp
{
−(αk − µα)
2
2σ2α
}
I[αk−1,αk+1] (αk)×
n∏
i=1
ni2∏
j=1
K∏
k=1
{
exp(αk − µij,2)
1 + exp(αk − µij,2) −
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2)
}yijk,2
× exp
{
−1
2
(
β2 − β˚2
)′
Σ˚−12
(
β2 − β˚2
)}
(4.3.04)
pi (β3|λ,bi3) ∝ exp
{
−1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
×
n∏
i=1
µδii exp(−µi)
∝ exp
{
−1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
×
n∏
i=1
(tλi exp(x
′
i3β3 + bi3))
δi exp(−tλi exp(x′i3β3 + bi3))
∝ exp
{
−1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
×
n∏
i=1
exp(λδi log(ti))[exp(x
′
i3β3 + bi3)]
δi exp(−tλi exp(x′i3β3 + bi3))
(4.3.05)
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pi (β3|λ,bi3) ∝ exp
{
−1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
×
exp
n∑
i=1
[
δi (x
′
i3β3 + bi3) + λδi log(ti)− tλi exp(x′i3β3 + bi3)
]
∝ exp
{
n∑
i=1
[
δi (x
′
i3β3 + bi3) + λδi log(ti)− tλi exp(x′i3β3 + bi3)
]
− 1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
∝ exp
{
n∑
i=1
[
δi (x
′
i3β3 + bi3)− tλi exp(x′i3β3 + bi3)
]
− 1
2
(
β3 − β˚3
)′
Σ˚−13
(
β3 − β˚3
)}
,
which is a log-concave function.
(4.3.06)
Similarly, the conditional marginal distribution of pi (λ|β3,bi3), and for the random effects
and their associated variance-covariance matrix are derived as
pi (λ|β3,bi3) ∝ (λ)n(%−1) exp {−ξλ} ×
n∏
i=1
[
µδii exp(−µi)
] [λ
ti
]δi
∝ (λ)n(%−1) exp {−ξλ} × (λ)nδi
×
n∏
i=1
t−δii (t
λ
i exp(x
′
i3β3 + bi3))
δi exp(−tλi exp(x′i3β3 + bi3))
∝ (λ)(%+δi−1) exp {−ξλ} × exp
n∑
i=1
[−δi log(ti)
+ δi (x
′
i3β3 + bi3) + λδi log(ti)− tλi exp(x′i3β3 + bi3)
]
∝ (λ)(%+δi−1) × exp
{
n∑
i=1
λδi log(ti)− ξλ
}
(By ignoring constants)
∝ (λ)(%+δi−1) × exp
{
nλ
n∑
i=1
δi log(ti)− ξλ
}
∝ (λ)(%+δi−1) × exp
{
−(ξ − n
n∑
i=1
δi log(ti))λ
}
∝ Gamma
(
%+ δi, ξ − n
n∑
i=1
δi log(ti)
)
.
(4.3.07)
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pi (b|.) ∝ |Γ|−n/2 exp
{
−1
2
n∑
i=1
b′iΓ
−1bi
}
× |Γ|−ν/2 exp
(
−1
2
tr
(
Γ−1Λ
))
× exp
{
− 1
2σ2e1
n∑
i=1
ni1∑
j=1
(yij,1 − µij,1)2
}
×
n∏
i=1
ni2∏
j=1
K∏
k=1
{
exp(αk − µij,2)
1 + exp(αk − µij,2) −
exp(αk−1 − µij,2)
1 + exp(αk−1 − µij,2)
}yijk,2
×
n∏
i=1
(tλi exp(x
′
i3β3 + bi3))
δi exp(−tλi exp(x′i3β3 + bi3))
(4.3.08)
pi (Γ|b) ∝ |Γ|−n/2 exp
{
−1
2
n∑
i=1
b′iΓ
−1bi
}
× |Γ|−ν/2 exp
(
−1
2
tr
(
Γ−1Λ
))
∝ |Γ|−(n+ν)/2 exp
(
−1
2
tr
[
Γ−1
(
Λ +
n∑
i=1
bib
′
i
)])
∝ IW
(
ν + n,Λ +
n∑
i=1
bib
′
i
)
.
(4.3.09)
Following the same procedures as in Section 3.3 Chapter 3, the parameters of interest
are estimated by drawing random variates from their full conditional posterior distributions.
Because the the variance-covariance parameters σ2e1 ,Γ and the shape parameter λ have
standard distributions, Gibbs sampling is employed to estimate these parameters. While
for the fixed and random effects parameters, (β1, α, β2, β3) and bi, Gamerman’s one step
Metropolis-Hasting (M-H) method is employed to sample from their respective conditional
posterior distributions [20]. The following steps are taken to estimate for instance, parameter
ϕ using a single iterative method of Gamerman[20].
Step 1: Start with ϕ = ϕ(0) and set t = 1;
Step 2a: Sample ϕ∗ from N(m(t), c(t)) proposal density and
Step 2b: Accept it with probability λ(ϕ(t−1), ϕ∗) and set ϕ(1) = ϕ∗; Otherwise, stay at
ϕ(t) = ϕ(t−1);
Step 3: Increase t by 1 and return to Step 2.
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The moments of the proposal density are given by
m(t) = (Σ−1ϕ +X
′W (ϕ(t−1))X)−1 × {Σ−1ϕ µϕ +X ′W (ϕ(t−1))[y˜(ϕ(t−1))− η˜]}
c(t) = (Σ−1ϕ +X
′W (ϕ(t−1))X)−1 (4.3.010)
where µϕ and Σϕ are respectively, the mean and variance-covariance matrix of the prior
distribution for ϕ, W (ϕ(t−1)) = diag(W11, · · · ,Wnni) is the usual weight matrix for iterative
weighted least squares (IWLS) algorithm. The components of the weight matrix Wij and the
transformed observations y˜ij are defined as
y˜ij(ϕ) = ηij + (yij − µij)g′(µij) and
W−1ij (ϕ) = Vij {g′(µij)}2 , i = 1, . . . , n; j = 1, . . . , ni, (4.3.011)
where Vij is the conditional variance function of the outcome variable, and g
′(µij) is the
derivative of the link function with respect to the mean value function. The vector η˜ known
as the offset in GLM is the part of the predictor associated with all the remaining effects in
the model. The acceptance probability is defined as
∆(ϕ(t−1), ϕ∗) = min
(
1,
pi(ϕ∗)q(ϕ(t−1), ϕ∗)
pi(ϕ(t−1))q(ϕ∗, ϕ(t−1))
)
, (4.3.012)
where pi(ϕ∗) and pi(ϕ(t−1)) is the posterior density of ϕ evaluated at ϕ∗ and ϕ(t−1), respectively;
q(ϕ(t−1), ϕ∗) is the density specified in Step 2a evaluated at ϕ∗ and q(ϕ∗, ϕ(t−1)) is a N(m∗, c∗)
density evaluated at ϕ(t−1). Thus, to draw samples from the full conditionals pi(β1|.), pi(α, β2|.),
and pi(bi|.) = pi (bi1, bi2|.), the steps above are followed.
For the β1 block, the transformed observations are y˜ij,1(β1) = x
′
ij,1β1+(yij,1−x′ij,1β1)g′(x′ij,1β1)
which gives the original observations, yij,1; the offset is the random effect part, z
′
ij,1bi1,
and the weights are Wij,1(β1) = σ
2
e1
Ini1 , i = 1, . . . , n; j = 1, . . . , ni1. The proposal density
N(m1
(t), c1
(t)) has moments
m1
(t) = (Σ˚−11 +X
′
1W1(β
(t−1)
1 )X1)
−1 ×
{
Σ˚−11 β˚1 +X
′
1W1(β
(t−1)
1 )
[
y˜1(β
(t−1)
1 )− z′1b1
]}
c1
(t) = (Σ˚−11 +X
′
1W1(β
(t−1)
1 )X1)
−1 (4.3.013)
where W1 = diag(W11,1, . . . ,Wnni1,1);X1 is the design matrix of fixed effects for outcome y1.
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For the θ2 = {α, β2} block associated with the ordinal outcome y2 with response vector
for the ith subject defined as yi2 = (yi1,2, · · · , yij,2, · · · , yini2,2)′, we define y∗ij,2 = 1 if yij,2 = k, 0
otherwise, with its expectation piij,2 = E(y
∗
ij,2) defined as in Equation (4.2.14). Thus, the
ni2 × 1 dimensional ordinal response vector yi2 is transformed into a ni2(K − 1) dimensional
binary vector y∗i2 = (yi11, · · · , yi1K−1, yi21, · · · , yini2K−1)′ with expectation pii2 = E(y∗i2). The
variance-convariance matrix Vi2 of the dichotomized binary response vector y
∗
i2 has typical
elements
cov(yijk, yij′k′) =

piijk(1− piijk) if j = j′, k = k′,
−piijkpiijk′ if j = j′, k 6= k′,
corr(yijk,yij′k′ )
[piijk(1−piijk)piij′k′ (1−piij′k′ )]
−1/2 if j 6= j′, any k, k′
(4.3.014)
Let µθ2 = (µα, β˚2) and Σθ2 =
 σ2αIK−1 0
0 Σ˚2
 be the mean vector and variance-
covariance matrix of θ2, respectively. Thus, the transformed observations used in estimating
θ2, are y˜ij,2(θ2) = ηij,2(θ2) + (y
∗
ij,2 − piij,2(θ2))g′(piij,2(θ2)), where ηij,2(θ2) = αk − x′ij,2β2. The
offset and weights are z′ij,2bi2 and Wij,2(θ2) = [ni2Vij,2 {g′(piij,2(θ2))}2]−1, respectively, where
[g′(piij,2(θ2))]−1 is the derivative of the mean function with respect to the linear predictor
whose elements are given as follows:
[g′(piij,2(θ2))]−1 =

exp(αk−x′ij,2β2)
(1+exp(αk−x′ij,2β2))2 k = 1,[
exp(αk−x′ij,2β2)
(1+exp(αk−x′ij,2β2))2 −
exp(αk−1−x′ij,2β2)
(1+exp(αk−1−x′ij,2β2))2
]
k ≥ 2.
(4.3.015)
The proposal density N(m2
(t), c2
(t)) has moments
m2
(t) = (Σ−1θ2 +X
′
2W2(θ
(t−1)
2 )X2)
−1 ×
{
Σ−1θ2 µθ2 +X
′
2W2(θ
(t−1)
2 )[y˜2(θ
(t−1)
2 )− z′2b2]
}
c2
(t) = (Σ−1θ2 +X
′
2W2(θ
(t−1)
2 )X2)
−1 (4.3.016)
where W2 = diag(W11,2, . . . ,Wnni2,2) and X2 is the design matrix of fixed effects for the binary
outcome associated with y2.
Given the scale parameter λ, the transformed observations for β3 block are δ˜i(β3) =
x′i3β3+(δi−µi(β3))g′(µi(β3)). The offset is η˜(β3) = log(tλi )+bi3 and the weights are Wi3(β3) =
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[µi {g′(µi(β3))}2]−1, where µi = tλi exp(x′i3β3 + bi3) and [g′(µi(β3))]−1 is the derivative of the
mean function µi(β3) with respect to the linear predictor x
′
i3β3. The proposal density
N(m3
(t), c3
(t)) has moments
m3
(t) = (Σ˚−13 +X
′
3W3(β
(t−1)
3 )X3)
−1 ×
{
Σ˚−13 β˚3 +X
′
3W3(β
(t−1)
3 )
[
δ˜i(β
(t−1)
3 )− η˜(β3)
]}
c3
(t) = (Σ˚−13 +X
′
1W3(β
(t−1)
3 )X3)
−1 (4.3.017)
where W3 = diag(W13, . . . ,Wn3);X3 is the design matrix of fixed effects for time-to-event.
Following the same steps, for the bi = (bi1, bi2, bi3) block, when estimated separately,
then for the bi1 block, we draw samples from the full conditional pi(bi1|.). The trans-
formed observations and weights are y˜ij,1(bi1) = z
′
ij,1bi1 + (yij,1 − z′ij,1bi1)g′(z′ij,1bi1) = yij,1 and
Wij,1(bi1) = σ
2
 Ini1 , respectively. The proposal density is N(m
(t)
i1 , c
(t)
i1 ) with moments
m
(t)
i1 = (Γ
−1
1 + Z
′
i1Wi1(b
(t−1)
i1 )Zi1)
−1Zi1Wi1(b
(t−1)
i1 )×
{
y˜i1(b
(t−1)
i1 )−X ′i1β1
}
c
(t)
i1 = (Γ
−1
1 + Z
′
i1Wi1(b
(t−1)
i1 )Zi1)
−1 (4.3.018)
where Wi1 = diag(Wi1,1, . . . ,Wini1,1) and Zi1 = (zi1,1, . . . , zini1,1)
′.
And for the bi2 block, we draw samples from the full conditional pi(bi2|.). The transformed
observations and weights for bi2 are y˜
∗
ij,2(bi2) = ηij,2(bi2) + (y
∗
ij,2 − piij,2(bi2))g′(piij,2(bi2)) and
Wij,2(bi2) = [ni2Vij,2{g′(piij,2(bi2))}2]−1, respectively. The proposal density is N(m(t)i2 , c(t)i2 )
with moments
m
(t)
i2 = (Γ
−1
2 + Z
′
i2Wi2(b
(t−1)
i2 )Zi2)
−1Zi2Wi2(b
(t−1)
i2 )×
{
y˜∗i2(b
(t−1)
i2 )− (αk −X ′i2β2)
}
c
(t)
i2 = (Γ
−1
2 + Z
′
i2Wi2(b
(t−1)
i2 )Zi2)
−1 (4.3.019)
where Wi2 = diag(Wi1,2, . . . ,Wini2,2) and Zi2 = (zi1,2, . . . , zini2,2)
′.
Similarly, for the bi3 block we draw samples from the full conditional pi(bi3|.). The transformed
observations and weights for bi3 are δ˜i(bi3) = ηi3(bi3) + (δi − µi(bi3))g′(µi(bi3)) and Wi3(bi3) =
[µi {g′(µi(bi3))}2]−1, respectively. The offset is η˜(bi3) = log(tλi ) + x′i3β3. The proposal density
is N(m
(t)
i3 , c
(t)
i3 ) with moments
m
(t)
i3 = (Γ
−1
3 + I
′
i3Wi3(b
(t−1)
i3 )Ii3)
−1Ii3Wi3(b
(t−1)
i3 )×
{
δ˜i(b
(t−1)
i3 )− η˜(bi3)
}
c
(t)
i3 = (Γ
−1
3 + I
′
i3Wi3(b
(t−1)
i3 )Ii3)
−1 (4.3.020)
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where Wi3 = diag(Wi1, . . . ,Win) and I. is an identity matrix.
Because the random effects are assumed to be correlated, we estimate them jointly from a
multivariate distribution. Following the same steps above, we draw samples from the full
conditional pi(bi|.). The proposal density is
qbi ∼MVN


m
(t)
i1
m
(t)
i2
m
(t)
i3
 ,

c
(t)
i1 ρ12
√
c
(t)
i1
√
c
(t)
i2 ρ13
√
c
(t)
i1
√
c
(t)
i3
ρ12
√
c
(t)
i2
√
c
(t)
i1 c
(t)
i2 ρ23
√
c
(t)
i2
√
c
(t)
i3
ρ13
√
c
(t)
i3
√
c
(t)
i1 ρ23
√
c
(t)
i3
√
c
(t)
i2 c
(t)
i3

 ,
where ρ12, ρ13, and ρ23 are the correlations between the continuous and ordinal, continuous
and survival, and ordinal and survival processes, respectively. All correlations are estimated
from the data.
4.4 SIMULATION STUDY
In order to examine the performance of the proposed joint model, we performed a series of
simulation studies. In particular, we compared the regression estimates from the proposed joint
model to the estimates from the separate regression models. The data were simulated from the
proposed joint model of continuous and ordinal outcomes and time-to-event correlated through
correlated and/or shared random effects. From each of the joint models, we simulated 500
data sets of sample sizes n = 100 and n = 50. In all simulations, number of repeated measures
per subject were randomly generated from a Poisson(1, 10) and time t between successive
visits from a Uniform(0.2, 2.0) distribution. In addition, one baseline treatment variable
indicator x was generated from a Bernoulli (0.5) distribution. For the correlated random
effects models, the random effects were generated from a multivariate normal distribution
with mean vector zero and variance-covariance matrix
Γ =

σ2b1 = 5.87 ρ12σb1σb2 ρ13σb1σb3
ρ12σb1σb2 σ
2
b2
= 4.89 ρ23σb2σb3
ρ13σb1σb3 ρ23σb2σb3 σ
2
b3
= 3.2
 .
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To determine the effect of correlation on the estimates from the joint model, we considered
exchangeable with strong, moderate, and zero correlation values and unstructured correlation
structures, which formed Part I of our simulations. Specifically, we considered exchangeable
of (ρ12 = ρ13 = ρ23 = 0.9), (ρ12 = ρ13 = ρ23 = 0.6), and (ρ12 = ρ13 = ρ23 = 0.0), respectively
and unstructured of (ρ12 = 0.9, ρ13 = 0.6, ρ23 = 0.3) . Similarly, for the shared random effects
models (bi2 = γ1bi1, bi3 = γ2bi1), we considered (γ1 = γ2 = 0.9), (γ1 = γ2 = 0.6), and (γ1 =
γ2 = −0.5), respectively as Part II of our simulations. The error ij,1 for the continuous
outcome was simulated from N
(
0, σ21 = 7.4
)
. The true values for the variances (error and
random effects) were obtained by fitting a joint model to the motivating data set of Chapter 3
of this dissertation because they looked more reasonable. Meanwhile, the true values for the
regression parameters were chosen based on the results of a joint correlated random effects
model fit to the current motivating data set. The β′s, (β10, β11, β12, β13) and (β20, β21, β22, β23)
denote the regression coefficients for the fixed effects (intercept, time, treatment, and time
by treatment interaction) for the continuous and ordinal outcomes, respectively, (β30, β31)
the regression coefficients for the baseline covariates (intercept, treatment) for the survival
outcome, and α2 the threshold parameter for the ordinal outcome. The true values for
the β′s and the threshold α2 were: (β10 = 13.50, β11 = −0.56, β12 = −3.35, β13 = −0.57),
(α2 = 0.45, β20 = 1.7, β21 = −0.27, β22 = 0.65, β23 = −0.1), and (β30 = −3.31, β31 = 0.37)
for continuous, ordinal, and survival outcomes, respectively. After generating the latent
parameters from their respective distributions and specifying the true values, the three
outcomes were then constructed as in Equation (4.2.17). For the continuous outcome, we
generated yij,1|bi1 from a normal distribution with mean µij,1 = β10 + β11 × tij + β12 × xi +
β13 × tij × xi + bi1 and standard deviation σ1 . For the ordinal outcome, we considered three
categories and the first threshold value α1 was set to zero to ensure identification. We then
generated yijk,2|bi2 from a multinational distribution with probabilities given by the marginal
probabilities constructed from the cumulative logit model as in Equation (4.2.14). The linear
predictor, ηijk,2 = αk − [β20 + β21 × tij + β22 × xi + β23 × tij × xi + bi2].
For time-to-event data, the survival time, T ∗i , for the i
th subject was generated from
a Weibul(λ, µi3) distribution, where log(µi3) = β30 + β31 × xi + bi3 and λ = 1, which is
essentially an exponential distribution with rate parameter µi3. The censoring time, Ci, was
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generated from a Uniform(0, 50) which accounted for about 40% censoring. The failure time,
Ti was taken as the minimum of survival time and censoring time, that is, Ti = min(T
∗
i , Ci)
and the event indicator, δi, was defined as
δi =
 1 T ∗i ≤ Ci0 otherwise
In summary, the following steps were taken for each simulation:
• For simulations in Part I, we generated data assuming the three processes are correlated
through correlated random effects bi1, bi2, and bi3 and then fitted the correlated and
separate models to the data sets generated.
• For simulations in Part II, we generated data assuming the processes are correlated
through shared random effects i.e., bi2 = γ1bi1 and bi3 = γ2bi1 and then fitted the shared
and separate models to the data sets generated.
The MCMC sampling was done using OpenBUGS (version 3.2.2) software and its R
interface BRugs Version 0.8.3. We ran two chains of 10,000 iterations with 2,000 iterations of
each chain used as burn-in period. The initial values for MCMC sampling were taken from a
linear mixed model fit to the continuous data and a generalized linear mixed model fit to the
ordinal data and time-to-event data. Let β1 = (β10, β11, β12, β13), β2 = (β20, β21, β22, β23), β3 =
(β30, β31). The following priors were considered for the different parameters: β1 ∼ N4 (0, 100I4),
β2 ∼ N4 (0, 100I4), α2 ∼ N (0, 106) I(0, ), σ2e1 ∼ IG (1.0, 1.0), σ2b1 ∼ IG (1.0, 1.0), σ2b2 ∼
IG (1.0, 1.0), γ ∼ N (0, 100), and Γ ∼ IW (3, 1I2), where Iq indicates an q × q identity
matrix.
The simulation results for Part I are shown in Tables 7-12 (exchangeable correlation
structure) and Tables 13-14 (unstructured correlation structure) . In each of the tables, the
estimated Bias, Monte Carlo Standard Deviation (MCSD), Posterior Standard Deviation
(SD), Coverage Probabilities (CP) of the 95% highest posterior density (HPD) intervals, and
the Relative Efficiency (RE) are shown. RE is calculated as the ratio of the mean squared
error loss (MSE) of estimates from the fitted models to the mean squared error loss (MSE) of
estimates for the same parameters from the true model. All estimates were calculated based
on 500 replicates.
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The results in Table 7 (ρ12 = ρ13 = ρ23 = 0.9 and n = 50), indicate that when the true
processes were correlated through correlated random effects both joint model and separate
model fits provided unbiased estimates but the estimated posterior means were more biased
for separate models with larger SD. These biases were larger for the ordinal outcome which
may be due to the less informative nature of ordinal data as compared to continuous data.
The gain in efficiency using joint model relative to the separate model was as high as 11% for
the fixed effects parameters and 52% for the variance parameters. The gain in efficiency was
more pronounced in the ordinal and survival outcomes. In addition, the results in Table 7
indicate that nominal coverage of 95% HPD intervals was maintained for the continuous
outcome in both joint and separate models but not for the ordinal and survival outcomes.
Increasing the sample size to n = 100 (Table 8) resulted in improved gain in efficiency, less
bias, and better coverage of 95% HPD intervals for the three outcomes in both joint and
separate models.
The results for moderate correlation of ρ12 = ρ13 = ρ23 = 0.6 and sample size n = 50 are
shown in Table 9. The results showed a similar trend as in Table 7. In particular, when we
fitted the correct model (JC) the biases were smaller than those when fitted the separate (SP)
models. The standard errors (SD) were smaller for the JC (true) model compared to SP model.
Apart from the survival outcome, the gain in efficiency reduced with reduced correlation
among the outcomes. In both models, coverage of 95% HPD intervals were adequate for
all estimates. Meanwhile, the results in Table 10 showed reduced gain in efficiency when
the sample was increased to n = 100 with same correlation of ρ12 = ρ13 = ρ23 = 0.6. The
coverage probabilities were robust to the sample size and bias reduced with sample size.
The results in Tables 11 & 12 when the true processes were uncorrelated, that is,
(ρ12 = ρ13 = ρ23 = 0) indicated the estimates from the separate and joint correlated random
effects models were quite similar, though there was some gain in efficiency for ordinal and
survival outcomes’ estimates.
The results for unstructured correlation structure (ρ12 = 0.9, ρ13 = 0.6, ρ23 = 0.3) in Ta-
bles 13 & 14 also indicated similar results as for strong exchangeable correlation structure in
Tables 7 & 8 with the estimates for the ordinal and survival outcomes having more gain in
efficiency compared to those of the continuous outcome.
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In all scenarios above, the MCSD and SD were quite similar implying the Monte Carlo
simulations performed as well as the MCMC sampling.
Similarly, when we fitted separate models to data that were correlated through shared
random effects (see Appendix A: Tables 23-28), the estimates had larger standard errors and
slightly more biased on average. There was gain in efficiency when a joint model (JS) was
fitted and was more pronounced in the ordinal outcome. The MCSD and SD were similar in
all scenarios and the coverage of 95% HPD intervals were adequate and robust to the sample
size.
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Table 7: Results when data were simulated under a correlated random effects model with strong correlation (ρ12 = ρ13 = ρ23 = 0.9)
and n = 50: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage
probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=50)
β10: intercept 13.50 0.010 0.219 0.412 0.95 0.014 0.219 0.417 0.95 1.00
β11: time -0.56 0.001 0.027 0.029 0.96 0.000 0.028 0.030 0.96 1.03
β12: treatment -3.35 0.022 0.422 0.414 0.95 0.019 0.420 0.417 0.94 0.99
β13: time×treatment -0.57 0.000 0.030 0.029 0.95 0.000 0.030 0.030 0.94 1.02
Ordinal Process
α2: threshold 0.45 -0.025 0.076 0.078 0.93 -0.026 0.076 0.079 0.93 1.01
β20: intercept 1.70 -0.044 0.289 0.418 0.95 -0.064 0.300 0.425 0.96 1.10
β21: time -0.27 0.007 0.039 0.035 0.94 0.008 0.041 0.036 0.95 1.07
β22: treatment 0.65 0.005 0.422 0.409 0.93 0.016 0.433 0.419 0.95 1.06
β23: time×treatment -0.10 0.004 0.036 0.034 0.96 0.003 0.038 0.035 0.96 1.09
Survival Process
β30: intercept -3.31 0.104 0.290 0.381 0.93 0.078 0.303 0.391 0.95 1.04
β31: treatment 0.37 0.001 0.353 0.357 0.93 0.000 0.372 0.365 0.92 1.11
Association Parameters & Variances
ρ12 0.90 -0.010 0.034 0.043 0.97 - - - - -
ρ13 0.90 0.006 0.042 0.066 0.93 - - - - -
ρ23 0.90 0.006 0.043 0.066 0.95 - - - - -
σ2b1 : bi1 5.87 0.013 0.655 1.375 0.94 -0.022 0.660 1.382 0.94 1.02
σ2b2 : bi2 4.89 -0.407 1.209 1.554 0.92 -0.522 1.372 1.669 0.92 1.32
σ2b3 : bi3 3.20 -0.439 1.282 1.488 0.92 -0.225 1.657 1.830 0.94 1.52
σ2e1 : error 7.40 -0.077 0.442 0.476 0.95 -0.056 0.442 0.475 0.95 0.98
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Table 8: Results when data were simulated under a correlated random effects model with strong correlation (ρ12 = ρ13 = ρ23 = 0.9)
and n = 100: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and
Coverage probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=100)
β10: intercept 13.50 0.020 0.161 0.286 0.95 0.007 0.162 0.293 0.95 1.00
β11: time -0.56 0.001 0.020 0.020 0.96 0.001 0.021 0.021 0.96 1.07
β12: treatment -3.35 -0.025 0.307 0.290 0.96 -0.029 0.308 0.292 0.96 1.01
β13: time×treatment -0.57 0.000 0.020 0.020 0.96 0.000 0.021 0.021 0.96 1.05
Ordinal Process
α2: threshold 0.45 -0.014 0.055 0.055 0.94 -0.016 0.056 0.055 0.94 1.02
β20: intercept 1.70 0.004 0.191 0.283 0.95 -0.021 0.194 0.292 0.95 1.04
β21: time -0.27 0.003 0.024 0.024 0.95 0.004 0.024 0.025 0.94 1.07
β22: treatment 0.65 -0.025 0.285 0.280 0.95 -0.034 0.292 0.287 0.95 1.06
β23: time×treatment -0.10 0.001 0.021 0.023 0.94 0.002 0.022 0.024 0.93 1.14
Survival Process
β30: intercept -3.31 0.044 0.199 0.256 0.95 0.019 0.204 0.264 0.95 1.01
β31: treatment 0.37 -0.004 0.235 0.241 0.95 -0.001 0.246 0.249 0.95 1.10
Association Parameters & Variances
ρ12 0.90 -0.009 0.026 0.032 0.95 - - - - -
ρ13 0.90 -0.008 0.033 0.047 0.97 - - - - -
ρ23 0.90 -0.002 0.037 0.049 0.96 - - - - -
σ2b1 : bi1 5.87 0.028 0.410 0.945 0.95 -0.004 0.414 0.953 0.95 1.02
σ2b2 : bi2 4.89 -0.101 0.703 1.017 0.96 -0.183 0.771 1.078 0.94 1.24
σ2b3 : bi3 3.20 -0.080 0.795 0.943 0.96 0.064 1.064 1.175 0.95 1.78
σ2e1 : error 7.40 -0.029 0.326 0.333 0.95 -0.010 0.325 0.332 0.95 0.98
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Table 9: Results when data were simulated under a correlated random effects model with moderate correlation (ρ12 = ρ13 =
ρ23 = 0.6) and n = 50: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation,
and Coverage probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=50)
β10: intercept 13.50 0.030 0.231 0.412 0.95 0.027 0.231 0.416 0.96 0.99
β11: time -0.56 -0.002 0.029 0.030 0.95 -0.002 0.029 0.030 0.95 1.03
β12: treatment -3.35 -0.011 0.413 0.413 0.95 -0.014 0.411 0.416 0.95 0.99
β13: time×treatment -0.57 -0.001 0.030 0.029 0.95 -0.002 0.030 0.030 0.95 1.00
Ordinal Process
α2: threshold 0.45 -0.023 0.077 0.078 0.94 -0.027 0.078 0.079 0.94 1.05
β20: intercept 1.70 -0.024 0.280 0.415 0.96 -0.061 0.281 0.427 0.94 1.05
β21: time -0.27 0.006 0.037 0.036 0.94 0.010 0.037 0.036 0.94 1.05
β22: treatment 0.65 -0.007 0.410 0.410 0.94 -0.012 0.421 0.419 0.95 1.05
β23: time×treatment -0.10 0.001 0.034 0.034 0.95 0.002 0.035 0.035 0.95 1.05
Survival Process
β30: intercept -3.31 0.038 0.268 0.336 0.95 0.049 0.303 0.383 0.95 1.28
β31: treatment 0.37 0.019 0.364 0.321 0.95 -0.007 0.391 0.359 0.95 1.15
Association Parameters & Variances
ρ12 0.60 -0.016 0.074 0.110 0.95 - - - - -
ρ13 0.60 -0.099 0.125 0.148 0.89 - - - - -
ρ23 0.60 -0.094 0.132 0.152 0.91 - - - - -
σ2b1 : bi1 5.87 0.083 0.682 1.363 0.95 -0.013 0.679 1.379 0.96 0.98
σ2b2 : bi2 4.89 -0.233 1.164 1.560 0.95 -0.515 1.221 1.669 0.94 1.25
σ2b3 : bi3 3.20 0.775 1.059 1.243 0.93 -0.064 1.521 1.754 0.95 1.34
σ2e1 : error 7.40 -0.052 0.466 0.475 0.94 -0.030 0.462 0.472 0.94 0.97
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Table 10: Results when data were simulated under a correlated random effects model with moderate correlation (ρ12 = ρ13 =
ρ23 = 0.6) and n = 100: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation,
and Coverage probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=100)
β10: intercept 13.50 0.016 0.165 0.289 0.96 0.007 0.165 0.292 0.96 0.99
β11: time -0.56 0.000 0.020 0.020 0.94 0.000 0.020 0.021 0.94 1.01
β12: treatment -3.35 0.015 0.285 0.290 0.94 0.012 0.284 0.291 0.94 0.99
β13: time×treatment -0.57 0.000 0.020 0.021 0.96 0.000 0.020 0.021 0.95 1.00
Ordinal Process
α2: threshold 0.45 -0.008 0.054 0.055 0.94 -0.010 0.054 0.055 0.94 1.02
β20: intercept 1.70 0.004 0.188 0.286 0.95 -0.018 0.189 0.293 0.94 1.02
β21: time -0.27 0.003 0.025 0.025 0.96 0.005 0.025 0.025 0.95 1.05
β22: treatment 0.65 0.022 0.278 0.283 0.95 0.014 0.283 0.288 0.95 1.03
β23: time×treatment -0.10 0.000 0.024 0.024 0.96 0.001 0.024 0.024 0.96 1.04
Survival Process
β30: intercept -3.31 0.008 0.197 0.241 0.95 0.016 0.213 0.266 0.94 1.17
β31: treatment 0.37 0.041 0.246 0.230 0.95 0.027 0.255 0.250 0.95 1.06
Association Parameters & Variances
ρ12 0.60 -0.005 0.049 0.079 0.95 - - - - -
ρ13 0.60 -0.086 0.096 0.112 0.84 - - - - -
ρ23 0.60 -0.080 0.104 0.115 0.87 - - - - -
σ2b1 : bi1 5.87 0.076 0.401 0.941 0.96 0.027 0.405 0.949 0.96 0.99
σ2b2 : bi2 4.89 -0.100 0.700 1.050 0.96 -0.240 0.726 1.089 0.94 1.17
σ2b3 : bi3 3.20 0.622 0.961 0.982 0.94 -0.001 1.152 1.197 0.96 1.01
σ2e1 : error 7.40 -0.022 0.326 0.333 0.95 -0.010 0.325 0.332 0.95 0.99
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Table 11: Results when data were simulated under a correlated random effects model but with ρ12 = ρ13 = ρ23 = 0.0 and n = 50:
MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability
of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=50)
β10: intercept 13.50 0.026 0.234 0.412 0.95 0.028 0.233 0.416 0.95 0.99
β11: time -0.56 -0.002 0.029 0.030 0.94 -0.002 0.029 0.030 0.94 1.00
β12: treatment -3.35 -0.004 0.408 0.414 0.95 -0.009 0.406 0.416 0.95 0.99
β13: time×treatment -0.57 -0.002 0.030 0.030 0.95 -0.002 0.030 0.030 0.95 0.99
Ordinal Process
α2: threshold 0.45 -0.027 0.075 0.078 0.94 -0.031 0.076 0.079 0.93 1.05
β20: intercept 1.70 -0.040 0.273 0.411 0.94 -0.067 0.277 0.422 0.93 1.07
β21: time -0.27 0.005 0.037 0.036 0.94 0.009 0.038 0.036 0.94 1.06
β22: treatment 0.65 -0.025 0.380 0.407 0.94 -0.031 0.385 0.415 0.95 1.03
β23: time×treatment -0.10 0.001 0.033 0.035 0.95 0.002 0.034 0.035 0.95 1.03
Survival Process
β30: intercept -3.31 0.002 0.253 0.312 0.95 0.062 0.301 0.387 0.95 1.18
β31: treatment 0.37 0.032 0.338 0.304 0.95 -0.014 0.376 0.362 0.96 1.08
Association Parameters & Variances
ρ12 0.00 -0.003 0.087 0.161 0.95 - - - - -
ρ13 0.00 0.015 0.230 0.277 0.95 - - - -
ρ23 0.00 0.000 0.254 0.282 0.96 - - - - -
σ2b1 : bi1 5.87 0.072 0.686 1.363 0.96 -0.019 0.683 1.379 0.96 0.98
σ2b2 : bi2 4.89 -0.140 1.170 1.545 0.95 -0.427 1.222 1.638 0.93 1.21
σ2b3 : bi3 3.20 1.370 1.381 1.303 0.96 -0.138 1.642 1.794 0.95 0.72
σ2e1 : error 7.40 -0.039 0.462 0.474 0.94 -0.030 0.462 0.473 0.94 0.99
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Table 12: Results when data were simulated under a correlated random effects model but with ρ12 = ρ13 = ρ23 = 0.0 and
n = 100: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage
probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=100)
β10: intercept 13.50 0.010 0.165 0.291 0.95 0.008 0.165 0.292 0.95 1.00
β11: time -0.56 0.000 0.020 0.021 0.94 0.000 0.020 0.021 0.94 1.00
β12: treatment -3.35 0.021 0.287 0.291 0.95 0.018 0.286 0.292 0.95 1.00
β13: time×treatment -0.57 0.000 0.020 0.021 0.95 0.000 0.020 0.021 0.95 1.00
Ordinal Process
α2: threshold 0.45 -0.015 0.054 0.055 0.94 -0.017 0.055 0.055 0.94 1.03
β20: intercept 1.70 -0.011 0.193 0.285 0.95 -0.026 0.198 0.293 0.94 1.07
β21: time -0.27 0.002 0.026 0.025 0.94 0.004 0.026 0.025 0.93 1.05
β22: treatment 0.65 -0.001 0.284 0.283 0.96 -0.012 0.285 0.287 0.96 1.01
β23: time×treatment -0.10 0.001 0.023 0.024 0.95 0.003 0.023 0.024 0.96 1.00
Survival Process
β30: intercept -3.31 -0.026 0.190 0.240 0.95 0.014 0.205 0.265 0.95 1.14
β31: treatment 0.37 0.041 0.241 0.230 0.95 0.023 0.251 0.250 0.95 1.06
Association Parameters & Variances
ρ12 0.00 0.003 0.055 0.115 0.95 - - - - -
ρ13 0.00 -0.011 0.136 0.172 0.94 - - - - -
ρ23 0.00 0.000 0.143 0.178 0.95 - - - - -
σ2b1 : bi1 5.87 0.069 0.403 0.943 0.95 0.021 0.403 0.950 0.95 0.97
σ2b2 : bi2 4.89 -0.064 0.798 1.053 0.96 -0.216 0.821 1.084 0.95 1.13
σ2b3 : bi3 3.20 0.733 1.145 1.095 0.91 0.022 1.076 1.183 0.96 0.63
σ2e1 : error 7.40 -0.015 0.325 0.333 0.95 -0.010 0.324 0.332 0.95 1.00
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Table 13: Results when data were simulated under a correlated random effects model with unstructured correlation (ρ12 =
0.9, ρ13 = 0.6, ρ23 = 0.3) and n = 50: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior
standard deviation, and Coverage probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=50)
β10: intercept 13.50 -0.019 0.228 0.413 0.96 -0.027 0.233 0.416 0.95 1.05
β11: time -0.56 0.002 0.028 0.029 0.95 0.002 0.029 0.030 0.94 1.09
β12: treatment -3.35 0.008 0.408 0.416 0.94 0.011 0.409 0.416 0.95 1.01
β13: time×treatment -0.57 0.001 0.029 0.029 0.95 0.002 0.030 0.030 0.95 1.05
Ordinal Process
α2: threshold 0.45 0.027 0.078 0.079 0.94 0.028 0.078 0.079 0.94 1.01
β20: intercept 1.70 0.058 0.278 0.418 0.94 0.076 0.287 0.427 0.94 1.09
β21: time -0.27 -0.010 0.037 0.036 0.94 -0.011 0.038 0.036 0.93 1.07
β22: treatment 0.65 0.020 0.402 0.412 0.95 0.021 0.415 0.418 0.95 1.07
β23: time×treatment -0.10 -0.002 0.034 0.034 0.95 -0.002 0.036 0.035 0.95 1.12
Survival Process
β30: intercept -3.31 0.006 0.269 0.345 0.95 -0.022 0.289 0.378 0.95 1.16
β31: treatment 0.37 0.000 0.335 0.330 0.96 0.014 0.350 0.355 0.94 1.10
Association Parameters & Variances
ρ12 0.90 -0.007 0.036 0.047 0.95 - - - - -
ρ13 0.60 0.034 0.127 0.161 0.95 - - - - -
ρ23 0.30 0.104 0.178 0.208 0.91 - - - - -
σ2b1 : bi1 5.87 0.023 0.675 1.377 0.96 0.018 0.683 1.380 0.96 1.02
σ2b2 : bi2 4.89 0.380 1.141 1.550 0.94 0.533 1.247 1.673 0.92 1.27
σ2b3 : bi3 3.20 -0.586 1.284 1.392 0.97 -0.028 1.543 1.705 0.96 1.19
σ2e1 : error 7.40 0.023 0.459 0.470 0.94 0.030 0.461 0.472 0.94 1.01
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Table 14: Results when data were simulated under a correlated random effects model with unstructured correlation (ρ12 =
0.9, ρ13 = 0.6, ρ23 = 0.3) and n = 100: MCSD, SD, and CP stand for Monte Carlo Standard Deviation, Posterior
standard deviation, and Coverage probability of 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJC
Correlated
Continuous Process
(n=100)
β10: intercept 13.50 -0.018 0.165 0.290 0.96 -0.008 0.166 0.292 0.95 1.00
β11: time -0.56 0.000 0.020 0.020 0.95 0.000 0.020 0.021 0.95 1.05
β12: treatment -3.35 -0.025 0.284 0.289 0.95 -0.020 0.286 0.292 0.95 1.01
β13: time×treatment -0.57 0.001 0.019 0.020 0.95 0.000 0.020 0.021 0.95 1.05
Ordinal Process
α2: threshold 0.45 0.012 0.052 0.055 0.95 0.013 0.052 0.055 0.94 1.00
β20: intercept 1.70 0.009 0.184 0.289 0.95 0.020 0.187 0.293 0.95 1.05
β21: time -0.27 -0.005 0.024 0.024 0.96 -0.005 0.025 0.025 0.95 1.05
β22: treatment 0.65 -0.019 0.270 0.282 0.96 -0.015 0.276 0.288 0.96 1.04
β23: time×treatment -0.10 -0.001 0.023 0.023 0.94 -0.002 0.024 0.024 0.95 1.09
Survival Process
β30: intercept -3.31 -0.017 0.199 0.255 0.95 -0.029 0.210 0.268 0.95 1.13
β31: treatment 0.37 -0.016 0.255 0.242 0.95 -0.013 0.262 0.252 0.95 1.05
Association Parameters & Variances
ρ12 0.90 -0.006 0.025 0.034 0.94 - - - - -
ρ13 0.60 0.025 0.088 0.112 0.94 - - - - -
ρ23 0.30 0.047 0.120 0.144 0.93 - - - - -
σ2b1 : bi1 5.87 -0.020 0.394 0.947 0.96 -0.020 0.405 0.949 0.96 1.06
σ2b2 : bi2 4.89 0.188 0.701 1.038 0.94 0.244 0.753 1.089 0.94 1.19
σ2b3 : bi3 3.20 -0.215 0.971 1.081 0.97 0.058 1.126 1.216 0.96 1.28
σ2e1 : error 7.40 0.008 0.323 0.331 0.94 0.011 0.324 0.332 0.95 1.01
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4.5 ANALYSIS OF UGANDAN DIABETES DATA
In this section, we apply our proposed joint model to the diabetes data introduced in
Section 4.1. These data were collected retrospectively from three hospitals (Mulago, Nsambya,
and Rubaga all in Kampala, Uganda) to determine the factors associated with time to
blood glucose normalization (Buhule et al., 2007) [8]. Because the blood glucose test is more
expensive than the urine glucose test, quite a number of individuals had no blood glucose
measurements taken on most of the hospital visits. About 825 of the 1010 patients had no
blood glucose measurements taken on most of the occasions but instead urine glucose was
taken. In the original 2007 study, only a survival (unshared frailty) model was fitted to these
data from which inferences were made. For the current study we considered data for type 2
diabetic patients who had blood glucose measurements taken and were not in the normal
range on the first hospital visit. We defined time-to-event as time to when blood glucose level
reached normal range of 70 − 180 mg/dl to include those who may have not been fasting
(scenario 1) and 70− 130 mg/dl the fasting glucose normal range (scenario 2). For scenario
1, we had a total of 500 patients and out of these, 314 experienced the event of interest
(37% censoring). While for scenario 2, we had 543 patients and 248 experienced the event of
interest, which was a 54% censoring rate.
Because high blood pressure and BMI are believed to be associated with type 2 diabetes
we used them as repeatedly measured biomarkers in this analysis. Our goal was to understand
how the biomarkers are related to time to normal blood glucose level for diabetic patients
given different treatments and other covariates. The covariates of interest included treatment
(Biguanides, Sulphonyureas, and Insulin (baseline)), baseline age in years, gender (male=1,
female=0), time of hospital visits in months, and time and treatment interaction. The
summary statistics of these covariates under the two scenarios are given in Table 15. We
observed similar distributions for all variables across the two scenarios. The average baseline
age was about 54 years with a standard deviation of 11 years and the majority of the patients
were female (about 70%). The median failure time was about 12 months while the median
censoring time was about 24 months. Most of the patients were treated with Biguanides at
baseline.
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Table 15: Descriptive statistics for baseline characteristics and survival times
Blood Glucose Normal Range (mg/dl)
70− 180 70− 130
Variable n = 500 n = 543
Age (years), x¯ (s) 53.8 (11.2) 53.9 (11.1)
Gender
Male, n (%) 151 (30.2) 159 (29.3)
Female, n (%) 349 (69.8) 384 (70.7)
Treatment
Biguanides, n (%) 198 (39.6) 212 (39.0)
Sulphonyureas, n (%) 149 (29.8) 166 (30.6)
Insulin, n (%) 153 (30.6) 165 (30.4)
Survival Times
Failure, x˜ (s) 11.9 (22.5) 12.3 (22.6)
Censoring, x˜ (s) 23.6 (29.9) 24.4 (28.5)
We jointly modeled the two biomarkers and time to normal blood glucose level (scenarios
1 & 2 separately) through correlated and shared random effects and compared the parameter
estimates to separate models.
For the continuous biomarker, we considered systolic blood pressure in millimeters of
mercury (mm Hg) which was square root transformed to improve normality. The conditional
transformed measurements were then modeled as Normal (yij,1|bi1 ∼ N(µij,1, σ2e1) and thus
linked to the linear predictor with an identity link. That is,
yij,1 = µij,1 = β10 + β11 × timeij + β12 ×Biguani + β13 × Sulphoni + β14 × agei + β15
× genderi + β16 ×Biguani × timeij + β17 × Sulphoni × timeij + bi1 + ij,1,
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where, yij,1 is the square root of systolic blood pressure (mm Hg) for the i
th subject measured
at the jth hospital visit, bi1 is the random intercept and ij,1 ∼ N(0, σ2e1) is the measurement
error independent of bi1.
Lastly, we defined the ordinal biomarker by grouping BMI into K = 4 categorizes as
below:
yijk,2 =

1 for BMI < 18.5 ⇒ Underweight
2 for 18.5 ≤ BMI ≤ 24.9 ⇒ Normal
3 for 25 ≤ BMI ≤ 29.9 ⇒ Overweight
4 for BMI ≥ 30 ⇒ Obesity
The conditional K − 1 measurements were modeled through a multinomial distribution
((yij1,2, . . . , yijK−1,2)|bi2 ∼ multinomial(piij1, . . . , piijK−1)). The marginal probabilities were
linked to the covariates through a cumulative logit link as follows:
log
(
Pr(yij,2 ≤ k)
1− Pr(yij,2 ≤ k)
)
= αk − [β21 × timeij + β22 ×Biguani + β23 × Sulphoni
+ β24 × agei + β25 × genderi + β26 ×Biguani × timeij
+ β27 × Sulphoni × timeij + bi2] ,
where k = 1, . . . , 4 and bi2 is the random intercept.
Lastly, time to normal blood glucose level T was modeled through a Weibull distribution
with frailty truncated to the left by the censoring times. Thus, Ti|bi3 ∼ Weibull(λ, µi3),
where log(µi3) = β30 +β31×Biguani +β32×Sulphoni +β33× agei +β34× genderi + bi3 and
bi3 is the frailty term. For simplicity, we set λ = 1 which gave an Exponential distribution.
For the correlated random effects joint model, the random effects were modeled as
bi1
bi2
bi3
 ∼ N3


0
0
0
 ,Γ =

σ2b1 ρ12σb1σb2 ρ13σb1σb3
ρ12σb2σb1 σ
2
b2
ρ23σb2σb3
ρ13σb3σb1 ρ23σb3σb2 σ
2
b3

 .
While for the shared random effects joint model, we assumed bi2 = γ1bi1 and bi3 = γ2bi1 with
bi1 ∼ N(0, σ2b1).
For all parameters, vague or non-informative priors were employed to allow the data to
dominate the inferences made. Specifically, multivariate normal priors with mean zero and
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precision matrices 0.01I8, 0.01I7, and 0.01I5 were employed for β1, β2, and β3, respectively,
where Iq indicates an q × q identity matrix. For the thresholds or cut points αk, a truncated
normal N(0, 106)I(αk−1, αk+1) ; k = 1, . . . , K−1, where I(·, ·) denotes truncation to specified
interval was employed. In addition, an inverse gamma prior was assumed for error variance σ2e1 ,
that is, σ2e1 ∼ Inverse Gamma(1, 1) or 1/σ2e1 ∼ Gamma(1, 1) and an Inverse Wishart for the
variance convariance matrix of the random effects, which are both conjugate priors. For the
separate models, we assumed half-Cauchy(s=25) priors for σb1 , σb2 , and σb3 , and for the shape
parameter λ of the Weibull distribution a conjugate Gamma prior (λ ∼ Gamma(0.1, 0.1))
was assumed when we didn’t set it to 1. The association parameters for shared random effects
model had normal priors, that is, γ1 ∼ N(0, 100) and γ2 ∼ N(0, 100).
To accelerate computation, time was standardized while age was centered, and the MCMC
was run for 30, 000 iterations with the first 5, 000 discarded as burn-in. The models were fitted
in OpenBUGS (version 3.2.2) and its R interface BRugs Version 0.8.3 and based on standard
MCMC diagnostic plots (see Appendix D Figures 11-18) and diagnostic tests (Table 16)
the estimated parameters converged though more iterations would be required for better
convergence of the ordinal outcome regression estimates.
Tables 17 & 18 give a summary of the posterior estimates of the regression coefficients
and their 95% credible intervals (CIs) for the joint versus separate analyses under scenario 1
and scenario 2, respectively.
The results in Table 17 for normal blood glucose range of 70− 180 mg/dl showed similar
point estimates across the three models but subtle differences were observed in their credible
intervals (CIs). The CIs for the parameter estimates for the ordinal and survival outcomes
shrunk in both the joint correlated and joint shared analyses but all shrunk in the joint
shared analysis indicating improved efficiency of parameter estimates. Age was found to be
significantly associated with systolic blood pressure in all three models. Diabetes patients
had increasing systolic blood pressure levels with age, indicating increased risk of systolic
hypertension among the elderly. These findings are consistent with studies that have indicated
that hypertension which is associated with type 2 diabetes is more common in women than in
men and that the age-related increase in systolic blood pressure is steeper in women (Williams,
2003)[98]. The results in Table 17 also showed that age, gender, and the Sulphonyureas
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treatment were significantly associated with BMI levels in all three models and Sulphonyureas
and time interaction was significant in the joint correlated and separate models. Male patients
tended to have lower BMI levels as compared to their female counterparts, and the elderly
patients had lower BMI levels. Patients who were treated with Sulphonyureas had higher
BMI levels at baseline as compared to those treated with Insulin but over time their BMI
levels decreased. This is supported by the fact that Sulphonyureas causes weight gain in the
first years which levels off with time. For the survival outcome, Sulphonyureas treatment
was significantly associated with time to normal blood glucose level in all three models while
gender was significant in the shared random effects model. The patients who were treated
with Sulphonyureas had their blood glucose levels reach normal range faster than those
treated with Insulin. These finding are different from the original study [8] where Biguanides
was found to work better than Insulin and Sulphonyureas. However, Sulphonyureas is only
given to Type 2 diabetics, thus by including the Type 1 diabetics in the original analysis
could have masked the effect of Sulphonyureas. The male patients had their blood glucose
levels reach normal range later than the female patients, which is consistent with the original
study [8].
Furthermore, the posterior estimates of the association parameters ρ12 and ρ23 in the
joint correlated random effects model and γ1 and γ2 in the joint shared random effects model
were positive and significantly different from zero. Implying, positive association between
the systolic blood pressure and BMI sub-models (ρ12 and γ1), BMI and survival sub-models
(ρ23), and systolic blood pressure and survival sub-models (γ2). Thus, the initial level of
systolic blood pressure was positively associated with the BMI levels and also with time to
normal blood glucose levels. In addition, the initial levels of BMI were positively associated
with time to normal blood glucose levels. The goodness of fit measure (DIC), indicated that
the joint correlated random effects model fit our data better than the shared random effects
model.
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Table 16: Convergence Diagnostic tests results for analysis of Type 2 Diabetes Data: Normal blood glucose 70− 180 mg/dl.
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
Gelman Geweke Heidelberg Gelman Geweke Heidelberg Gelman Geweke Heidelberg
Parameter Estimate Z-score Stationarity Halfwidth Estimate Z-score Stationarity Halfwidth Estimate Z-score Stationarity Halfwidth
Continuous Process: systolic blood pressure
Intercept 1.00 -1.015 passed passed 1.00 1.242 passed passed 1.00 -0.429 passed passed
Time 1.00 0.472 passed failed 1.00 -1.834 passed passed 1.00 0.673 passed passed
Treatment
Biguanides 1.00 -0.437 passed passed 1.00 -0.621 passed failed 1.00 0.076 passed passed
Sulphonyureas 1.00 -1.063 passed passed 1.00 -0.471 passed passed 1.00 -1.324 passed passed
Age in years 1.00 0.233 passed passed 1.00 2.267 failed < NA > 1.00 0.672 passed passed
Male 1.00 1.771 passed passed 1.00 -1.197 passed passed 1.00 1.666 passed passed
Treatment×Time
Biguanides×Time 1.00 1.374 passed passed 1.00 1.963 passed passed 1.00 -0.699 passed passed
Sulphonyureas×Time 1.00 1.473 passed passed 1.00 -0.043 passed passed 1.00 -0.371 passed passed
Ordinal Process: BMI categories
Threshold-1 1.02 0.137 passed passed 1.03 -0.647 passed passed 1.02 0.845 passed passed
Threshold-2 1.02 1.447 passed passed 1.03 -0.620 passed passed 1.06 1.848 passed passed
Threshold-3 1.01 1.279 passed passed 1.01 -0.541 passed passed 1.08 2.697 failed < NA >
Time 1.00 -1.561 passed passed 1.00 -1.457 passed passed 1.00 -0.992 passed failed
Treatment
Biguanides 1.03 1.960 passed failed 1.03 -0.267 passed failed 1.07 0.971 passed failed
Sulphonyureas 1.04 0.829 passed passed 1.02 -0.178 passed passed 1.08 -0.693 passed failed
Age in years 1.01 1.234 passed passed 1.01 1.621 failed < NA > 1.00 -0.183 passed passed
Male 1.06 2.267 passed passed 1.03 -0.521 passed passed 1.06 -0.979 passed passed
Treatment×Time
Biguanides×Time 1.00 1.236 passed passed 1.00 1.719 passed passed 1.00 -0.775 passed passed
Sulphonyureas×Time 1.00 0.490 passed passed 1.01 0.049 passed passed 1.00 0.336 passed passed
Survival Process: time to a normal blood glucose level
Intercept 1.00 -1.870 passed passed 1.00 0.833 passed passed 1.00 0.959 passed passed
Treatment
Biguanides 1.00 -1.971 passed passed 1.00 -0.370 failed < NA > 1.00 0.231 passed passed
Sulphonyureas 1.00 1.073 passed passed 1.00 0.240 passed passed 1.00 -1.215 passed passed
Age in years 1.00 1.314 passed passed 1.00 2.363 failed < NA > 1.00 1.447 passed passed
Male 1.00 1.620 passed passed 1.00 -0.157 passed passed 1.00 0.668 passed passed
Association Parameters & Variances
ρ12 1.00 -1.797 passed passed - - - - - - - -
ρ13 1.00 2.049 passed failed - - - - - - - -
ρ23 1.02 -1.054 passed passed - - - - - - - -
γ1 - - - - 1.05 -1.355 passed passed - - - -
γ2 - - - - 1.00 -1.598 passed passed - - - -
σ2b1 1.00 1.099 passed passed 1.01 1.655 passed passed 1.00 1.306 passed passed
σ2b2 1.00 -0.732 passed passed - - - - 1.00 1.226 passed passed
σ2b3 1.01 1.483 passed passed - - - - 1.00 -0.703 passed passed
σ2e1 1.00 -0.877 passed passed 1.00 0.521 passed passed 1.00 0.876 passed passed
Multivariate Test 1.10 - - - 1.07 - - - 1.06 - - -
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The results for normal blood glucose range of 70− 130 mg/dl are shown in Table 18. The
convergence diagnostic results (see Appendix D: Figures 15-18) indicated that all parameters
converged except for regression estimates of the ordinal outcome. The point estimates were
also quite similar across the three models but the CIs differed. There were slightly more
significant variables than in scenario 1 (Table 17) but the trends were similar. Sulphonyureas
treatment and age were found to be significantly associated with systolic blood pressure. The
patients who were treated with Sulphonyureas at baseline had systolic blood pressure that
were lower as compared to those treated with Insulin. Again, the elderly were associated with
higher levels of systolic blood pressure. For the ordinal outcome, the significant variables
remained the same as in Table 17 but Sulphonyureas treatment and time interaction was
significantly associated with BMI levels in all the three models. Similar results as in Table 17
were obtained for the survival outcome, with Sulphonyureas significant in all models and
gender in shared random effects model. Here, the only association parameters significantly
different from zero were ρ12 and γ1; indicating positive correlation between systolic blood
pressure and BMI but no association with survival outcome. Also, the DIC indicated joint
correlated random effects model fit the data better than the shared random effects model.
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Table 17: Analysis of Ugandan Type 2 Diabetes Data: Normal blood glucose 70−180
mg/dl
Joint-Correlated Random Effects Joint-Shared Random Effects Separate
Parameter Mean 95% CI Mean 95% CI Mean 95% CI
Continuous Process: systolic blood pressure
Intercept 11.88 (11.720, 12.050) 11.93 (11.800, 12.060) 11.88 (11.720, 12.050)
Time 0.015 (-0.095, 0.125) 0.028 (-0.078, 0.134) 0.033 (-0.072, 0.137)
Treatment
Biguanides -0.053 (-0.254, 0.148) -0.017 (-0.187, 0.153) -0.051 (-0.254, 0.152)
Sulphonyureas -0.127 (-0.346, 0.092) -0.131 (-0.304, 0.043) -0.119 (-0.336, 0.095)
Age in years 0.018 (0.011, 0.026) 0.022 (0.016, 0.029) 0.018 (0.010, 0.026)
Male -0.069 (-0.260, 0.120) -0.124 (-0.287, 0.040) -0.074 (-0.261, 0.112)
Treatment×Time
Biguanides×Time -0.056 (-0.215, 0.104) -0.016 (-0.177, 0.147) -0.079 (-0.236, 0.081)
Sulphonyureas×Time 0.112 (-0.066, 0.289) 0.157 (-0.001, 0.314) 0.115 (-0.061, 0.288)
Ordinal Process: BMI categories
Threshold-1 -14.4 (-17.55, -11.780) -12.1 (-14.25, -10.110) -14.71 (-17.73, -12.090)
Threshold-2 -4.294 (-6.108, -2.602) -3.822 (-5.155, -2.491) -4.506 (-6.134, -2.938)
Threshold-3 2.788 (1.233, 4.497) 2.105 (0.895, 3.407) 2.694 (1.209, 4.156)
Time 0.483 (-0.088, 1.057) 0.464 (-0.021, 0.943) 0.244 (-0.353, 0.810)
Treatment
Biguanides 1.499 (-0.305, 3.396) 0.99 (-0.531, 2.475) 1.343 (-0.500, 3.056)
Sulphonyureas 3.034 (1.219, 5.200) 2.283 (0.905, 3.767) 2.814 (0.834, 4.711)
Age in years -0.084 (-0.155, -0.014) -0.071 (-0.127, -0.014) -0.082 (-0.157, -0.011)
Male -3.712 (-5.409, -1.938) -3.226 (-4.593, -1.835) -3.697 (-5.598, -1.948)
Treatment×Time
Biguanides×Time -0.5 (-1.356, 0.356) -0.441 (-1.181, 0.305) -0.531 (-1.418, 0.353)
Sulphonyureas×Time -0.898 (-1.789, -0.068) -0.626 (-1.378, 0.132) -0.891 (-1.794, -0.034)
Survival Process: time to a normal blood glucose level
Intercept -3.922 (-4.239, -3.620) -3.882 (-4.128, -3.643) -3.893 (-4.211, -3.590)
Treatment
Biguanides 0.286 (-0.078, 0.654) 0.285 (-0.009, 0.580) 0.242 (-0.127, 0.610)
Sulphonyureas 0.925 (0.549, 1.305) 0.766 (0.475, 1.059) 0.894 (0.519, 1.283)
Age in years 0.003 (-0.011, 0.016) 0.002 (-0.009, 0.013) 0.002 (-0.011, 0.016)
Male -0.242 (-0.561, 0.079) -0.357 (-0.610, -0.110) -0.23 (-0.555, 0.107)
Association Parameters & Variances
ρ12 0.195 (0.071, 0.315) - - - -
ρ13 -0.032 (-0.289, 0.215) - - - -
ρ23 0.357 (0.160, 0.555) - - - -
γ1 - - 21.04 (17.590, 24.490) - -
γ2 - - 0.987 (0.488, 1.531) - -
σ2b1 0.513 (0.415, 0.622) 0.092 (0.064, 0.127) 0.512 (0.415, 0.622)
σ2b2 60.87 (42.970, 84.500) - - 63.25 (45.010, 89.450)
σ2b3 0.764 (0.373, 1.233) - - 0.836 (0.003, 1.395)
σ2e1 0.695 (0.631, 0.766) 1.297 (1.196, 1.406) 0.696 (0.631, 0.767)
Goodness of fit (DIC)
Continuous 3316 - 3815 - 3321 -
Ordinal 1091 - 1196 - 1083 -
Survival 2815 - 2880 - 2825 -
Total 7222 - 7890 - - -
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Table 18: Analysis of Ugandan Type 2 Diabetes Data: Normal blood glucose 70−130
mg/dl
Joint-Correlated Random Effects Joint-Shared Random Effects Separate
Parameter Mean 95% CI Mean 95% CI Mean 95% CI
Continuous Process: systolic blood pressure
Intercept 11.93 (11.780, 12.080) 11.94 (11.830, 12.050) 11.93 (11.770, 12.080)
Time 0.005 (-0.087, 0.097) 0.032 (-0.055, 0.119) 0.027 (-0.062, 0.116)
Treatment
Biguanides -0.091 (-0.279, 0.096) -0.061 (-0.203, 0.080) -0.083 (-0.274, 0.107)
Sulphonyureas -0.242 (-0.442, -0.041) -0.27 (-0.418, -0.125) -0.227 (-0.424, -0.027)
Age in years 0.017 (0.010, 0.024) 0.016 (0.011, 0.021) 0.017 (0.010, 0.024)
Male -0.116 (-0.292, 0.060) -0.125 (-0.260, 0.010) -0.124 (-0.300, 0.053)
Treatment×Time
Biguanides×Time 0.048 (-0.086, 0.182) 0.041 (-0.092, 0.174) 0.026 (-0.109, 0.158)
Sulphonyureas×Time 0.059 (-0.069, 0.188) 0.091 (-0.028, 0.211) 0.062 (-0.068, 0.189)
Ordinal Process: BMI categories
Threshold-1 -15.65 (-18.240, -13.300) -13.34 (-15.44, -11.380) -15.87 (-18.750, -13.400)
Threshold-2 -4.791 (-6.324, -3.281) -4.342 (-5.729, -2.896) -4.825 (-6.464, -3.348)
Threshold-3 2.73 (1.235, 4.210) 2.221 (0.924, 3.700) 2.789 (1.348, 4.187)
Time 0.261 (-0.227, 0.771) 0.236 (-0.181, 0.639) 0.183 (-0.340, 0.710)
Treatment
Biguanides 1.813 (-0.050, 3.537) 1.211 (-0.433, 2.889) 1.798 (0.185, 3.544)
Sulphonyureas 2.651 (0.832, 4.290) 2.161 (0.136, 3.960) 2.69 (0.932, 4.551)
Age in years -0.105 (-0.174, -0.031) -0.093 (-0.152, -0.038) -0.098 (-0.170, -0.022)
Male -4.177 (-5.891, -2.389) -3.564 (-5.225, -2.144) -4.05 (-5.919, -2.081)
Treatment×Time
Biguanides×Time 0.008 (-0.749, 0.764) -0.035 (-0.668, 0.620) 0.038 (-0.720, 0.830)
Sulphonyureas×Time -0.874 (-1.588, -0.174) -0.741 (-1.361, -0.102) -0.853 (-1.568, -0.114)
Survival Process: time to a normal blood glucose level
Intercept -4.268 (-4.631, -3.927) -4.15 (-4.412, -3.898) -4.283 (-4.658, -3.935)
Treatment
Biguanides -0.057 (-0.470, 0.363) 0.012 (-0.301, 0.331) -0.077 (-0.513, 0.361)
Sulphonyureas 0.554 (0.135, 0.987) 0.426 (0.112, 0.736) 0.562 (0.120, 1.002)
Age in years 0.008 (-0.007, 0.024) 0.005 (-0.007, 0.016) 0.009 (-0.007, 0.025)
Male -0.298 (-0.682, 0.083) -0.335 (-0.615, -0.062) -0.299 (-0.685, 0.086)
Association Parameters & Variances
ρ12 0.183 (0.071, 0.292) - - - -
ρ13 -0.107 (-0.314, 0.096) - - - -
ρ23 0.159 (-0.013, 0.332) - - - -
γ1 - - 24.42 (21.390, 28.080) - -
γ2 - - 0.402 (-0.103, 0.921) - -
σ2b1 0.533 (0.445, 0.633) 0.086 (0.063, 0.115) 0.531 (0.444, 0.630)
σ2b2 70.7 (53.830, 92.350) - - 73.29 (54.400, 95.570)
σ2b3 1.249 (0.627, 1.978) - - 1.484 (0.832, 2.210)
σ2e1 0.683 (0.635, 0.735) 1.256 (1.177, 1.340) 0.683 (0.635, 0.735)
Goodness of fit (DIC)
Continuous 5042 - 5886 - 5047 -
Ordinal 1426 - 1524 - 1421 -
Survival 2427 - 2529 - 2416 -
Total 8895 - 9938 - - -
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4.6 DISCUSSION
In this chapter we have developed a full Bayesian hierarchical multivariate generalized linear
mixed effects model for repeatedly measured continuous and ordinal measures of disease
severity and time-to-event outcome. This model extended the work in Chapter 3 to include
time-to-event data. Although this model is more complex, use of Bayesian MCMC methods
for parameter estimation makes it more user-friendly, given that in many clinical studies there
is more than one biomarker that is associated with the event of interest. Moreover, we have
used a parametric approach to model the baseline hazard in proportional hazards model for
survival outcome which is more flexible than the semi-parametric approach especially when
the Cox proportional hazards assumption is violated. In addition, we have illustrated how
the three outcomes can be modeled jointly through correlated and shared random effects with
a real data example after examining their performance through simulations. In addition, our
proposed joint model can easily be fit in OpenBUGS with code we provide (see Appendix F).
The results from the simulation study illustrated that joint modeling leads to efficient
estimates and adequate 95% coverage probabilities for the population parameters. For the
correlated random effects joint model, the efficiency gain was larger for the ordinal and
survival outcomes estimates than for the continuous outcome. While, for the shared random
effects joint model, the gain in efficiency was larger for the ordinal outcomes compared
to that of the continuous and survival outcomes. Overall, the gain in efficiency increased
with the increase in correlation among the three outcomes and decrease in the sample size.
Furthermore, the diabetes data analysis results showed improved efficiency or more precise
estimates when systolic blood pressure, body mass index, and time to normalization of blood
glucose were modeled jointly. However, the large treatment effects could be due to the fact
that these treatments are given at different stages of the disease.
While in the final stages of this dissertation, two papers by Luo (2014)[66] and Baghfalaki,
Ganjali, and Berridge (2014)[2] came out that have dealt with joint modeling of multivariate
longitudinal outcomes and time-to-event data. Luo [66] worked on joint modeling of binary,
ordinal, and continuous longitudinal outcomes, and time-to-event data and used Bayesian
approach for parameter estimation. In modeling the longitudinal outcomes, multilevel item
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response theory (MLIRT) model was employed where each of the outcomes was modeled first
as a function of latent measure of disease severity θij and then at the second level, θij was
regressed on the covariates of interest. For the time-to-event data, the accelerated failure
time (AFT) model was employed, and the longitudinal outcomes were linked to time-to-event
data through shared random effects. Baghfalaki et al. [2] on the other hand have worked on
continuous and ordinal longitudinal outcomes and time-to-event data, and have also employed
Bayesian approach for parameter estimation like we did. However, for the ordinal outcome,
they considered a continuous latent variable model (logistic) and for the time-to-event data
they employed AFT model, and linked the longitudinal and time-to-event processes through
shared random effects. Our work differs from the above two in several ways: first we employed
generalized linear mixed effects models and modeled the outcomes as multivariate generalized
linear mixed effects model linked through both correlated (general case) and shared random
effects. Secondly, time-to-event data was modeled through a parametric Weibull distribution
with unshared frailty to account for unobserved heterogeneity within individuals as well as
correlation with the longitudinal biomarkers.
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5.0 CONCLUSION
5.1 SUMMARY
In this dissertation, we have developed a multivariate joint model for repeatedly measured
mixed (continuous and ordinal) biomarkers of disease severity and time-to-event for highly
unbalanced data. This work was motivated by a diabetes observational study with highly
unbalanced data, because patients reported for check-ups at different time points and the
number of hospital visits varied from patient to patient. The main markers of diabetes
disease severity in this study were blood glucose in mg/dl (continuous) and urine glucose
levels (ordinal). Other markers taken that are associated with type 2 diabetes in particular;
included blood pressure in mmHG and body mass index.
This dissertation work was done in two parts, where in Part 1 (Chapter 3), we developed
a multivariate joint model for highly unbalanced repeatedly measured continuous and ordinal
markers of disease severity. Each of the outcomes was assumed to be from a distribution that
is in the exponential family, where the conditional mean function was linked to the linear
predictor through some known monotonic function. Thus, for the continuous outcomes, we
assumed an identity link function while for the ordinal outcome a cumulative logit link function
was assumed. Given the random effects, the two outcomes were assumed to be independent
of each other and the repeated measures within an individual were independent observations
from a known distribution in the exponential family. The two outcomes were then modeled
as multivariate generalized linear mixed models linked through correlated and /or shared
random effects. We employed the Bayesian MCMC methods for parameter estimation because
they have the capacity to handle these complex models with ease. Simulation studies were
conducted to assess the performance of our proposed joint model, and the results indicated
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gain in efficiency, unbiased estimates, and adequate 95% coverage probabilities when the two
correlated outcomes were modeled jointly. In addition, we fitted our proposed models to
the diabetes data, and the results showed improved efficiency when blood glucose and urine
glucose were modeled jointly. Lastly, a sensitivity analysis was conducted to asses the effect
of the priors for the variance parameters on the regression parameters. Although differences
were observed in the estimates of variance parameters especially when the hyper-parameters
for Gamma priors were varied, the regression parameters of interest were not affected.
In Part 2 of this dissertation, we extended the work in Part 1 to include time-to-event
data (Chapter 4). Following the same steps, the three outcomes were modeled as multivariate
generalized linear mixed models linked through correlated and/or shared random effects. For
time-to-event, we followed Aitkin and Clayton (1980) [1] and modeled the indicator variable δi
(i.e. whether event occurred or not) as a Poisson variate with mean µi, where the mean was
linked to the linear predictor through a log link function. The simulation study results also
indicated gain in efficiency for estimates from the proposed joint model compared to separate
models. The estimates from the proposed joint model were less biased and had adequate 95%
coverage probabilities. Finally, the results from fitting the proposed joint model to diabetes
data indicated more efficient estimates when systolic blood pressure, BMI, and time to when
blood glucose reached the normal range were modeled jointly than separately.
5.2 EXTENSIONS AND FUTURE WORK
5.2.1 Predictions
The work in this thesis has mainly focused on the joint evaluation of the repeatedly measured
biomarkers of disease severity and time-to-event data. However, one of the key aims of
modeling markers and time-to-event simultaneously, is to predict the event of interest after
adjusting for longitudinal or repeatedly measured markers. Thus, the immediate focus will
be on predictions of either an event of interest given both the longitudinal measurements and
survival data or vise verse. Specifically, we can predict the event of interest or longitudinal
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value for a new subject or individual from the posterior predictive distribution. Supposing
there are m individuals with full data on longitudinal markers (continuous and ordinal)
and time-to-event summarized as Dm = (y11, . . . ,ym1, y12, . . . ,ym2, y13, . . . ,ym3), where
yi1, yi2, and yi3 = (Ti, δi) are the continuous, ordinal, and time-to-event data for the i
th
subject or individual, respectively. As defined earlier, Ti = min(T
∗
i , Ci) is the failure time
and δi = I(T
∗
i ≤ Ci) is an event indicator which indicates whether the observed failure time
is a true failure time, T ∗i , or a censoring time Ci for the i
th subject. Now suppose we have a
new (m+ 1th) subject who has survived up to time s and provided continuous and ordinal
measurements up to this time all summarized as y =
(
y(m+1)1, y(m+1)2, y(m+1)3
)
, where,
y(m+1)3 = (Tm+1 = s, δm+1 = 0). Then, given this data, the predictive distribution for a
new observation y˜ (continuous or ordinal) from this distribution with random effects b˜ and
hyper-parameters Θ = (β1, β2, β3, α, σ
2
 , λ,Γ) is
p(y˜|Dm, y) =
∫ ∫
p(y˜|y, b˜,Θ)p(b˜|y,Θ)p(Θ|Dm)dΘdb˜.
In the same way, the predicted survival probability for the time to event T˜ for the new
subject, at time t given survival up to time s is
p(T˜ ≥ t|Dm, T˜ > s,y(m+1)1,y(m+1)2) =
∫ ∫
p(T˜ ≥ t|T˜ > s,y(m+1)1,y(m+1)2, b˜)p(b˜|T˜ > s,y(m+1)1,y(m+1)2,Θ)p(Θ|Dm)dΘdb˜,
where p(b˜|T˜ > s,y(m+1)1,y(m+1)2,Θ) is the posterior distribution of the random effects for the
new subject conditional on their data and the hyper-parameters Θ (Sweeting and Thompson,
2011) [89]. We will compare predictions of survival probabilities given different scenarios (i.e.,
only survival data, survival and ordinal, survival and continuous, and (survival, ordinal, and
continuous)). In addition, several methods that include but limited to calibration measures
(Schemper and Henderson, 2000; Henderson et al., 2002) [82, 43] and discrimination measures
(Heagerty et al., 2000; Heagerty and Zheng, 2005) [37, 38] will be employed to assess the
accuracy of these predictions.
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5.2.2 Recurrent and multiple events
Based on our motivating diabetes data, diabetics always have their blood glucose levels
fluctuating given other conditions surrounding them. Thus, the blood glucose levels can
be normal, too low (hypoglycemia), or to high (hyperglycemia) and these conditions are
recurrent. One of our desirable future work will therefore include extending the survival
submodel to account for recurrent and/or multiple events.
5.2.2.1 Recurrent events Considering only the recurrent events (e.g. normal blood
glucose), one way would be to use a shared frailty model as defined by Equation 2.2.41
or 2.2.42. Because these events are assumed to be correlated, the shared frailty will account
for this correlation within individuals as well as among the outcomes when we jointly model
the biomarkers and time-to-event.
5.2.2.2 Multiple recurrent events For the multiple recurrent events, a possible way
will be to employ a Multistate Markov model (Huzurbazar, 2005) [50], where each of the
conditions, hypoglycemia, normal, and hyperglycemia is taken as a state. That is, we
depict the transitions among three possible states (1=hypoglycemia, 2=normal, and 3
=hyperglycemia ) as a Markov chain. Let λjk(s) denote the hazard of progression from
state j to k at time t. Then normal blood glucose is reached from hypoglycemia according
to hazard λ12(s), from hyperglycemia according to hazard λ32(s). Alternatively, someone
can move from having normal blood glucose to hypoglycemia according to hazard λ21(s) or
normal to hyperglycemia with hazard λ23(s). To include covariate information and link to the
longitudinal submodels, we will construct a proportional hazards model with frailty for each
transition. This allows great flexibility for different covariates and different linking functions
in each hazard submodel.
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5.3 PUBLIC HEALTH SIGNIFICANCE
Diabetes is one of the most challenging public health problems globally. Its associated
complications such as heart attack and stroke are the leading causes of death especially in the
developed world. Because diabetes is a chronic illness and the severity of its complications can
be so awful, it is a very costly disease to the individuals, families, and to the health-personnel
as well as institutions. Proper treatment, however, can control and prevent the development
of these complications and hence improve the quality of life of millions of people, and reduce
the associated costs. The work in this dissertation proposes more effective statistical methods
that can be employed to estimate the treatment effects efficiently. This will help researchers
as well as clinicians identify effective treatments that can slow down the disease progression.
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APPENDIX A
CHAPTER 3 SIMULATION RESULTS WHEN THE TRUE PROCESSES
ARE CORRELATED THROUGH SHARED RANDOM EFFECTS
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Table 19: Results when data were simulated under a shared random effects model (γ = 0.9): SD and CP, stand for posterior
standard deviation and coverage probabilities of the 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias SD CP RE1 =
MSEJC
MSEJS
Bias SD CP Bias SD CP RE2 =
MSESP
MSEJS
Shared
Continuous Process
(n=50)
β10: intercept 15.34 -0.067 0.584 0.95 0.96 -0.129 0.606 0.94 -0.075 0.600 0.95 0.97
β11: time -0.56 0.001 0.069 0.95 1.00 0.002 0.068 0.95 0.002 0.072 0.95 1.10
β12: treatment -0.50 0.028 0.849 0.96 0.97 0.136 0.864 0.95 0.052 0.848 0.96 0.97
β13: time×treatment 0.30 -0.001 0.097 0.94 1.01 -0.001 0.097 0.94 -0.002 0.101 0.95 1.09
Ordinal Process
α2: threshold 1.25 0.073 0.167 0.92 1.05 0.059 0.169 0.94 0.056 0.166 0.94 1.00
β20: intercept 1.80 0.071 0.565 0.95 1.01 -0.031 0.582 0.95 0.090 0.615 0.94 1.10
β21: time -0.35 -0.026 0.074 0.94 1.06 -0.021 0.071 0.95 -0.020 0.076 0.95 1.10
β22: treatment -0.50 -0.054 0.805 0.94 1.01 0.080 0.819 0.95 -0.109 0.838 0.95 1.04
β23: time×treatment 0.10 0.012 0.100 0.96 1.03 0.010 0.094 0.96 0.011 0.103 0.95 1.10
Association Parameters & Variances
γ 0.9 - - - - 0.076 0.137 0.92 - - - -
σ2b1 : bi1 5.87 0.142 1.503 0.96 0.87 0.276 1.603 0.95 0.276 1.596 0.95 1.00
σ2b2 : bi2 4.75 0.847 1.776 0.92 - - - - 1.125 2.093 0.91 -
σ2e1 : error 7.40 -0.047 0.623 0.94 0.98 0.041 0.631 0.94 0.044 0.644 0.94 1.06
Shared
Continuous Process
(n=100)
β10: intercept 15.34 -0.020 0.420 0.94 1.02 -0.025 0.415 0.94 -0.060 0.426 0.94 1.03
β11: time -0.56 0.006 0.048 0.96 1.00 0.006 0.048 0.96 0.006 0.050 0.95 1.08
β12: treatment -0.50 0.036 0.604 0.94 1.00 0.064 0.592 0.94 0.067 0.606 0.94 0.99
β13: time×treatment 0.30 -0.002 0.068 0.95 1.00 -0.002 0.068 0.95 -0.003 0.071 0.95 1.07
Ordinal Process
α2: threshold 1.25 0.030 0.116 0.95 1.04 0.021 0.116 0.95 0.020 0.118 0.95 0.99
β20: intercept 1.80 0.054 0.399 0.96 1.04 0.018 0.389 0.95 -0.023 0.402 0.96 1.05
β21: time -0.35 -0.011 0.050 0.95 1.02 -0.006 0.050 0.96 -0.004 0.053 0.94 1.07
β22: treatment -0.50 0.007 0.559 0.94 0.99 0.061 0.536 0.95 0.092 0.549 0.94 1.06
β23: time×treatment 0.10 0.003 0.066 0.94 1.00 -0.001 0.066 0.95 -0.004 0.070 0.96 1.07
Association Parameters & Variances
γ 0.9 - - - - 0.035 0.090 0.93 - - - -
σ2b1 : bi1 5.87 0.102 1.046 0.94 0.96 0.108 1.060 0.94 0.137 1.083 0.94 1.06
σ2b2 : bi2 4.75 0.472 1.151 0.93 - - - - 0.472 1.260 0.94 -
σ2e1 : error 7.40 -0.010 0.436 0.95 0.95 0.069 0.447 0.95 0.064 0.449 0.95 1.02
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Table 20: Results when data were simulated under a shared random effects model (γ = 0.6): SD and CP, stand for posterior
standard deviation and coverage probabilities of the 95% HPD intervals, respectively.
Fitted Model
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias SD CP RE1 =
MSEJC
MSEJS
Bias SD CP Bias SD CP RE2 =
MSESP
MSEJS
Shared
Continuous Process
(n=50)
β10: intercept 15.34 -0.031 0.592 0.95 0.98 -0.079 0.609 0.95 -0.047 0.607 0.95 1.00
β11: time -0.56 0.002 0.071 0.94 1.00 0.003 0.070 0.94 0.002 0.073 0.94 1.06
β12: treatment -0.50 0.030 0.849 0.94 0.98 0.114 0.869 0.94 0.060 0.852 0.94 1.00
β13: time×treatment 0.30 0.000 0.099 0.94 1.00 -0.001 0.099 0.94 0.000 0.102 0.94 1.07
Ordinal Process
α2: threshold 1.25 0.075 0.151 0.91 1.16 0.048 0.152 0.94 0.045 0.150 0.94 1.01
β20: intercept 1.80 0.119 0.446 0.94 1.10 0.030 0.438 0.96 0.076 0.457 0.94 1.09
β21: time -0.35 -0.027 0.068 0.93 1.12 -0.016 0.064 0.93 -0.015 0.069 0.94 1.10
β22: treatment -0.50 -0.040 0.613 0.96 1.05 0.045 0.609 0.95 -0.032 0.613 0.96 1.04
β23: time×treatment 0.10 0.013 0.091 0.95 1.05 0.009 0.084 0.94 0.008 0.092 0.94 1.11
Association Parameters & Variances
γ 0.6 - - - - 0.044 0.097 0.92 - - - -
σ2b1 : bi1 5.87 0.095 1.501 0.96 0.87 0.291 1.611 0.96 0.341 1.611 0.96 1.01
σ2b2 : bi2 2.11 0.517 0.848 0.92 - - - - 0.432 0.927 0.93 -
σ2e1 : error 7.40 0.032 0.637 0.95 0.96 0.100 0.645 0.95 0.086 0.649 0.95 1.04
Shared
Continuous Process
(n=100)
β10: intercept 15.34 -0.035 0.419 0.96 1.00 -0.042 0.418 0.96 -0.066 0.425 0.95 1.01
β11: time -0.56 0.002 0.049 0.95 1.00 0.001 0.049 0.95 0.002 0.050 0.95 1.07
β12: treatment -0.50 0.038 0.598 0.94 0.99 0.063 0.592 0.95 0.063 0.604 0.95 1.00
β13: time×treatment 0.30 -0.001 0.069 0.95 1.00 -0.002 0.069 0.95 -0.003 0.071 0.95 1.08
Ordinal Process
α2: threshold 1.25 0.039 0.105 0.93 1.11 0.021 0.105 0.95 0.021 0.108 0.95 1.03
β20: intercept 1.80 0.061 0.303 0.96 1.10 0.010 0.298 0.96 -0.008 0.305 0.96 1.07
β21: time -0.35 -0.016 0.045 0.93 1.12 -0.007 0.045 0.95 -0.007 0.048 0.95 1.12
β22: treatment -0.50 -0.013 0.416 0.94 1.06 0.036 0.401 0.94 0.055 0.408 0.94 1.04
β23: time×treatment 0.10 0.008 0.060 0.96 1.05 0.002 0.060 0.96 0.000 0.063 0.96 1.07
Association Parameters & Variances
γ 0.6 - - - - 0.020 0.063 0.95 - - - -
σ2b1 : bi1 5.87 -0.003 1.033 0.95 0.95 0.046 1.052 0.95 0.100 1.075 0.95 1.06
σ2b2 : bi2 2.11 0.289 0.542 0.92 - - - - 0.165 0.570 0.94 -
σ2e1 : error 7.40 -0.029 0.438 0.95 0.97 0.030 0.450 0.94 0.015 0.446 0.95 1.01
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APPENDIX B
RESULTS FROM FITTING THE JOINT AND SEPARATE MODELS IN
CHAPTER 3 TO UGANDAN TYPE 2 DIABETES DATA
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Table 21: Convergence Diagnostic tests results for analysis of Type 2 Diabetes data.
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
Gelman Geweke Heidelberg Gelman Geweke Heidelberg Gelman Geweke Heidelberg
Parameter Estimate Z-score Stationarity Halfwidth Estimate Z-score Stationarity Halfwidth Estimate Z-score Stationarity Halfwidth
Continuous Process: blood glucose levels
Intercept 1.00 -0.956 passed passed 1.00 0.053 passed passed 1.00 0.536 passed passed
Time 1.00 0.512 passed passed 1.00 -1.169 passed failed 1.00 0.908 passed passed
Treatment
Biguanides 1.00 1.806 passed passed 1.00 -0.063 passed passed 1.00 0.945 passed passed
Sulphonyureas 1.00 1.592 passed passed 1.00 -0.466 passed passed 1.00 1.575 passed passed
BMI 1.00 1.055 passed passed 1.00 -0.015 passed passed 1.00 0.561 passed passed
Male 1.00 -0.452 passed passed 1.00 -1.583 passed passed 1.00 -0.621 passed passed
Treatment×Time
Biguanides×Time 1.00 -0.821 passed passed 1.00 1.410 passed passed 1.00 0.191 passed passed
Sulphonyureas×Time 1.00 0.574 passed passed 1.00 1.528 passed passed 1.00 0.521 passed passed
Ordinal Process: urine glucose categories
Threshold-1 1.00 -1.760 passed passed 1.01 -0.160 passed passed 1.00 0.778 passed passed
Threshold-2 1.00 -1.512 passed passed 1.01 -0.186 passed passed 1.00 0.407 passed passed
Threshold-3 1.00 -1.654 passed passed 1.00 -0.266 passed passed 1.00 0.571 passed passed
Threshold-4 1.00 -1.401 passed passed 1.00 -0.353 passed passed 1.00 -0.631 passed passed
Time 1.00 0.032 passed passed 1.00 -0.990 passed passed 1.00 0.141 passed passed
Treatment
Biguanides 1.00 -1.719 passed passed 1.01 -0.191 passed passed 1.00 0.228 passed passed
Sulphonyureas 1.00 0.432 passed passed 1.00 -0.156 passed passed 1.00 -1.384 passed passed
BMI 1.00 1.065 passed passed 1.01 0.157 passed passed 1.00 1.281 passed passed
Male 1.00 -0.413 passed passed 1.00 -1.282 passed passed 1.00 -1.263 passed passed
Treatment×Time
Biguanides×Time 1.00 0.772 passed passed 1.00 1.517 passed passed 1.00 -0.494 passed passed
Sulphonyureas×Time 1.00 0.272 passed passed 1.01 1.203 passed passed 1.00 0.385 passed passed
Association Parameters & Variances
ρ 1.00 -0.838 passed passed - - - - - - - -
γ - - - - 1.00 -0.552 passed passed - - - -
σ2b1 1.00 1.630 passed passed 1.00 1.124 passed passed 1.00 -1.077 passed passed
σ2b2 1.00 1.412 passed passed - - - - 1.27 0.995 passed failed
σ2e1 1.00 0.156 passed passed 1.00 -0.795 passed passed 1.00 0.607 passed passed
Multivariate Test 1.01 - - - 1.03 - - - 1.00 - - -
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Table 22: Analysis of Ugandan Type 2 Diabetes Data
Joint-Correlated (JC) Joint-Shared (JS) Separate (SP)
Parameter Mean 95% CI Mean 95% CI Mean 95% CI
Continuous Process: blood glucose levels
Intercept 15.82 (15.210, 16.440) 16.14 (15.570, 16.690) 15.74 (15.090, 16.380)
Time -0.39 (-0.793, 0.020) -0.08 (-0.474, 0.314) -0.42 (-0.825, -0.006)
Treatment
Biguanides -0.31 (-0.968, 0.344) -0.58 (-1.197, 0.041) -0.26 (-0.940, 0.430)
Sulphonyureas -0.39 (-1.118, 0.341) -0.79 (-1.461, -0.103) -0.20 (-0.942, 0.547)
BMI -0.03 (-0.096, 0.030) -0.04 (-0.097, 0.009) -0.03 (-0.093, 0.034)
Male -0.54 (-1.492, 0.451) -1.06 (-1.890, -0.232) -0.46 (-1.420, 0.523)
Treatment×Time
Biguanides×Time 0.39 (-0.117, 0.909) 0.36 (-0.145, 0.860) 0.41 (-0.108, 0.925)
Sulphonyureas×Time 0.54 (-0.082, 1.156) 0.46 (-0.156, 1.073) 0.48 (-0.150, 1.112)
Ordinal Process: urine glucose categories
Threshold-1 -0.91 (-1.391, -0.433) -0.73 (-1.137, -0.312) -1.08 (-1.519, -0.612)
Threshold-2 -0.45 (-0.926, 0.024) -0.30 (-0.701, 0.107) -0.62 (-1.059, -0.159)
Threshold-3 0.46 (-0.004, 0.935) 0.54 (0.149, 0.948) 0.29 (-0.145, 0.748)
Threshold-4 2.60 (2.102, 3.111) 2.51 (2.087, 2.963) 2.44 (1.959, 2.933)
Time -0.42 (-0.699, -0.145) -0.45 (-0.708, -0.199) -0.28 (-0.569, 0.010)
Treatment
Biguanides -0.58 (-1.061, -0.080) -0.44 (-0.864, -0.003) -0.76 (-1.253, -0.239)
Sulphonyureas -0.33 (-0.849, 0.188) -0.20 (-0.664, 0.270) -0.45 (-0.981, 0.101)
BMI -0.04 (-0.082, 0.009) -0.03 (-0.067, 0.015) -0.04 (-0.084, 0.009)
Male 0.72 (0.020, 1.410) 0.85 (0.231, 1.442) 0.52 (-0.148, 1.231)
Treatment×Time
Biguanides×Time 0.31 (-0.055, 0.668) 0.26 (-0.075, 0.599) 0.26 (-0.106, 0.628)
Sulphonyureas×Time 0.45 (-0.001, 0.895) 0.38 (-0.009, 0.782) 0.38 (-0.070, 0.830)
Association Parameters & Variances
ρ 0.60 (0.465, 0.716) - - - -
γ - - 0.83 (0.603, 1.085) - -
σ2b1 6.97 (5.310, 8.889) 4.07 (2.697, 5.862) 7.02 (5.389, 8.972)
σ2b2 3.46 (2.444, 4.719) - - 3.33 (2.364, 4.512)
σ2e1 7.42 (6.713, 8.211) 9.53 (8.383, 10.720) 7.40 (6.684, 8.177)
Goodness of Fit (DIC)
Continuous 5160 5323 5170
Ordinal 2573 2639 2591
Total 7733 7962 -
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Table 23: Results when data were simulated under a shared random effects model (γ1 = γ2 = 0.9) and n = 50: MCSD, SD, and
CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability of 95% HPD
intervals, respectively.
Fitted Model
Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJS
Shared
Continuous Process
(n=50)
β10: intercept 13.50 -0.013 0.410 0.412 0.94 -0.020 0.411 0.414 0.95 1.01
β11: time -0.56 0.001 0.027 0.028 0.95 0.001 0.028 0.030 0.95 1.09
β12: treatment -3.35 -0.005 0.426 0.409 0.96 0.001 0.429 0.415 0.95 1.02
β13: time×treatment -0.57 0.000 0.030 0.028 0.96 0.000 0.031 0.030 0.95 1.10
Ordinal Process
α2: threshold 0.45 0.032 0.074 0.079 0.92 0.029 0.074 0.079 0.92 0.97
β20: intercept 1.70 0.062 0.403 0.419 0.94 0.051 0.409 0.422 0.94 1.02
β21: time -0.27 -0.011 0.036 0.035 0.95 -0.008 0.038 0.036 0.96 1.05
β22: treatment 0.65 -0.014 0.418 0.405 0.96 -0.019 0.421 0.414 0.95 1.02
β23: time×treatment -0.10 0.000 0.033 0.032 0.95 0.000 0.035 0.035 0.95 1.17
Survival Process
β30: intercept -3.31 -0.107 0.435 0.440 0.95 -0.046 0.433 0.450 0.95 0.95
β31: treatment 0.37 0.021 0.401 0.403 0.94 0.014 0.413 0.416 0.95 1.06
Association Parameters & Variances
γ1: bi2 ∝ bi1 0.90 0.062 0.109 0.106 0.92 - - - - -
γ2: bi3 ∝ bi1 0.90 0.064 0.151 0.150 0.93 - - - - -
σ2b1 : bi1 5.87 -0.036 1.348 1.364 0.96 0.026 1.349 1.382 0.96 1.00
σ2b2 : bi2 4.75 - - - - 0.571 1.660 1.650 0.92 -
σ2b3 : bi3 4.75 - - - - 0.264 2.303 2.417 0.95 -
σ2e1 : error 7.40 0.043 0.445 0.466 0.95 0.038 0.450 0.472 0.94 1.02
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Table 24: Results when data were simulated under a shared random effects model (γ1 = γ2 = 0.9) and n = 100: MCSD, SD, and
CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability of 95% HPD
intervals, respectively.
Fitted Model
Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJS
Shared
Continuous Process
(n=100)
β10: intercept 13.50 -0.024 0.293 0.291 0.96 -0.028 0.293 0.293 0.96 1.00
β11: time -0.56 0.002 0.020 0.020 0.95 0.002 0.021 0.021 0.94 1.06
β12: treatment -3.35 -0.003 0.285 0.290 0.94 -0.005 0.285 0.292 0.94 1.00
β13: time×treatment -0.57 0.000 0.021 0.020 0.95 0.000 0.022 0.021 0.96 1.12
Ordinal Process
α2: threshold 0.45 0.014 0.054 0.055 0.94 0.012 0.054 0.055 0.94 0.98
β20: intercept 1.70 0.025 0.275 0.287 0.95 0.016 0.283 0.290 0.95 1.05
β21: time -0.27 -0.006 0.024 0.024 0.93 -0.004 0.026 0.025 0.94 1.15
β22: treatment 0.65 0.017 0.268 0.280 0.95 0.011 0.278 0.286 0.95 1.07
β23: time×treatment -0.10 -0.003 0.023 0.022 0.94 -0.002 0.025 0.024 0.95 1.17
Survival Process
β30: intercept -3.31 -0.062 0.318 0.299 0.95 -0.048 0.332 0.315 0.94 1.07
β31: treatment 0.37 0.006 0.270 0.276 0.94 -0.008 0.281 0.291 0.94 1.08
Association Parameters & Variances
γ1: bi2 ∝ bi1 0.90 0.030 0.074 0.071 0.93 - - - - -
γ2: bi3 ∝ bi1 0.90 0.029 0.099 0.099 0.93 - - - - -
σ2b1 : bi1 5.87 0.021 0.957 0.951 0.96 0.041 0.958 0.958 0.96 1.00
σ2b2 : bi2 4.75 - - - - 0.322 1.127 1.080 0.94 -
σ2b3 : bi3 4.75 - - - - 0.230 1.670 1.631 0.95 -
σ2e1 : error 7.40 0.030 0.327 0.329 0.94 0.029 0.331 0.333 0.95 1.03
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Table 25: Results when data were simulated under a shared random effects model (γ1 = γ2 = 0.6) and n = 50: MCSD, SD, and
CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability of 95% HPD
intervals, respectively.
Fitted Model
Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJS
Shared
Continuous Process
(n=50)
β10: intercept 13.50 -0.014 0.408 0.412 0.95 -0.020 0.412 0.415 0.95 1.02
β11: time -0.56 0.001 0.028 0.029 0.95 0.001 0.028 0.030 0.95 1.05
β12: treatment -3.35 -0.004 0.426 0.410 0.95 0.002 0.429 0.415 0.95 1.01
β13: time×treatment -0.57 0.000 0.030 0.029 0.96 0.000 0.031 0.030 0.95 1.06
Ordinal Process
α2: threshold 0.45 0.025 0.070 0.072 0.94 0.023 0.071 0.072 0.94 1.00
β20: intercept 1.70 0.052 0.304 0.316 0.94 0.047 0.310 0.319 0.94 1.03
β21: time -0.27 -0.009 0.031 0.031 0.94 -0.007 0.033 0.033 0.95 1.10
β22: treatment 0.65 -0.006 0.313 0.305 0.95 -0.006 0.325 0.312 0.94 1.08
β23: time×treatment -0.10 -0.001 0.031 0.030 0.94 -0.001 0.034 0.032 0.95 1.19
Survival Process
β30: intercept -3.31 -0.088 0.344 0.342 0.94 -0.049 0.334 0.345 0.95 0.90
β31: treatment 0.37 0.023 0.320 0.315 0.94 0.017 0.329 0.327 0.95 1.05
Association Parameters & Variances
γ1: bi2 ∝ bi1 0.60 0.037 0.072 0.074 0.92 - - - - -
γ2: bi3 ∝ bi1 0.60 0.050 0.128 0.127 0.93 - - - - -
σ2b1 : bi1 5.87 -0.044 1.348 1.364 0.95 0.025 1.349 1.381 0.96 1.00
σ2b2 : bi2 2.11 - - - - 0.249 0.706 0.733 0.93 -
σ2b3 : bi3 2.11 - - - - 0.268 1.280 1.366 0.93 -
σ2e1 : error 7.40 0.049 0.447 0.470 0.95 0.038 0.450 0.472 0.95 1.01
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Table 26: Results when data were simulated under a shared random effects model (γ1 = γ2 = 0.6) and n = 100: MCSD, SD, and
CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability of 95% HPD
intervals, respectively.
Fitted Model
Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJS
Shared
Continuous Process
(n=100)
β10: intercept 13.50 -0.027 0.292 0.291 0.96 -0.028 0.293 0.293 0.96 1.01
β11: time -0.56 0.002 0.020 0.020 0.95 0.002 0.021 0.021 0.94 1.03
β12: treatment -3.35 -0.003 0.287 0.291 0.95 -0.005 0.286 0.292 0.94 0.99
β13: time×treatment -0.57 0.000 0.021 0.020 0.95 0.000 0.022 0.021 0.96 1.09
Ordinal Process
α2: threshold 0.45 0.013 0.048 0.050 0.95 0.012 0.048 0.050 0.95 0.97
β20: intercept 1.70 0.031 0.210 0.218 0.94 0.025 0.215 0.222 0.94 1.04
β21: time -0.27 -0.006 0.022 0.022 0.94 -0.005 0.024 0.023 0.94 1.10
β22: treatment 0.65 0.014 0.212 0.213 0.95 0.011 0.212 0.216 0.96 1.01
β23: time×treatment -0.10 -0.002 0.022 0.021 0.95 -0.002 0.023 0.022 0.96 1.08
Survival Process
β30: intercept -3.31 -0.055 0.242 0.231 0.93 -0.043 0.247 0.238 0.94 1.02
β31: treatment 0.37 0.008 0.216 0.215 0.95 -0.003 0.224 0.226 0.95 1.07
Association Parameters & Variances
γ1: bi2 ∝ bi1 0.60 0.018 0.051 0.050 0.93 - - - - -
γ2: bi3 ∝ bi1 0.60 0.025 0.090 0.084 0.95 - - - - -
σ2b1 : bi1 5.87 0.019 0.960 0.953 0.96 0.041 0.959 0.958 0.96 1.00
σ2b2 : bi2 2.11 - - - - 0.133 0.471 0.485 0.94 -
σ2b3 : bi3 2.11 - - - - 0.137 0.923 0.943 0.95 -
σ2e1 : error 7.40 0.032 0.329 0.331 0.94 0.029 0.331 0.333 0.95 1.01
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Table 27: Results when data were simulated under a shared random effects model (γ1 = γ2 = −0.5) and n = 50: MCSD, SD,
and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability of 95%
HPD intervals, respectively.
Fitted Model
Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJS
Shared
Continuous Process
(n=50)
β10: intercept 13.50 -0.017 0.414 0.414 0.95 -0.020 0.412 0.415 0.95 0.99
β11: time -0.56 0.001 0.027 0.029 0.96 0.001 0.028 0.030 0.95 1.07
β12: treatment -3.35 0.001 0.428 0.411 0.95 0.001 0.428 0.415 0.95 1.00
β13: time×treatment -0.57 0.000 0.031 0.029 0.95 0.000 0.031 0.030 0.95 1.03
Ordinal Process
α2: threshold 0.45 0.019 0.068 0.069 0.94 0.017 0.068 0.069 0.95 0.98
β20: intercept 1.70 0.057 0.286 0.285 0.95 0.039 0.291 0.289 0.95 1.01
β21: time -0.27 -0.009 0.032 0.030 0.95 -0.008 0.033 0.032 0.94 1.05
β22: treatment 0.65 -0.008 0.262 0.274 0.95 -0.007 0.267 0.280 0.96 1.04
β23: time×treatment -0.10 0.001 0.029 0.029 0.95 0.001 0.032 0.031 0.95 1.16
Survival Process
β30: intercept -3.31 -0.071 0.312 0.307 0.94 -0.058 0.316 0.317 0.94 1.01
β31: treatment 0.37 0.040 0.301 0.287 0.95 0.041 0.320 0.303 0.95 1.13
Association Parameters & Variances
γ1: bi2 ∝ bi1 -0.50 -0.025 0.065 0.066 0.94 - - - - -
γ2: bi3 ∝ bi1 -0.50 -0.036 0.124 0.119 0.94 - - - - -
σ2b1 : bi1 5.87 -0.041 1.340 1.366 0.96 0.026 1.349 1.382 0.96 1.01
σ2b2 : bi2 1.47 - - - - 0.143 0.508 0.517 0.94 -
σ2b3 : bi3 1.47 - - - - 0.293 0.850 1.081 0.93 -
σ2e1 : error 7.40 0.047 0.443 0.471 0.95 0.038 0.450 0.472 0.95 1.03
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Table 28: Results when data were simulated under a shared random effects model (γ1 = γ2 = −0.5) and n = 100: MCSD, SD,
and CP stand for Monte Carlo Standard Deviation, Posterior standard deviation, and Coverage probability of 95%
HPD intervals, respectively.
Fitted Model
Joint-Shared (JS) Separate (SP)
True Model
(n) Parameter Truth Bias MCSD SD CP Bias MCSD SD CP RE = MSESPMSEJS
Shared
Continuous Process
(n=100)
β10: intercept 13.50 -0.028 0.293 0.292 0.95 -0.028 0.292 0.293 0.96 0.99
β11: time -0.56 0.002 0.020 0.020 0.94 0.002 0.021 0.021 0.94 1.03
β12: treatment -3.35 -0.011 0.285 0.291 0.95 -0.005 0.286 0.292 0.94 1.00
β13: time×treatment -0.57 0.001 0.021 0.020 0.94 0.000 0.022 0.021 0.96 1.07
Ordinal Process
α2: threshold 0.45 0.012 0.049 0.049 0.95 0.011 0.049 0.049 0.95 0.99
β20: intercept 1.70 0.039 0.207 0.200 0.94 0.028 0.206 0.201 0.94 0.98
β21: time -0.27 -0.004 0.022 0.021 0.94 -0.003 0.023 0.022 0.95 1.01
β22: treatment 0.65 0.014 0.188 0.193 0.95 0.012 0.189 0.195 0.95 1.02
β23: time×treatment -0.10 -0.001 0.020 0.020 0.94 -0.001 0.021 0.021 0.94 1.08
Survival Process
β30: intercept -3.31 -0.036 0.214 0.209 0.95 -0.026 0.218 0.215 0.95 1.02
β31: treatment 0.37 0.023 0.190 0.195 0.94 0.013 0.202 0.206 0.94 1.11
Association Parameters & Variances
γ1: bi2 ∝ bi1 -0.50 -0.014 0.044 0.045 0.94 - - - - -
γ2: bi3 ∝ bi1 -0.50 -0.018 0.082 0.080 0.95 - - - - -
σ2b1 : bi1 5.87 0.010 0.959 0.951 0.96 0.041 0.959 0.959 0.96 1.00
σ2b2 : bi2 1.47 - - - - 0.086 0.331 0.349 0.95 -
σ2b3 : bi3 1.47 - - - - 0.128 0.694 0.741 0.94 -
σ2e1 : error 7.40 0.036 0.332 0.332 0.95 0.029 0.331 0.333 0.95 0.99
119
APPENDIX D
CONVERGENCE DIAGNOSTIC PLOTS
120
Marginal posterior densities (upper panel) and trace plots (lower panel) of β1: plots in the left,
middle, and right panels are from fitting, joint correlated random effects, joint shared random
effects, and separate models to Ugandan diabetes data, respectively (results in Table 6).
Figure 5: Marginal posterior densities and trace plots of β1 using joint and separate models
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β2: plots in the left,
middle, and right panels are from fitting, joint correlated random effects, joint shared random effects,
and separate models to Ugandan diabetes data, respectively (results in Table 6).
Figure 6: Marginal posterior densities and trace plots of β2 using joint and separate models
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Autcorrelation function plots of parameter estimates using joint and separate models for Ugandan
diabetes data (results in Table 6): plots in the left, middle, and right panels are from fitting, joint
correlated random effects, joint shared random effects, and separate models, respectively.
Figure 7: Autcorrelation function plots of selected parameter estimates using joint and
separate models
123
Marginal posterior densities (upper panel) and trace plots (lower panel) of β1: plots in the left,
middle, and right panels are from fitting, joint correlated random effects, joint shared random effects,
and separate models to Ugandan Type 2 diabetes data, respectively (results in Table 22).
Figure 8: Marginal posterior densities and trace plots of β1 using joint and separate models
for Ugandan Type 2 diabetes data
124
Marginal posterior densities (upper panel) and trace plots (lower panel) of β2: plots in the left,
middle, and right panels are from fitting, joint correlated random effects, joint shared random effects,
and separate models to Ugandan Type 2 diabetes data, respectively (results in Table 22).
Figure 9: Marginal posterior densities and trace plots of β2 using joint and separate models
for Ugandan Type 2 diabetes data
125
Autcorrelation function plots of parameter estimates using joint and separate models for Ugandan
Type 2 diabetes data (results in Table 22): plots in the left, middle, and right panels are from fitting,
joint correlated random effects, joint shared random effects, and separate models, respectively.
Figure 10: Autcorrelation function plots of selected parameter estimates using joint and
separate models for Ugandan Type 2 diabetes data
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β1 using joint and separate
models for Ugandan Type 2 diabetes data (results in Table 17): plots in the left, middle, and right
panels are from fitting, joint correlated random effects, joint shared random effects, and separate models,
respectively.
Figure 11: Marginal posterior densities and trace plots of β1 using joint and separate models
(Normal blood glucose 70− 180 mg/dl)
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β2 using joint and separate
models for Ugandan Type 2 diabetes data (results in Table 17): plots in the left, middle, and right
panels are from fitting, joint correlated random effects, joint shared random effects, and separate models,
respectively.
Figure 12: Marginal posterior densities and trace plots of β2 using joint and separate models
(Normal blood glucose 70− 180 mg/dl)
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β3 using joint and separate
models for Ugandan Type 2 diabetes data (results in Table 17): plots in the left, middle, and right
panels are from fitting, joint correlated random effects, joint shared random effects, and separate models,
respectively.
Figure 13: Marginal posterior densities and trace plots of β3 using joint and separate models
(Normal blood glucose 70− 180 mg/dl)
129
Autcorrelation function plots of parameter estimates using joint and separate models for Ugandan
Type 2 diabetes data (results in Table 17): plots in the left, middle, and right panels are from fitting,
joint correlated random effects, joint shared random effects, and separate models, respectively.
Figure 14: Autcorrelation function plots of selected parameter estimates using joint and
separate models (Normal blood glucose 70− 180 mg/dl)
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β1 using joint and separate
models for Ugandan Type 2 diabetes data (results in Table 18): plots in the left, middle, and right
panels are from fitting, joint correlated random effects, joint shared random effects, and separate models,
respectively.
Figure 15: Marginal posterior densities and trace plots of β1 using joint and separate models
(Normal blood glucose 70− 130 mg/dl)
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β2 using joint and separate
models for Ugandan Type 2 diabetes data (results in Table 18): plots in the left, middle, and right
panels are from fitting, joint correlated random effects, joint shared random effects, and separate models,
respectively.
Figure 16: Marginal posterior densities and trace plots of β2 using joint and separate models
(Normal blood glucose 70− 130 mg/dl)
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Marginal posterior densities (upper panel) and trace plots (lower panel) of β3 using joint and separate
models for Ugandan Type 2 diabetes data (results in Table 18): plots in the left, middle, and right
panels are from fitting, joint correlated random effects, joint shared random effects, and separate models,
respectively.
Figure 17: Marginal posterior densities and trace plots of β3 using joint and separate models
(Normal blood glucose 70− 130 mg/dl)
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Autcorrelation function plots of parameter estimates using joint and separate models for Ugandan
Type 2 diabetes data (results in Table 18): plots in the left, middle, and right panels are from fitting,
joint correlated random effects, joint shared random effects, and separate models, respectively.
Figure 18: Autcorrelation function plots of selected parameter estimates using joint and
separate models (Normal blood glucose 70− 130 mg/dl)
134
APPENDIX E
CODES USED TO FIT THE JOINT AND SEPARATE MODELS TO
DIABETES DATA IN CHAPTER 3
The following codes were used to fit the joint and separate models to diabetes data (Results
in Table 6)
# #####################################################
##### Model 3.1: Joint correlated  random effects #####
# #####################################################
sink("diab -model_4-6-13.txt") ## save model to file
cat("
###################################
# OpenBUGS program ###
###################################
model {# begin model
for (j in 1:Npat){ # loop over subjects (random effects)
U[j,1:2]~dmnorm(U0[],tau[,])
U1[j]<-U[j,1]
U2[j]<-U[j,2]
}
## Means for the continuous and ordinal variables
for (i in 1:Nobs){ # begin loop over observations
Z[i]<-sqrt(bglucse[i])
Z[i]~dnorm(mu1[i],tauz)
time[i]<-(month[i]-mean(month []))/(sd(month []))
mu1[i]<-beta1 [1]+ beta1 [2]*time[i]+beta1 [3]*biguan[i]+ beta1 [4]*sulphony[i]
+beta1 [5]*(age[i]-mean(age[]))+beta1 [6]*male[i]+beta1 [7]*sulphony[i]*time[i]
+beta1 [8]*biguan[i]*time[i]+U1[patient[i]]
mu2[i]<-beta2 [1]*time[i]+beta2 [2]*biguan[i]+ beta2 [3]*sulphony[i]
+beta2 [4]*(age[i]-mean(age[]))+beta2 [5]*male[i]+beta2 [6]*sulphony[i]*time[i]
+beta2 [7]*biguan[i]*time[i]+U2[patient[i]]
## cumulative logistic probabilities for the ordinal variable
logit(Q[i, 1]) <-alpha[1]-mu2[i]
p[i,1] <-Q[i,1]
for (k in 2:4) {
logit(Q[i,k])<-alpha[k]-mu2[i]
p[i,k]<-Q[i,k] - Q[i,k-1]
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}p[i, 5]<-1- Q[i, 4]
ursugar[i]~dcat(p[i, 1:5])
}# end loop over observations
#priors for the threshold parameters for the ordinal outcome
alpha [1]~dnorm(0, 1.0E-06) T(, alpha [2])
alpha [2]~dnorm(0, 1.0E-06) T(alpha[1], alpha [3])
alpha [3]~dnorm(0, 1.0E-06) T(alpha[2], alpha [4])
alpha [4]~dnorm(0, 1.0E-06) T(alpha[3], )
#construct variance for the error
sigmaz <-1/tauz
# construct variance -convariance matrix for the random effects
sigma1 [1:2 ,1:2] <-inverse(tau[,])
sigma11 <-sigma1 [1,1]
sigma22 <-sigma1 [2,2]
sigma12 <-sigma1 [1,2]
cor1 <-sigma12/(sqrt(sigma11*sigma22))
#prior for error precision
tauz~dgamma (0.001 ,0.001)
#prior for the precision matrix for the random effects
tau [1:2 ,1:2]~dwish(R1[,],3)
#prior for the regression coefficients
beta1 [1:8]~dmnorm(betamu1 [],Sigma1 [,])# continuous outcome
beta2 [1:7]~dmnorm(betamu2 [],Sigma2 [,])# ordinal outcome
}# end model
",fill=TRUE)
sink()
# ##################################
# R program ###
# ##################################
#Bundle data
betamu1 <-c(0,0,0,0,0,0,0,0)
betamu2 <-c(0,0,0,0,0,0,0)
Sigma1 <-diag (0.01, nrow=8,ncol =8)
Sigma2 <-diag (0.01, nrow=7,ncol =7)
U0<-c(0,0)
R1<-diag(1,nrow=2, ncol =2)
# Place data in a list to be read by OpenBUGS
diab.data <-list(Nobs =1363 ,
Npat =321,
U0=U0,
R1=R1,
betamu1=betamu1 ,
betamu2=betamu2 ,
Sigma1=Sigma1 ,
Sigma2=Sigma2 ,
bglucse=data12[,1],
ursugar=data12[,2],
month=data12[,3],
sulphony=data12[,4],
biguan=data12[,5],
age=data12[,6],
male=data12[,8],
patient=data12 [,9])
# Initial values for MCMC sampling
inits <-function (){list(
beta1=c(15.905 , -0.024 , -0.2362 , -0.3229 , -0.00015 , -0.6978 ,0.0025 ,0.01017),
tauz=1,
alpha=c( -1.1512 , -0.8419 , -0.2657 ,1.260),
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beta2=c( -0.009 , -0.6985 ,0.0145 , -0.0052 ,0.7088 , -0.0088 ,0.0128))
}
# Parameters  to estimate
params <-c("alpha","beta1","beta2","cor1","sigma11","sigma22","sigmaz")
# Start MCMC Sampling
outdiab08v1 <- BRugsFit(data=diab.data ,
inits=inits ,
parameters=params ,
modelFile="diab -model_4-6-13.txt",
numChains=2,
nBurnin =5000,
nIter =30000 ,
nThin=1,
coda=FALSE ,
DIC=TRUE ,
digits=5,
BRugsVerbose=getOption("BRugsVerbose"))
# #####################################################
###### Model 3.2: Joint shared random effects ######
# #####################################################
sink("diab -model_4-7-13v2.txt")
cat("
###################################
# OpenBUGS program ###
###################################
model {# begin model
# random effects
for (j in 1:Npat) {U[j]~dnorm (0.0,tau)}
##Means for the continuous and ordinal variables
for (i in 1:Nobs){# begin loop over observations
Z[i]<-sqrt(bglucse[i])
Z[i]~dnorm(mu1[i], tauz)
time[i]<-(month[i]-mean(month []))/(sd(month []))
mu1[i]<-beta1 [1] beta1 [2]*time[i]+beta1 [3]*biguan[i]+ beta1 [4]*sulphony[i]
+beta1 [5]*(age[i]-mean(age[]))+beta1 [6]*male[i]+beta1 [7]*sulphony[i]*time[i]
+beta1 [8]*biguan[i]*time[i]+U[patient[i]]
mu2[i]<-beta2 [1]*time[i]+beta2 [2]*biguan[i]+ beta2 [3]*sulphony[i]
+beta2 [4]*(age[i]-mean(age[]))+beta2 [5]*male[i]+beta2 [6]*sulphony[i]*time[i]
+beta2 [7]*biguan[i]*time[i]+r*(U[patient[i]])
## cumulative logistic probabilities for the ordinal outcome
logit(Q[i, 1]) <-alpha[1]-mu2[i]
p[i,1] <-Q[i,1]
for (k in 2:4) {
logit(Q[i,k])<-alpha[k]-mu2[i]
p[i,k]<-Q[i,k]-Q[i,k-1]
}
p[i, 5]<-1-Q[i, 4]
ursugar[i]~dcat(p[i, 1:5])
}# end loop over observations
# prior for the threshold parameters for the ordinal outcome
alpha [1]~dnorm(0, 1.0E-06) T(, alpha [2])
alpha [2]~dnorm(0, 1.0E-06) T(alpha[1], alpha [3])
alpha [3]~dnorm(0, 1.0E-06) T(alpha[2], alpha [4])
alpha [4]~dnorm(0, 1.0E-06) T(alpha[3], )
# construct error variance and random effects variance
sigmaz <-1/tauz
137
sigma <-1/tau
# priors for precision
tau~dgamma (0.001 ,0.001)
tauz~dgamma (0.001 ,0.001)
# priors for regresion coefficients
beta1 [1:8]~dmnorm(betamu1[],Sigma1 [,])
beta2 [1:7]~dmnorm(betamu2[],Sigma2 [,])
# prior for the association parameter under shared random effects
r~dnorm (0 ,0.1)
}# end model
",fill=TRUE)
sink()
# ##################################
# R program ###
# ##################################
# Bundle data
betamu1 <-c(0,0,0,0,0,0,0,0)
betamu2 <-c(0,0,0,0,0,0,0)
Sigma1 <-diag (0.01, nrow=8,ncol =8)
Sigma2 <-diag (0.01, nrow=7,ncol =7)
#Place data in a list to be read by OpenBUGS
diab.data <-list(Nobs =1363 ,
Npat =321,
betamu1=betamu1 ,
betamu2=betamu2 ,
Sigma1=Sigma1 ,
Sigma2=Sigma2 ,
bglucse=data12[,1],
ursugar=data12[,2],
month=data12[,3],
sulphony=data12[,4],
biguan=data12[,5],
age=data12[,6],
male=data12[,8],
patient=data12 [,9])
# Initial values for MCMC sampling
inits <-function (){list(
beta1=c(15.905 , -0.024 , -0.2362 , -0.3229 , -0.00015 , -0.6978 ,0.0025 ,0.01017),
tauz=1,
tau=1,
r=0.0,
alpha=c( -1.1512 , -0.8419 , -0.2657 ,1.260),
beta2=c( -0.009 , -0.6985 ,0.0145 , -0.0052 ,0.7088 , -0.0088 ,0.0128))
}
# Parameters  to estimate
params <- c("alpha","beta1","beta2","r","sigma","sigmaz")
# Start MCMC Sampling
outdiab08v3 <- BRugsFit(data=diab.data ,
inits=inits ,
parameters=params ,
modelFile="diab -model_4-6-13v2.txt",
numChains=2,
nBurnin =5000,
nIter =30000 ,
nThin=1,
coda=FALSE ,
DIC=TRUE ,
digits=5,
BRugsVerbose=getOption("BRugsVerbose"))
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# #####################################################
##### Model 3.3: Separate models ######
# #####################################################
sink("diab -model_4-7-13v3.txt")
cat("
###################################
# OpenBUGS program ###
###################################
model {# begin model
for (j in 1:Npat) {# loop over subjects (random effects)
U1[j]~dnorm (0.0, tau1)
U2[j]~dnorm (0.0, tau2)
}
## Means for the continuous and ordinal variables
for (i in 1:Nobs){# begin loop over observations
Z[i]<-sqrt(bglucse[i])
Z[i]~dnorm(mu1[i], tauz)
time[i]<-(month[i]-mean(month []))/(sd(month []))
mu1[i]<-beta1 [1]+ beta1 [2]*time[i]+beta1 [3]*biguan[i]+ beta1 [4]*sulphony[i]
+beta1 [5]*(age[i]-mean(age[]))+beta1 [6]*male[i]+beta1 [7]*sulphony[i]*time[i]
+beta1 [8]*biguan[i]*time[i]+U1[patient[i]]
mu2[i]<-beta2 [1]*time[i]+beta2 [2]*biguan[i]+ beta2 [3]*sulphony[i]
+beta2 [4]*(age[i]-mean(age[]))+beta2 [5]*male[i]+beta2 [6]*sulphony[i]*time[i]
+beta2 [7]*biguan[i]*time[i]+U2[patient[i]]
## cumulative logistic probabilities for the ordinal outcome
logit(Q[i, 1]) <-alpha[1]-mu2[i]
p[i,1] <-Q[i,1]
for (k in 2:4) {
logit(Q[i,k])<-alpha[k]-mu2[i]
p[i,k]<-Q[i,k]-Q[i,k-1]
}
p[i, 5]<-1-Q[i, 4]
ursugar[i]~dcat(p[i, 1:5])
}# end loop over observations
# prior for the threshold parameters for the ordinal outcome
alpha [1]~dnorm(0, 1.0E-06) T(, alpha [2])
alpha [2]~dnorm(0, 1.0E-06) T(alpha[1], alpha [3])
alpha [3]~dnorm(0, 1.0E-06) T(alpha[2], alpha [4])
alpha [4]~dnorm(0, 1.0E-06) T(alpha[3], )
# construct error variance and random effects variances
sigmaz <-1/tauz
sigma1 <-1/tau1
sigma2 <-1/tau2
# priors for precisions
tauz~dgamma (0.001 ,0.001)
tau1~dgamma (0.001 ,0.001)
tau2~dgamma (0.001 ,0.001)
# priors for regresion coefficients
beta1 [1:8]~dmnorm(betamu1[],Sigma1 [,])
beta2 [1:7]~dmnorm(betamu2[],Sigma2 [,])
} #end model
",fill=TRUE)
sink()
# ##################################
# R program ###
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# ##################################
# Bundle data
betamu1 <-c(0,0,0,0,0,0,0,0)
betamu2 <-c(0,0,0,0,0,0,0)
Sigma1 <-diag (0.01, nrow=8,ncol =8)
Sigma2 <-diag (0.01, nrow=7,ncol =7)
# Place data in a list to be read by OpenBUGS
diab.data <-list(Nobs =1363 ,
Npat =321,
betamu1=betamu1 ,
betamu2=betamu2 ,
Sigma1=Sigma1 ,
Sigma2=Sigma2 ,
bglucse=data12[,1],
ursugar=data12[,2],
month=data12[,3],
sulphony=data12[,4],
biguan=data12[,5],
age=data12[,6],
male=data12[,8],
patient=data12 [,9])
# Initial values for MCMC sampling
inits <-function (){list(
beta1=c(15.905 , -0.024 , -0.2362 , -0.3229 , -0.00015 , -0.6978 ,0.0025 ,0.01017),
tauz=1,
tau1=1,
tau2=1,
alpha=c( -1.1512 , -0.8419 , -0.2657 ,1.260),
beta2=c( -0.009 , -0.6985 ,0.0145 , -0.0052 ,0.7088 , -0.0088 ,0.0128))
}
# Parameters  to estimate
params <- c("alpha","beta1","beta2","sigma1","sigma2","sigmaz")
# Start MCMC Sampling
outdiab08v4 <- BRugsFit(data=diab.data ,
inits=inits ,
parameters=params ,
modelFile="diab -model_4-6-13v3.txt",
numChains=2,
nBurnin =5000,
nIter =30000 ,
nThin=1,
coda=FALSE ,
DIC=TRUE ,
digits=5,
BRugsVerbose=getOption("BRugsVerbose"))
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APPENDIX F
CODES USED TO FIT THE JOINT AND SEPARATE MODELS TO
DIABETES DATA IN CHAPTER 4
The following codes were used to fit the joint and separate models to diabetes data (Results
in Table 17)
long.data ## Longitudinal  data
surv.data ## Survival data
# ###############################################
## Generating  initial values for MCMC sampling #
# ################################################
# Continuous  outcome
fit1 <-lme(sqrt(ubp)~month + biguan + sulphony + month*biguan + month*sulphony
+ mage + male ,data=long.data ,method="ML",random=~1| patient)
b1 <- unlist(fit1$coef [1])
# Ordinal outcome
fit2 < vglm(bmi_grp2~month + biguan + sulphony + month*biguan + month*sulphony
+ mage + male ,family=cumulative(parallel=TRUE),data=long.data)
b2 <- coef(fit2 , matrix=F)
# Survival outcome
temp <-ifelse(is.na(surv.data$surt ),surv.data$ cens2 ,surv.data$surt)
these <- temp >0
test.fit3 <-survreg(Surv(temp ,surv.data$cens2 ==0)~surv.data$biguan + surv.data$sulphony
+ surv.data$mage + surv.data$male ,subset=these ,dist="weibull")
b3<- -as.vector(test.fit3$coefficients)/test.fit3$scale
# #####################################################
###### Model 4.1: Joint correlated  random effects #####
# #####################################################
sink("diab -model_4-6-14.txt") # Save the model to file in your working directory
cat("
###################################
# OpenBUGS program ###
###################################
model { # begin model
for (i in 1:Nobs){ #Loop over observations to handle unbalanced data
Z[i]<-sqrt(ubp[i])## transform systolic blood pressure
Z[i]~dnorm(mu1[i], tauz)
time[i]<-(month[i]-mean(month []))/(sd(month [])) ## standardize time
mu1[i]<-beta1 [1]+ beta1 [2]*time[i]+beta1 [3]*Biguan[i]+ beta1 [4]*Sulphony[i]
+beta1 [5]*(age[i]-mean(age[]))+beta1 [6]*male[i]+beta1 [7]*Biguan[i]*time[i]
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+beta1 [8]*Sulphony[i]*time[i]+U1[patient[i]]
mu2[i]<-beta2 [1]*time[i]+beta2 [2]*Biguan[i]+ beta2 [3]*Sulphony[i]
+beta2 [4]*(age[i]-mean(age[]))+beta2 [5]*male[i]+beta2 [6]*Biguan[i]*time[i]
+beta2 [7]*Sulphony[i]*time[i]+U2[patient[i]]
## Cumulative logistic probabilities for the ordinal outcome
logit(Q[i, 1]) <-alpha[1]-mu2[i]
p[i,1] <-Q[i,1]
for (k in 2:3){
logit(Q[i,k]) <- alpha[k]-mu2[i]
p[i,k]<-Q[i,k]-Q[i,k-1]
}
p[i, 4]<-1- Q[i, 3]
bmi_grp2[i]~dcat(p[i, 1:4])
} #end loop over observations
for (j in 1:Npat) { # begin loop over subjects/patients
# Survival Model
log(mut[j])<-beta3 [1]+ beta3 [2]*biguan[j]+ beta3 [3]*sulphony[j]
+beta3 [4]*(mage[j]-mean(mage []))+beta3 [5]*malet[j]+U3[j]
surt[j]~dweib(lamda ,mut[j])C(cens[j],)
## Random effects
U[j,1:3]~dmnorm(U0[],tau[,])
U1[j]<-U[j,1]
U2[j]<-U[j,2]
U3[j]<-U[j,3]
} # end loop over subjects/patients
## Prior for the threshold parameters for the ordinal outcome
alpha [1]~dnorm(0, 1.0E-06) T(, alpha [2])
alpha [2]~dnorm(0, 1.0E-06) T(alpha[1], alpha [3])
alpha [3]~dnorm(0, 1.0E-06) T(alpha[2], )
## Prior for the shape parameter for the Weibull
lamda <-1 ## exponetial
lamda~dgamma (.1 ,.1) ## Weibull
## construct error variance
sigmaz <-1/tauz
## prior for error precision
tauz~dgamma (1.0, 1.0)
## construct variance -covariance matrix for random effects
sigma1 [1:3 ,1:3] <-inverse(tau[,])
sigma11 <-sigma1 [1,1]
sigma22 <-sigma1 [2,2]
sigma33 <-sigma1 [3,3]
sigma12 <-sigma1 [1,2]
sigma13 <-sigma1 [1,3]
sigma23 <-sigma1 [2,3]
cor12 <-sigma12/(sqrt(sigma11*sigma22))
cor13 <-sigma13/(sqrt(sigma11*sigma33))
cor23 <-sigma23/(sqrt(sigma22*sigma33))
## prior for precision of random effects
tau [1:3 ,1:3]~dwish(R1[,], 4)
## Priors for regression coefficients (Betas)
beta1 [1:8]~dmnorm(betamu1[],Sigma1 [,])# continuous outcome
beta2 [1:7]~dmnorm(betamu2[],Sigma2 [,])# ordinal outcome
beta3 [1:5]~dmnorm(betamu3[],Sigma3 [,])# survival outcome
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} # end model
",fill=TRUE)
sink()
# ##################################
# R program ###
# ##################################
## Bundle data
betamu1 <-c(0,0,0,0,0,0,0,0)
betamu2 <-c(0,0,0,0,0,0,0)
betamu3 <-c(0,0,0,0,0)
Sigma1 <-diag (0.01, nrow=8,ncol =8)
Sigma2 <-diag (0.01, nrow=7,ncol =7)
Sigma3 <-diag (0.01, nrow=5,ncol =5)
U0<-c(0,0,0)
R1<-diag(1,nrow=3,ncol =3)
# Place data in a list to be read by OpenBUGS
diab.data <-list(Nobs =1225 ,
Npat =500,
U0=U0,
R1=R1,
betamu1=betamu1 ,
betamu2=betamu2 ,
betamu3=betamu3 ,
Sigma1=Sigma1 ,
Sigma2=Sigma2 ,
Sigma3=Sigma3 ,
ubp=long.data$ubp ,
bmi_grp2=long.data$bmi_grp2 ,
month=long.data$month ,
Sulphony=long.data$sulphony ,
Biguan=long.data$biguan ,
age=long.data$mage ,
male=long.data$male ,
patient=long.data$patient ,
surt=surv.data$surt ,
cens=surv.data$cens2 ,
biguan=surv.data$biguan ,
sulphony=surv.data$sulphony ,
malet=surv.data$male ,
mage=surv.data$mage)
# Initial values for MCMC sampling
inits <-function (){list(
beta1=c(b1[1],b1[2],b1[3],b1[4],b1[5],b1[6],b1[7],b1[8]),
tauz=1,
tau=diag (3),
U=matrix(rnorm (500*3,0,0.5) ,500,3),
alpha=c(b2[1],b2[2],b2[3]),
beta2=c(-b2[4],-b2[5],-b2[6],-b2[7],-b2[8],-b2[9],-b2[10]) ,
beta3=c(b3[1],b3[2],b3[3],b3[4],b3[5]),
surt=ifelse(is.na(surv.data$surt),runif (500, surv.data$cens2 ,surv.data$cens2
+10),NA))
}
# Parameters  to estimate
params <-c("alpha","beta1","beta2","beta3","cor12","cor13","cor23","sigma11",
"sigma22","sigma33","sigmaz")
# Start MCMC Sampling
long.surv.out <-BRugsFit(data=diab.data ,
inits=inits ,
parameters=params ,
modelFile="diab -model_4-6-14.txt",
numChains=2,
nBurnin =5000,
nIter =30000 ,
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nThin=1,
coda=FALSE ,
DIC=TRUE ,
digits=5,
BRugsVerbose=getOption("BRugsVerbose"))
print(long.surv.out)
# #####################################################
###### Model 4.2: Joint shared random effects ######
# #####################################################
sink("diab -model_4-6-14v2.txt")
cat("
###################################
# OpenBUGS program ###
###################################
model { # begin model
for (i in 1:Nobs){ # begin loop over observations
Z[i]<-sqrt(ubp[i])
Z[i]~dnorm(mu1[i], tauz)
time[i]<-(month[i]-mean(month []))/(sd(month []))
mu1[i]<-beta1 [1]+ beta1 [2]*time[i]+beta1 [3]*Biguan[i]+ beta1 [4]*Sulphony[i]
+beta1 [5]*(age[i]-mean(age[]))+beta1 [6]*male[i]+beta1 [7]*Biguan[i]*time[i]
+beta1 [8]*Sulphony[i]*time[i]+U1[patient[i]]
mu2[i]<-beta2 [1]*time[i]+beta2 [2]*Biguan[i]+ beta2 [3]*Sulphony[i]
+beta2 [4]*(age[i]-mean(age[]))+beta2 [5]*male[i]+beta2 [6]*Biguan[i]*time[i]
+beta2 [7]*Sulphony[i]*time[i]+r1*(U1[patient[i]])
## cumulative logistic probabilities for the ordinal outcome
logit(Q[i, 1]) <-alpha[1]-mu2[i]
p[i,1] <-Q[i,1]
for (k in 2:3) {
logit(Q[i,k])<-alpha[k]-mu2[i]
p[i,k]<-Q[i,k]-Q[i,k-1]
}
p[i, 4]<-1-Q[i, 3]
bmi_grp2[i]~dcat(p[i, 1:4])
} # end loop over observations
for (j in 1:Npat) { # begin loop over subjects
# Survival Model
log(mut[j])<-beta3 [1]+ beta3 [2]*biguan[j]+ beta3 [3]*sulphony[j]
+beta3 [4]*(mage[j]-mean(mage []))+beta3 [5]*malet[j]+r2*U1[j]
surt[j]~dweib(lamda ,mut[j])C(cens[j],)
## Random effects
U1[j]~ dnorm (0.0,tau)
} # end loop over subjects
## Prior for the threshold parameters for the ordinal outcome
alpha [1]~dnorm(0, 1.0E-06) T(, alpha [2])
alpha [2]~dnorm(0, 1.0E-06) T(alpha[1], alpha [3])
alpha [3]~dnorm(0, 1.0E-06) T(alpha[2], )
## Prior for the shape parameter for the Weibull
lamda <-1
#lamda~dgamma (.1 ,.1)
## construct error variance
sigmaz <-1/tauz
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## prior for error precision
tauz~dgamma (1,1)
## construct variance for random effect
sigma <-1/tau
## prior (half -Cauchy(s=25)) for standard deviation of random effect
numertau~dnorm (0,1)
denomtau~dnorm (0 ,0.0016)
tau <-pow(numertau/denomtau ,2)
## Priors for regression coefficients (Betas)
beta1 [1:8]~dmnorm(betamu1[],Sigma1 [,])
beta2 [1:7]~dmnorm(betamu2[],Sigma2 [,])
beta3 [1:5]~dmnorm(betamu3[],Sigma3 [,])
# prior for the association parameters (gamma)
r1~dnorm (0.0 ,0.01)
r2~dnorm (0.0 ,0.01)
} # end model
",fill=TRUE)
sink()
# ##################################
# R program ###
# ##################################
# Bundle data
betamu1 <-c(0,0,0,0,0,0,0,0)
betamu2 <-c(0,0,0,0,0,0,0)
betamu3 <-c(0,0,0,0,0)
Sigma1 <-diag (0.01, nrow=8,ncol =8)
Sigma2 <-diag (0.01, nrow=7,ncol =7)
Sigma3 <-diag (0.01, nrow=5,ncol =5)
# Place data in a list to be read by OpenBUGS
diab.data <-list(Nobs =1225 ,
Npat =500,
betamu1=betamu1 ,
betamu2=betamu2 ,
betamu3=betamu3 ,
Sigma1=Sigma1 ,
Sigma2=Sigma2 ,
Sigma3=Sigma3 ,
ubp=long.data$ubp ,
bmi_grp2=long.data$bmi_grp2 ,
month=long.data$month ,
Sulphony=long.data$sulphony ,
Biguan=long.data$biguan ,
age=long.data$mage ,
male=long.data$male ,
patient=long.data$patient ,
surt=surv.data$surt ,
cens=surv.data$cens2 ,
biguan=surv.data$biguan ,
sulphony=surv.data$sulphony ,
malet=surv.data$male ,
mage=surv.data$mage)
# Initial values for MCMC sampling
inits <-function (){list(
beta1=c(b1[1],b1[2],b1[3],b1[4],b1[5],b1[6],b1[7],b1[8]),
tauz=1,
numertau=rnorm (1),
denomtau=rnorm (1),
r1=rnorm (1,0,.1),
r2=rnorm (1,0,.1),
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U1=rnorm (500 ,0 ,0.5),
alpha = c(b2[1], b2[2], b2[3]),
beta2=c(-b2[4],-b2[5],-b2[6],-b2[7],-b2[8],-b2[9],-b2[10]) ,
beta3=c(b3[1],b3[2],b3[3],b3[4],b3[5]),
surt=ifelse(is.na(surv.data$surt),runif (500, surv.data$cens2 ,surv.data$cens2
+10),NA))
}
# Parameters  to estimate
params <-c("alpha","beta1","beta2","beta3","r1","r2","sigma","sigmaz")
# Start MCMC Sampling
long.surv.out2 <-BRugsFit(data=diab.data ,
inits=inits ,
parameters=params ,
modelFile="diab -model_4-6-14v2.txt",
numChains=2,
nBurnin =5000,
nIter =30000 ,
nThin=1,
coda=FALSE ,
DIC=TRUE ,
digits=5,
BRugsVerbose=getOption("BRugsVerbose"))
print(long.surv.out2)
# #####################################################
##### Model 4.3: Separate models ######
# #####################################################
sink("diab -model_4-6-14v3.txt")
cat("
###################################
# OpenBUGS program ###
###################################
model { # begin model
for (i in 1:Nobs){ # begin loop over observations
Z[i]<-sqrt(ubp[i])
Z[i]~dnorm(mu1[i],tauz)
time[i]<-(month[i]-mean(month []))/(sd(month []))
mu1[i]<-beta1 [1]+ beta1 [2]*time[i]+beta1 [3]*Biguan[i]+ beta1 [4]*Sulphony[i]
+beta1 [5]*(age[i]-mean(age[]))+beta1 [6]*male[i]+beta1 [7]*Biguan[i]*time[i]
+beta1 [8]*Sulphony[i]*time[i]+U1[patient[i]]
mu2[i]<-beta2 [1]*time[i]+beta2 [2]*Biguan[i]+ beta2 [3]*Sulphony[i]
+beta2 [4]*(age[i]-mean(age[]))+beta2 [5]*male[i]+beta2 [6]*Biguan[i]*time[i]
+beta2 [7]*Sulphony[i]*time[i]+U2[patient[i]]
## Cumulative logistic probabilities for ordinal outcome
logit(Q[i, 1]) <-alpha[1]-mu2[i]
p[i,1] <-Q[i,1]
for (k in 2:3) {
logit(Q[i,k])<-alpha[k]-mu2[i]
p[i,k]<-Q[i,k] - Q[i,k-1]
}
p[i, 4]<-1- Q[i, 3]
bmi_grp2[i]~dcat(p[i, 1:4])
} # end loop over observations
for (j in 1:Npat) { # begin loop over subjects
# Survival Model
log(mut[j])<- beta3 [1]+ beta3 [2]*biguan[j]+ beta3 [3]*sulphony[j]
+beta3 [4]*(mage[j]-mean(mage []))+beta3 [5]*malet[j]+U3[j]
surt[j]~dweib(lamda ,mut[j])C(cens[j],)
146
## Random effects
U1[j]~dnorm (0.0, tau1)
U2[j]~dnorm (0.0, tau2)
U3[j]~dnorm (0.0, tau3)
} # end loop over subjects
## Prior for the threshold parameters for the ordinal outcome
alpha [1]~dnorm(0, 1.0E-06) T(, alpha [2])
alpha [2]~dnorm(0, 1.0E-06) T(alpha[1], alpha [3])
alpha [3]~dnorm(0, 1.0E-06) T(alpha[2], )
## Prior for the shape parameter for the Weibull
lamda <-1 # exponetial
#lamda~dgamma (.1 ,.1) # Weibull
## construct error variance
sigmaz <-1/tauz
## prior for error precision
tauz~dgamma (1.0, 1.0)
## construct variances for random effects
sigma1 <-1/tau1
sigma2 <-1/tau2
sigma3 <-1/tau3
## prior (half -Cauchy(s=25)) for standard deviations of random effects
numertau1~dnorm (0,1)
denomtau1~dnorm (0 ,0.0016)
tau1 <-pow(numertau1/denomtau1 ,2)
numertau2~dnorm (0,1)
denomtau2~dnorm (0 ,0.0016)
tau2 <-pow(numertau2/denomtau2 ,2)
numertau3~dnorm (0,1)
denomtau3~dnorm (0 ,0.0016)
tau3 <-pow(numertau3/denomtau3 ,2)
## Priors for regression coefficients (Betas)
beta1 [1:8]~dmnorm(betamu1[],Sigma1 [,])
beta2 [1:7]~dmnorm(betamu2[],Sigma2 [,])
beta3 [1:5]~dmnorm(betamu3[],Sigma3 [,])
} # end model
",fill=TRUE)
sink()
# ##################################
# R program ###
# ##################################
# Bundle data
betamu1 <-c(0,0,0,0,0,0,0,0)
betamu2 <-c(0,0,0,0,0,0,0)
betamu3 <-c(0,0,0,0,0)
Sigma1 <-diag (0.01, nrow=8,ncol =8)
Sigma2 <-diag (0.01, nrow=7,ncol =7)
Sigma3 <-diag (0.01, nrow=5,ncol =5)
# Place data in a list to be read by OpenBUGS
diab.data <-list(Nobs =1225 ,
Npat =500,
betamu1=betamu1 ,
betamu2=betamu2 ,
betamu3=betamu3 ,
Sigma1=Sigma1 ,
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Sigma2=Sigma2 ,
Sigma3=Sigma3 ,
ubp=long.data$ubp ,
bmi_grp2=long.data$bmi_grp2 ,
month=long.data$month ,
Sulphony=long.data$sulphony ,
Biguan=long.data$biguan ,
age=long.data$mage ,
male=long.data$male ,
patient=long.data$patient ,
surt=surv.data$surt ,
cens=surv.data$cens2 ,
biguan=surv.data$biguan ,
sulphony=surv.data$sulphony ,
malet=surv.data$male ,
mage=surv.data$mage)
# Initial values for MCMC sampling
inits <-function (){list(
beta1=c(b1[1],b1[2],b1[3],b1[4],b1[5],b1[6],b1[7],b1[8]),
numertau1=rnorm (1),
denomtau1=rnorm (1),
numertau2=rnorm (1),
denomtau2=rnorm (1),
numertau3=rnorm (1),
denomtau3=rnorm (1),
alpha=c(b2[1],b2[2],b2[3]),
beta2=c(-b2[4],-b2[5],-b2[6],-b2[7],-b2[8],-b2[9],-b2[10]) ,
beta3=c(b3[1],b3[2],b3[3],b3[4],b3[5]),
U1=rnorm (500 ,0 ,0.5),
U2=rnorm (500 ,0 ,0.5),
U3=rnorm (500 ,0 ,0.5),
surt=ifelse(is.na(surv.data$surt),runif (500, surv.data$cens2 ,surv.data$cens2
+10),NA))
}
# Parameters  to estimate
params <-c("alpha","beta1","beta2","beta3","sigma1","sigma2","sigma3","sigmaz")
# Start MCMC Sampling
long.surv.out3 <-BRugsFit(data=diab.data ,
inits=inits ,
parameters=params ,
modelFile="diab -model_4-6-14v3.txt",
numChains=2,
nBurnin =5000,
nIter =30000 ,
nThin=1,
coda=FALSE ,
DIC=TRUE ,
digits=5,
BRugsVerbose=getOption("BRugsVerbose"))
print(long.surv.out3)
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